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CHAPTER 1  
GENERAL INTRODUCTION 
Treating panic disorder: Update on current status 
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1.1 Clinical features of panic disorder with or without agoraphobia 
 
Fear protects us from danger by triggering an adaptive response to threat. The 
original formulation of the ‘fight or flight response’
1
 explained how the sympathetic 
nervous system is triggered enabling animals in potential danger to flee or fight. 
Physiological reactions associated with this innate fight of flight response include, 
among others, acceleration of heart and lung action, inhibition of stomach and 
upper-intestinal action, constriction of blood vessels, tunnel vision, and shaking. 
People who suffer from panic attacks experience similar physiological reactions but 
without the presence of an external threat making them extremely anxious and 
often catastrophizing their bodily experiences.   
 In distinguishing normal fear from pathological fear characterizing anxiety 
disorders, pathological fear is (a) excessive in relation to the situation, (b) cannot be 
reasoned away, (c) is beyond voluntary control, (d) leads to avoidance of the feared 
object or situation, (e) persists over time, (f) is maladaptive, and (g) is not age 
specific.(1) What was initially called ‘agoraphobia with panic attacks’ in DSM-III (APA, 
1980) was renamed ‘panic disorder with or without agoraphobia’ in the DSM-III-R 
(APA, 1987). In the DSM-IV (APA, 1994) panic disorder (PD) is characterized by 
recurrent panic attacks and fear for subsequent attacks and/or their consequences 
(see boxes 1.1 to 1.3 for DSM-IV criteria). A panic attack is defined by a cluster of 
physical and cognitive symptoms and is described as a purely terrifying experience by 
those who go through them. Although panic attacks are common to all anxiety 
disorders, in PD they are mostly unexpected of without an obvious external trigger. 
For most PD sufferers, their first panic attack has been stamped indelibly into their 
memory. In order to prevent the onset of subsequent panic attacks, PD patients tend 
to avoid certain situations or behaviors often resulting in concurrent agoraphobia 
(AG) (literally referring to fear of the marketplace). 
                     
1
 Fight or flight: original formulation by Walter Cannon in 1929. 
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 Box 1.1. 
DSM-IV criteria for panic attack:
A discrete period of intense fear or discomfort, in which four (or more) of the 
following symptoms developed abruptly and reached a peak within 10 minutes:
1)  palpitations, pounding heart, or accelerated heart rate
2)  sweating
3)  trembling or shaking
4)  sensations of shortness of breath or smothering
5)  feeling of choking
6)  chest pain or discomfort
7)  nausea or abdominal distress
8)  feeling dizzy, unsteady, lightheaded, or faint
9)  derealization (feelings of unreality) or
depersonalization (being detached from oneself)
10) fear of losing control or going crazy
11) fear of dying
12) paresthesias (numbness or tingling sensations)
13) chills or hot flushes
 
 
 Box 1.2. 
DSM-IV criteria for panic disorder:
A) Both (1) and (2):
(1) Recurrent unexpected Panic Attacks
(2) At least one of the attacks has been followed by 1 month (or more) of one 
(or more) of the following:
(a) persistent concern about having additional attacks
(b) worry about the implications of the attack or its consequences (e.g., 
losing control, having a heart attack, "going crazy")
(c) a significant change in behavior related to the attacks
B) The Panic Attacks are not due to the direct physiological effects of a 
substance (e.g., a drug of abuse, a medication) or a general medical 
condition (e.g., hyperthyroidism).
C) The Panic Attacks are not better accounted for by another mental disorder 
(e.g., social anxiety disorder, specific phobia) 
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 In the DSM-IV, PD with AG, PD without AG, and AG without a history of PD are 
distinguished. Data on prevalence of these different disorders are inconclusive and 
there is still debate regarding the relationship between PD and AG.
(2,3)
 Isolated panic 
attacks are not diagnosed as a disorder. However, they are relatively common in 
non-clinical populations and also frequently associated with a variety of anxiety 
disorders besides PD such as social anxiety disorder or specific phobias.
(4)
  
 The life-time prevalence rates for PD with or without AG fluctuate between 2% 
and 4%
(5,6)
 with a recent study in the United States reporting a life-time prevalence of 
3.8%.
(7)
 In the Netherlands, a lifetime prevalence of 3.8% was found as well.
(8)
 Most 
studies reporting on PD consistently show higher rates for women than for men.(4) 
PD typically runs a chronic course(9,10) and is associated with substantial reduction in 
quality of life.(11,12)   
 
 Box 1.3. 
DSM-IV criteria for Agoraphobia:
A)   Anxiety about being in places or situations from which escape might be 
difficult (or embarrassing) or in which help may not be available in the event 
of having an unexpected or situationally predisposed Panic Attack or panic-
like symptoms. Agoraphobic fears typically involve characteristic clusters of 
situations that include being outside the home alone; being in a crowd, or 
standing in a line; being on a bridge; and traveling in a bus, train, or 
automobile.
B)   The situations are avoided (e.g., travel is restricted) or else are endured with 
marked distress or with anxiety about having a Panic Attack or panic-like 
symptoms, or require the presence of a companion.
C)  The anxiety or phobic avoidance is not better accounted for by another 
mental disorder, such as Social Phobia (e.g., avoidance limited to social 
situations because of fear of embarrassment), Specific Phobia (e.g., 
avoidance limited to a single situation like elevators), Obsessive-Compulsive 
Disorder (e.g., avoidance of dirt in someone with an obsession about 
contamination), Posttraumatic Stress Disorder (e.g., avoidance of stimuli 
associated with a severe stressor), or Separation Anxiety Disorder (e.g., 
avoidance of leaving home or relatives).
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1.2 Understanding panic disorder: Onset and maintenance 
 
Throughout the years, several models explaining the origins of PD have been 
developed. Traditionally, the biological view has been predominant but in the 1980s 
psychological theories became increasingly influential. Since the late 1990s, the 
biological and psychological viewpoints have started to merge, making room for an 
integrated viewpoint on the origins and workings mechanisms involved in PD. A 
stress-diathesis model is most commonly used to explain the genesis and 
maintenance of PD in which an interaction between life stress and genetic 
susceptibility is proposed as being the root cause of PD. The concept of anxiety 
sensitivity 
(13,14)
 may help in understanding why some individuals respond different 
than others to the bodily sensations associated with anxiety. When fear of fear 
develops, initial panic attacks may spiral into PD. With the onset of the disorder, 
changes in the neural circuits of the brain of patients with PD (emphasizing the role 
of the amygdala and related structures) are thought to play a role in the 





1.3 The context-safety hypothesis 
 
Contemporary learning theory is consistent with data supporting cognitive theories 
emphasizing catastrophic misinterpretations 
(e.g.16)
 and stresses that catastrophic 
cognitions can be seen as a part of ‘context’ or constellation of cues that have been 
linked to panic.(17) Understanding the role of context is important in predicting the 
return of fear and anxiety often observed in PD.(18) It is suggested that patients 
receiving CBT have tested and disconfirmed their feared catastrophes regarding 
feared bodily sensations (through interoceptive exposure) and feared situations 
(through exposure in vivo). In this way, a sense of safety is relearned. When this 
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relearning of safety is context dependent, there are some implications for clinical 
treatment. For CBT this means that conducting exposure in multiple contexts is 
important. Regarding medication treatment, it is important to realize that internal 
states are also considered to be part of context.
(17,19-23)
 A mismatch of internal state 
during treatment (while on medication) and follow-up (after tapering medication) 
may result in fear renewal.
(18,24)
 In the present thesis, there will be referred to this 




In clinical practice today, PD is mostly treated with some form of either a 
psychopharmacological treatment, most often with a Serotonin Selective Reuptake 
Inhibitor (SSRI), or with a psychological treatment, most often cognitive behavioral 
therapy (CBT). Besides offering either CBT or an SSRI, the combination of these two 
treatment modalities appears to be common place in today’s clinical practice as well. 
In the following paragraphs, these different treatment modalities are introduced and 
empirical data on treatment effectiveness is reviewed.  
 
 1.4.1 Treating PD today: SSRIs  
 
Discovered in the late 1950s, benzodiazepines have been the mainstay in the 
treatment of panic disorder for decades.
(25) 
Initial enthusiasm waned due to 
observations of risks on over-sedation, cognitive impairment, long-lasting 
withdrawal symptoms and dependence. The first antidepressants that were found to 
be effective for PD were tricyclic with imipramine and clomipramine being most 
investigated.(26) Although proven efficacious, the side effect profile of this class of 
drugs limits the more widespread use of tricyclic antidepressants (TCAs).(27) At the 
end of the 1980s and throughout the 1990s, more and more studies were performed 
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on the effects of a new class of psychotropic drugs, the SSRIs. The first SSRI to be 
indicated for use in treating PD was paroxetine in 1989
(28)
 which was later 
accompanied by fluoxetine, sertraline, fluvoxamine, and citalopram. At present, 
SSRIs are considered as first-line pharmacotherapy agents for PD
(29)
 due to their 
overall levels of efficacy, safety and tolerability.
(26,29,30)
 
 The specific mechanism of action of the SSRIs is not entirely clear.
(31) 
It is 
suggested that a dysfunction of serotonin neuronal pathways may mediate PD. 
Consequently, antidepressants that modulate serotonergic systems may be effective 
in treating PD. SSRIs enhance serotonergic transmission by blocking the presynaptic 
active membrane transport mechanism for the reuptake of serotonin and 
consequently increases serotonergic activity at the postsynaptic receptor resulting in 
increased overall levels of brain 5-HT.(31,32) The ‘selective’ quality of the SSRIs stems 
from their high affinity to serotonin uptake sites, low affinity to noradrenaline 
uptake sites, and very low affinity for neurotransmitter receptors.(33)  
 A potential drawback of the SSRIs is the delayed response treatment effect; it 
takes approximately three to eight weeks before benefit may be noticed. Also, 
starting doses should be low and the doses should be increased slowly because panic 
symptoms may be exacerbated when the starting dose is too high.(34,35)  
 Compared to other psychotropic drugs, SSRIs exhibit a low side-effects 
profile.(36) Mostly reported side effects by patients receiving SSRIs include sweating, 
diarrhea, nausea, jitteriness, headaches, dizziness, and abnormal ejaculation or 
anorgasmia.
(26,28,37)
 Regarding the length of treatment, most clinicians recommend 
continuing treatment at least 6 months to 1 year after recovery
(38)
 although there is 
clearly a lack of studies into this matter.
(27)
  
 As with any pharmacological agent, the discontinuation of an SSRI may cause 
patients to experience time-limited withdrawal symptoms(39) which could be an 
interoceptive stimulus that triggers or contributes to PD relapse.(15,40) Frequently 
reported withdrawal symptoms include dizziness, light-headedness, insomnia, 
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fatigue, anxiety, agitation, nausea, headache, and sensory disturbance. It must be 
noted that the different SSRIs seem to have somewhat different side-effects profiles 
and may present patients with different withdrawal symptoms as well. To prevent 
withdrawal symptoms, a gradual taper is recommended.
(34)
   
 Not all patients remain symptom free following medication taper. However, 
studies presenting relapse rates after SSRI discontinuation are scarce. Most studies 
on the subject of relapse deal with other (and older) pharmacotherapeutical agents 
such as benzodiazepines or tricyclic antidepressants. As one expert states “the 
systematic study of the outcome of pharmacological treatment in a naturalistic 




 1.4.2 Treating PD today: CBT  
 
Up to the early 1980s, CBT for PD with AG emphasized in vivo exposure strategies 
targeting agoraphobic avoidance (in accordance with the formulation in the DSM-III 
(1980) in which the disorder was named ‘agoraphobia with panic attacks’).  
 The cognitive component received more attention in the 1980s as the cognitive 
theory of PD was developed by researchers such as Clark(16) and Beck.(42) It proposes 
that patients suffering from panic attacks interpret bodily sensations in a 
catastrophic way. The interaction of symptoms and interpretations of these 
symptoms produces a vicious circle leading up to a panic attack. This cognitive 
theory proved fruitful and yielded new applications for treatment. These new 
developments resulted in a shift within the field of CBT throughout the 80s from 
behavioral techniques targeting agoraphobic avoidance to behavioral and cognitive 
techniques targeting panic attacks directly. 
 Two important treatment protocols both framed within the cognitive behavioral 
model are the panic control treatment developed by Barlow, Craske and co-
workers(43-45), and the cognitive therapy by Clarks research group.(16,46) In practice, the 
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similarities between these protocols are probably greater than their differences. In 
the approach by Barlow the emphasis is on the interoceptive sensations while in the 
approach by Clark the emphasis is more on the erroneous cognitions.
(47)
  
 Controlled clinical trials evaluating cognitive-behavioral approaches for PD have 
accumulated during the last two decades. CBT is generally considered to be a cost 
effective treatment, is not associated with side effects
2
, and is seen as durable with 
patients needing no additional treatment after completion and low relapse rates. 
 
 Figure 1.1. Cognitive model of panic disorder according to Clark (1986) 
 
 
 In recent years, attempts have been made to improve accessibility to CBT by 
delivering CBT in a brief format (e.g. 48,49), in groups(e.g. 50-52), online(e.g. 53), or as self-
administered variant.(54) In reviewing the existing evidence for the efficacy of CBT, it 
should be noted that different treatment protocols are applied in different studies 
with subtle of less subtle differences in treatment focus. Common techniques in CBT 
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treatment protocols include psycho-education, cognitive restructuring, breathing 
retraining, interoceptive exposure, and exposure in vivo or situational exposure. A 
meta-analysis evaluating different CBT techniques found the combination of 
exposure and relaxation and/or breathing retraining to be most beneficial for PD 
patients.
(47)
 In the same line of research, behavioral experiments, considered a 
cognitive strategy, were found to be adding to the effect of exposure alone.
(55)
 
Regarding treatment length, most protocols consist of 12 to 16 sessions although 
shorter durations have also been reported.
(49)
 In general, the focus of CBT treatment 
is the present, not the past. Also, CBT is directly aimed at the complaints as 
experienced by patients in their daily lives. Finally, CBT relies on an active attitude of 
patients expecting them not only to be actively involved during sessions, but also at 
home by doing homework assignments. In a meta-analysis, the latter has been 
shown to improve benefits of treatment.(47)  
 
 1.4.3 Treating PD today: Combined treatments  
 
In clinical practice in the Netherlands, PD sufferers are regularly being prescribed 
medication by their general practitioner. When symptoms do not remit, patients 
may subsequently be referred to a general health clinic where they might be offered 
additional CBT. The reversed order (first CBT, than additional SSRI) is also 
encountered but probably somewhat less frequent. Besides adding one modality to 
the other, both treatment modalities can also be offered together as an integrated 
approach.  
 Delivering both CBT and pharmacotherapy as an integrated approach might 
facilitate both treatment modalities. CBT might be facilitated by adding 
pharmacotherapy because the medication might elevate mood, improve self-
directed exposure, and enhance self-appraisal of accomplishments. In turn, 
pharmacotherapy might be facilitated by adding CBT with respect to medication 
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acceptance, tolerance of side-effects, tolerance or relieve of withdrawal, and 
prevention of relapse.
(24)
 Next to possible advantages of combining treatments, there 
are also concerns. For instance, some experts believe that medication interferes with 
CBT by blocking physical fear reactions and thereby preventing patients to 
disconfirm erroneous cognitions.
(56) 
It is important to note that although combined 
treatment seems commonly recommended and is by some thought to facilitate both 
individual modalities; empirical support for the combined treatment is limited.
(56)
 
There is a clear lack of studies comparing monotreatments to the combined 
treatment (see also paragraph 1.4.4) with respect to short and especially long-term 
effectiveness. Other significant issues awaiting further investigation relating to the 
integrated approach include the optimal sequencing of treatments, the optimal 
duration of medication with respect to CBT, the optimal duration of CBT with respect 
to medication, and treatment rationales offered to patients and its relation to 
outcome.  
 
 1.4.4 General considerations on treatment allocation and patients’ preferences  
 
With more than one effective treatment modality being available, mental healthcare 
professionals might apply some general considerations in treatment allocation. They 
may consider one treatment modality more suitable for a particular patient than 
another based on clinical experience. Also, patients themselves might come to the 
treatment clinic with expectations concerning different treatment modalities. 
Empirical data underpinning treatment allocation is scarce however. There are some 
indications that patients prefer cognitive coping strategies over taking medication
(57)
 
but on the whole, little is known about patients’ preferences. Little is also known 
about the influence on outcome of treatment allocation based on preference. One 
study comparing PD patients treated with cognitive therapy by allocation and 
patients treated by preference did not find evidence for a moderating effect of 
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preference on treatment effect.(58) 
 Next to preferences patients might have beforehand, there is also a paucity of 
research on patient satisfaction after completing treatment. In a study comparing 
group behavior therapy and telephone behavior therapy for PD with AG, patients 
completed a satisfaction questionnaire which asked patients whether they found 
various treatment components useful. Also, ratings of ‘liking’ were collected for each 
component.
(59)
 For self-directed in vivo exposure, usefulness ratings were 
significantly higher than ‘personally liked’ ratings. For psycho-education, usefulness 
and liking ratings were both high. We found no studies evaluating patients’ 
satisfaction following a pharmacological treatment and no data on the comparison 
between psychological and pharmacological treatments regarding treatment 
satisfaction. 
 In general, the following considerations might be important in treatment 
allocation from the patient’s perspective. Patients having received CBT often 
experience a sense of control over their complaints that was not present before. 
Also, CBT patients might derive a sense of satisfaction from the fact that they 
themselves have been able to tackle their fears. After treatment completion they 
often feel confident about their ability to cope with possible future complains. A 
potential drawback of CBT is its intense and time consuming nature. Patients are 
expected to exercise not only during treatment sessions but also outside of the clinic 
in their daily lives. Some patients experience CBT as difficult because they feel 
confronted with various personal issues they had not foreseen.   
 The greatest advantage of pharmacotherapy is probably the fact that patients 
almost effortlessly reach a better level of functioning. This treatment does not make 
heavy demands on patients; it is easy and costs little time. Patients might still 
experience physical symptoms resembling panic but actual panic attacks might cease 
to occur. In general, patients feel less anxious. This might give them confidence and 
enables them to encounter situations and places they previously avoided because of 
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fear of subsequent panic attacks. A potential drawback of SSRI treatment is that an 
SSRI needs time to kick-in (on average: three to eight weeks) while patients often 
long for immediate relief. Also, during the first weeks of the SSRI use, patients often 
experience side effects, including elevated levels of anxiety, which usually abate as 
treatment continues. Other side effects however, may persevere while continuing 
treatment, for instance regarding sexual dysfunction. Women who experience panic 
complaints and who wish to become pregnant in the nearby future may for this 
reason feel reluctant to start pharmacotherapy. An often heard concern of patients 
is the fear of becoming dependent on medication. Another potential drawback is 
that some patients suffer from treatment adherence problems for instance because 
of trouble remembering to take medication on a daily basis. Also, once patients 
experience a relief from their complaints, they sometimes dread medication taper. 
Many patients express the fear that complaints will return after tapering medication. 
This problem should be tackled by providing clear information about what might be 
expected during and after medication taper.  
 The rationale that patients receive may also contribute to treatment satisfaction 
and possibly to treatment outcome. Patients receiving CBT are basically explained 
that panic attacks result from catastrophic misinterpretations of harmless bodily 
sensations. With pharmacotherapy, patients are usually explained that panic attacks 
result from a central neurochemical abnormality which causes the body’s ‘alarm 
system’ to be hypersensitive and pharmacotherapy should corrects this abnormality. 
Patients about to receive CBT might like the idea of controllability that is included in 
the CBT rationale. Patients about to receive SSRI might like the idea that it is not 
their fault that they experience these complaints; there is an identifiable cause 
outside of their control. Interestingly, patients receiving both CBT and SSRI might 
receive both rationales. The importance of these rationales and their possible 
influence on treatment effect has not been subject to research to date but might be 
an important issue in future studies, especially with respect to the combined 
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treatment. Data on attribution of effect might also gain insight in this matter: little is 
yet known about to which treatment modality patients attribute reached gains when 
receiving both CBT and SSRI. 
 In conclusion, more research is needed on the subject of treatment preference, 
treatment satisfaction, and on how patients explain possible improvement in 
relation to the treatment rationale they received.  
 
 1.4.5 Treatment guidelines 
 
Multidisciplinary treatment guidelines for mental health care in the Netherlands 
were developed from 2001; these guidelines are based on scientific data gathered in 
reviews and meta-analyses, and consensus when empirical data is lacking. The first 
Dutch treatment guidelines for anxiety disorders were finally published in December 
2003. For the present study however, patients were enrolled between April 2001 
and September 2003.  
 The following text is based on the latest revision of the guidelines which was 
published in 2009.(60) Regarding psychotherapy, exposure in vivo is recommended for 
PD patients with AG while panic management is advised when avoidance behavior is 
absent or limited. In the guidelines, panic management refers to different 
interventions such as coping, offering alternative and reassuring explanations for 
experienced symptoms, and interoceptive exposure. The panic control treatment 
(see section 1.4.2) is mentioned as an example of a panic management protocol. 
With respect to pharmacotherapy, SSRIs are considered the first treatment of choice. 
Benzodiazepines should only be considered as a later step in pharmacotherapy and 
only if CBT has been offered prior. Further, benzodiazepines may be used 
temporarily if starting an SSRI causes initial higher anxiety levels. Only for patients 
with a co-morbid severe depression, pharmacotherapy is advised as first-step 
treatment. When depressive symptoms start to wane, additive CBT may be started. 
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In the guidelines, a distinction is made between mild PD and severe PD. Other than 
suggesting that concurrent AG may affect the severity of the PD, no criteria for mild 
or severe PD are proposed however. Regarding treatment, it is suggested that in 
case of mild PD, CBT should be offered first before considering pharmacotherapy.  
 From a stepped-care perspective, the following algorithm is presented for 
severe PD with or without AG (because SSRIs are considered first choice, we will 
write SSRI in stead of pharmacotherapy): 
1. First step interventions (e.g. psycho-education, (computerized) self-help, 
counseling). 
2. Either SSRI or CBT. This choice can be made by the caregiver (e.g. therapist) 
and patient together. Evaluate after twelve weeks. If CBT is successful: 
relapse prevention and completion of treatment. If SSRI is successful, 
continue for one year, than offer relapse prevention and gradually taper. If 
SSRI is not successful: taper and subsequently start CBT. If CBT is not 
successful: end treatment and subsequently start pharmacotherapy. If CBT 
or SSRI remission is partial, go to step 3:  
3. Add pharmacotherapy to ongoing CBT of add CBT to ongoing 
pharmacotherapy. 
 
 The combined treatment is thus considered the next step in treating PD when 
monotreatment has been only partially successful. Note that in the guidelines, the 
presence or severity of AG may be of influence regarding choosing psychotherapy 
(e.g. exposure in vivo or panic management) and may partially influence the severity 
of the PD but in itself has no place within the proposed algorithm. 
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1.5 Empirical Studies  
 
Hereafter, we provide a review of empirical studies on the treatment of PD with or 
without AG with an emphasis on evidence derived from randomized controlled trials. 
It must be noted that PD has enjoyed considerable attention in the literature since 
its introduction in the DSM-III. We have limited our review by focusing only on 
studies investigating CBT and / or SSRI in the treatment for PD with a special interest 
in studies comparing these monotherapies to the combination of both (see sections 
1.5.1 through 1.5.5). Of further interest was data on cost-effectiveness of PD 
treatments (1.5.6) and conclusions regarding treatments for PD derived from several 
meta-analyses (1.5.7).  
 
 1.5.1 Cognitive behavioral therapy  
 
A number of studies established the superiority of cognitive behavioral treatments 
over no treatment waiting-list, a psychosocial placebo, or a pill placebo (for reviews 
on the effectiveness of CBT see(44,47,61,62) ). There is also some evidence for superiority 
over other active treatment modalities such as medication. To highlight a few 
individual studies; CBT was compared to a control group(63) and after six weeks CBT 
superiority was established. When compared to applied relaxation and 
imipramine,
(64) 
cognitive therapy was superior to both relaxation and imipramine 
after the acute treatment phase of three months. At 15-month follow-up, cognitive 
therapy was again superior to both applied relaxation and imipramine. CBT was 
compared to medication (the benzodiazepine alprazolam), pill placebo and waiting 
list control(65) and results indicated that CBT significantly outperformed the latter 
two. Another study also applying the panic control treatment(45) found this treatment 
protocol as effective as panic control combined with in vivo exposure.  
 With respect to long-term effectiveness, Brown et al.(66) reported that 47.6% of 
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patients having received CBT and seen for a 24-month follow-up still met criteria for 
high end-state functioning and had sought no further treatment during the follow-up 
period. Results suggested that PD patients treated with CBT do reasonably well over 
the long term but still suffer from periods of exacerbation of their PD. In another 
study three CBT modalities, standard, group, and brief CBT, were compared
(67)
 and 
results indicated a maintained beneficial effect of all modalities at a two-year 
naturalistic follow-up. It must be noted however that in this study, patients were 
allowed concurrent anxiolytic or antidepressant medication.  
 
 1.5.2 SSRI treatment 
 
A substantial body of research on the effectiveness of SSRIs is currently available.(68)  
Reported studies differ regarding several aspects e.g. patient samples, medication 
dosages, outcome measures, and design (e.g. whether or not double-blind). Overall, 
SSRIs are considered effective agents in the acute treatment of PD.
(69-71)
 Less clarity 
exists regarding the issue of using SSRI as maintenance therapy(72) and regarding 
relapse after treatment discontinuation. In the present thesis the following five SSRIs 
were evaluated, with references of published general reviews on these agents 
between brackets: fluoxetine(73), paroxetine,(31,74)  fluvoxamine,(75) sertraline,(76) and 
citalopram.(77)  
 Regarding the treatment of PD, especially the evidence for short term 












 Long-term studies are essential but are nevertheless conducted less 
frequently.(91) Lecrubier et al.(92) extended their 12-week study on the effects of 
paroxetine with another 36 weeks and found efficacy maintained. In another 
maintenance study, the continuing effect of paroxetine (as compared to 
clonazepam) was studied for a total of three years and effects were found to be 
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maintained.(93) In the same line of research, Schneier et al.(94) report on a 12- month 
study on fluoxetine and found that 67% of the patients reported moderate to 
marked improvement. Another one-year study
(95)
 established good results for 




 Next to long-term effectiveness studies, there is also a need for studies on the 
effect of maintenance after tapering. Patients who had been treated for sertraline 
for a year were subsequently randomized to continue sertraline for 28 weeks or to 
switch to placebo for 28 weeks.
(97)
 Significantly more patients experienced an 
exacerbation of panic symptomatology in the placebo group (33%) as compared to 
the sertraline group (13%). It was concluded that continuing sertraline prevented 
relapse. In a three year naturalistic outcome study using paroxetine(98) patients who 
had been on maintenance therapy for twelve months were given the choice to 
continue or taper and both groups were monitored. Only 14% of the patients who 
had discontinued medication relapsed during the follow-up phase. Note that patients 
were not randomized at random but by preference. 
 
 1.5.3 Monotherapies compared: SSRI-only vs. CBT-only 
 
Black et al.(99) randomly assigned 75 patients to receive cognitive therapy (CT), 
fluvoxamine, or placebo for eight weeks. Significant differences favoring fluvoxamine 
over placebo were observed at almost each week of the trial and for most outcome 
variables. CT was superior to placebo on some measures but not all. CT was not 
superior to fluvoxamine on any measure.  
 Bakker et al.(100) compared the relative efficacy of paroxetine, clomipramine (a 
TCA), placebo, and cognitive therapy in 131 PD patients. After 12 weeks, 37% of the 
patients treated with pill placebo, 59% of the patients treated with clomipramine, 
54% of the patients treated with CT, and 75% of the patients treated with paroxetine 
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were free from panic attacks. CT treatment yielded significant advantages over 
placebo only on two measures: panic frequency and patient global evaluation. As 
noted by the authors, the effects of CT fall behind those of most other controlled 
studies on the efficacy of CT for PD. This might be explained by the fact that, in 
contrast to other studies
(e.g. 101)
 severe agoraphobia was allowed. Also, the duration 
of PD was longer as compared to patient samples in other studies. 
 
 1.5.4 Combining treatments: SSRI use in the context of CBT and CBT use in the 
context of SSRI  
   
Apart from controlled studies investigating the differential effects of 
pharmacotherapy and CBT, five (mostly clinical case) studies were reported on in 
which CBT and SSRI were added in the context of the other. A group-CBT was offered 
to 24 pharmacotherapy non-responders(102) who achieved significant clinical gains 
after twelve weeks. Schmidt et al.
(103)
 investigated whether providing CBT to 22 
patients currently using antidepressants would facilitate these patients tapering their 
medication and reported that discontinuation in the context of CBT did not produce 
the adverse withdrawal symptoms that usually occur when tapering medication. A 
no discontinuation group without CBT was included in the design. In the same line, in 
a study by Whittal et al.(40) PD patients using an SSRI successfully discontinued SSRI 
treatment while receiving group CBT.  
 A related study investigated the possible benefits of adding an SSRI to a very 
brief CBT.
(104)
 Two groups of PD patients, one receiving placebo, the other 
paroxetine, received brief CBT and it was concluded that adding an SSRI to very brief 
CBT failed to improve outcome.  
 Patients who had not responded to CBT were randomized to receive additional 
paroxetine next to continued CBT or additional placebo next to continued CBT.(105) 
Patients in the first group improved significantly on anxiety discomfort and 
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agoraphobic behavior while patients in the latter group did not.  
 In summary, pharmacotherapy nonresponders responded well to group CBT.
(102)
 
Further, CBT nonresponders responded well to an SSRI addition.
(103)
 Also, CBT 
seemed to facilitate SSRI tapering.
(40,103)
 Finally, adding an SSRI had no beneficial 




1.5.5 Combining treatments: Studying different treatment modalities within one 
design  
 
Studies investigating a combined SSRI and CBT treatment package for PD with or 
without AG are scarce. In this section, we intended to only include studies which 
employ a combined CBT+SSRI treatment and both monotreatments. Only two of the 
studies described in this section however meet this criterion: Sharp et al.(106) and 
Azhar et al.(107) with the latter study providing too little information regarding 
methodological aspects to validly interpret the results. In Table 1.1, these two 
studies are included together with several other studies investigating a combined 
pharmacotherapy and CBT treatment modality. Note that in the Barlow et al. study, 
a TCA rather than an SSRI was investigated. Other differences between studies listed 
in Table 1.1 concern methodological aspects like different inclusion criteria (e.g. level 
of agoraphobia, additional benzodiazepines), applied treatment protocols, and 
treatment setting.   
 Oehrberg et al.
(108)
 found the combination of paroxetine and cognitive therapy 
to be more effective as compared to the combination of placebo and cognitive 
therapy for PD patients with or without AG who first had received a placebo for two 
weeks. 
 De Beurs et al.(109) compared five treatment groups and found the combined 
fluvoxamine and exposure group to be most effective after twelve weeks of 
treatment. Subsequently, a naturalistic follow-up was conducted after two years.(110) 
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Of the patients randomized in the original study to receive fluvoxamine, about 50% 
had been able to both taper medication and remain free of panic complaints. 
Patients in all treatment groups had further improved as compared to treatment 
endpoint and the superiority of the combined fluvoxamine and exposure group was 
no longer observed at follow-up. 
 Sharp et al.
(106)
 enumerate five methodological weaknesses observed in 
treatment outcome studies on PD performed up to the middle nineties. A first point 
of consideration concerns the fact that most studies did not require patients 
receiving CBT to be medication-free. Secondly, most studies employed a 
psychological-treatment-plus-placebo-treatment group instead of a psychological-
treatment-only group. The assumption here is that the first treatment is functionally 
equivalent to the latter. Since no evidence is present to confirm this assumption, 
studies should employ a psychological-treatment-only group as well. A third point of 
consideration concerns the lack of control for therapist contact. According to the 
authors, therapist contact time should be balanced in the psychopharmacological 
and psychological treatments in order to adequately compare these treatment 
modalities. Finally, most outcome studies were conducted in specialist clinics or 
hospital settings. To answer the question of practical utility and clinical applicability, 
studies should be conducted in the primary care setting. 
 In an attempt to correct the above-mentioned methodological flaws, Sharp and 
colleagues conducted a study in which five treatment groups were employed: 
fluvoxamine, placebo, CBT, fluvoxamine plus CBT, and placebo plus CBT. At end 
point, day 84, no significant differences were found between any of the active 
treatment groups (placebo thus not included). However, the results for the CBT 
groups seemed more robust than for the fluvoxamine groups. Six months after 
completing CBT and after discontinuing fluvoxamine, patients were re-assessed.  
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Table 1.1. Overview of studies comparing combined SSRI and CBT treatment to 
monotreatment(s)  
Authors (year of publication) 
Oehrberg et al. (1995) 
Subjects 
n = 120, DSM-III-R, PD with or without AG 
Duration of treatment 
12 weeks 
Treatment modalities 
1. P followed by paroxetine + CT followed by P 
2.  P followed by P + CT followed by P 
Main ingredients of treatments 
Paroxetine: titrated upwards to max 60 mg/day. No taper but switch to P after 
twelve weeks. 
Main results 
1 >  2 
Follow-up (duration and results) 
No follow-up 
Remarks 
- No information is provided regarding the contents of CT 
- Paroxetine was not investigated as monotreatment 
- C(B)T was not investigated as monotreatment 
Authors (year of publication) 
De Beurs et al. (1995) 
Subjects 
n = 88, DSM-III-R PD with moderate or severe AG 
Duration of treatment 
12 weeks 
Treatment modalities 
1. fluvoxamine followed by EIV 
2. P followed by EIV 
3. PPM followed by EIV 
4. EIV 
Main ingredients of treatments 
- Fluvoxamine: titrated upwards to 150 mg/day. No taper. 
- PPM: presenting a cognitive model of panic, hyperventilation provocation, 
respiratory training.  
- EIV: gradually prolonged self-exposure in vivo   
Main results 
- 1 > 2, 3 and 4 
- 2 and 3 ≈ 4 
Follow-up (duration and results) 
see De Beurs et al 1998 
Remarks 
Fluvoxamine was not investigated as monotreatment 
Page 30   
Table 1.1. continued. Overview of studies comparing combined SSRI and CBT 
treatment to monotreatment(s)  
Authors (year of publication) 
De Beurs et al. (1998) 
Subjects 
n = 71 
Duration of treatment 
see De Beurs et al. 1995 
Treatment modalities 
see De Beurs et al. 1995 
Main ingredients of treatments 
see De Beurs et al. 1995 
Main results 
- Between 61 and 67% of Pt panic free 
- No significant changes between groups 
- 51% recovered, 25% reliably changed, 24% unchanged 
- 77% received some form of additional treatment. Pt having received 1 required the 
least aftercare 
Follow-up (duration and results) 
2 year naturalistic FU 
Remarks    / 
Authors (year of publication) 
Sharp et al. (1996) 
Subjects 
n =  190, DSM-III-R PD with or without AG 





3. fluvoxamine + CBT 
4. P + CBT 
5. CBT 
Main ingredients of treatments 
- Fluvoxamine: fixed dosed, titrated upwards to 150 mg/day. Discontinued without 
taper at day 84. 
- CBT: Mainly exposure but no interoceptive exposure. 
Main results 
- 3 > 1, 2, 4, and 5 on rate of panic free Pt 
- 1 ≈ 3 ≈ 4≈ 5 on other measures 
- on CSC: 3 and 5 > 2 and 4  
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Table 1.1. continued. Overview of studies comparing combined SSRI and CBT 
treatment to monotreatment(s)  
Follow-up (duration and results) 
- FU at 6 months 
- Highest number of Pt who did not receive treatment during FU: 3 
- 3, 4 and 5 > 1 and 2 on CSC  
Remarks 
- A single therapist treated all Pt 
- Only Pt without additional treatment during FU were included in analyses 
Authors (year of publication) 
Stein et al. (2000) 
Subjects 
n = 33, DSM IV PD with or without AG 
Duration of treatment 
10 weeks 
Treatment modalities 
1. very brief CBT + placebo 
2. very brief CBT + paroxetine 
Main ingredients of treatments 
- Paroxetine: max 60 mg/day. No taper. 
- Very brief CBT: 3 sessions and self-help book 
Main results 
2 > 1 except on panic free status 
Follow-up (duration and results) 
No FU 
Remarks 
- Pilot study 
- Only two CBT therapists 
- CBT was not investigated as monotreatment 
- Paroxetine was not investigated as monotreatment 
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Table 1.1. continued. Overview of studies comparing combined SSRI and CBT 
treatment to monotreatment(s)  
Authors (year of publication) 
Azhar et al. (2000) 
Subjects 
n = 66, DSM IV PD 




2. CBT + fluvoxamine 
3. fluvoxamine 
Main ingredients of treatments 
- Fluvoxamine: max 200 mg/day. No taper. 
- CBT: according to Clark. 
Main results 
1 and 2  > 3 
Follow-up (duration and results) 
No FU 
Remarks 
- No information regarding AG status 
- Methodological information very limited 
Authors (year of publication) 
Barlow et al. (2000) 
Subjects 
n = 312, DSM-III-R PD with or without mild AG 
Duration of treatment 
For all Pt: 3 months. For responders: 9 months 
Treatment modalities 
1) CBT  
2) imipramine   
3) P  
4) CBT +  imipramine  
5) CBT + P 
Main ingredients of treatments 
- Imipramine: max 300 mg/day. Taper (1-2 weeks) after 9 months.  
- CBT: interoceptive exposure, cognitive restructuring and breathing retraining. 
Main results 
- 1 and 2 > 3 
- among responders: 2 produced higher quality of improvement 
- 4 confers limited advantages acutely but at end of maintenance: 4 > 1 and 5 
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Table 1.1. continued. Overview of studies comparing combined SSRI and CBT treatment to 
monotreatment(s)  
Follow-up (duration and results) 
- Fu at 6 months 
- 1 and 5 > 3 
- 2 and 4 ≈ 3 
- Highest relapse rate for 4 
Remarks 
- Imipramine is not an SSRI 
- Moderate or severe AG excluded 
Abbreviations: PD = panic disorder, EIV = exposure in vivo, B = benzodiazepines, n = number of participants at start 
treatment, Pt = patients, AG = agoraphobia, CBT = cognitive behavioral therapy, P = placebo, PPM = psychological 
panic management, FU = follow-up, CSC = clinically significant change, CT = cognitive therapy, > outperformed, ≈ no 
significant differences. 
 
Of the patients who had received no additional treatment during follow-up, the 
proportion of patients achieving clinically significant change was consistently higher 
for the groups which received psychological treatment (fluvoxamine plus CBT, 
placebo plus CBT, and CBT alone) as compared to the medication-only groups 
(fluvoxamine and placebo). 
 In sum, results showed that fluvoxamine produced considerable gains but there 
was a fall-off in these gains over follow-up. CBT also produced gains and these were 
better maintained over follow-up. There was some evidence that improvement was 
more rapid in the combined CBT and fluvoxamine group as compared to CBT alone. 
The generalizability of results is restricted due to the fact that only a single therapist 
performed all treatments. Also, the fact that patients in all treatment groups 
received an equal amount of treatment sessions and the same amount of therapist 
contact time jeopardizes generalizability to clinical practice. In clinical practice, 
patients receiving medication generally spent less time with their pharmacotherapist 
as compared to the time that patients receiving CBT spent with their therapist. 
 In a study by Azhar et al.,(107) CBT and CBT combined with fluvoxamine 
outperformed fluvoxamine-only after nine weeks but as stated, too little information 
regarding important methodological aspects is provided. A study comparing very 
brief CBT + paroxetine to very brief CBT + placebo established superiority of the first 
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over the latter.(104)  
 A large randomized trial was conducted by Barlow and colleagues.
(101) 
Patients 
were randomly assigned to receive imipramine, CBT, placebo, CBT plus imipramine, 
or CBT plus placebo. Although imipramine is not an SSRI but a TCA, the study is 
included in this section because it is well-designed, involved a large study sample and 
because there is some evidence to suggest that the effect of a TCA may be more or 
less comparable to those of the SSRIs. The total study duration was fifteen months, 
consisting of an acute treatment phase of three months, a maintenance phase of six 
months, and subsequently a follow-up phase of another six months. During the acute 
treatment phase, CBT patients received eleven 50-minute sessions. Patients 
receiving imipramine visited their pharmacotherapist eleven times as well. During 
the maintenance phase, treatment was continued on a monthly basis. Responders to 
these nine months of treatment then discontinued the treatments and were 
assessed again six months later. Medication was discontinued after nine months of 
treatment by tapering during a one- to two-week period. 
 Results indicated that both imipramine and CBT were more effective in treating 
PD than placebo. After nine months, imipramine had produced a superior quality of 
response in imipramine responders as compared to the quality of the response to 
CBT in CBT responders. At follow-up, CBT proved to have more durability. A 4% 
relapse was observed for patients who had received CBT, compared to a 25% relapse 
for patients who had received imipramine. Also, CBT seems to be somewhat better 
tolerated. Acute co-administration of imipramine and CBT resulted in limited benefit 
over monotherapy, so a surplus value of a combined therapy was, as in the Sharp 
study, not established. Also, the addition of CBT did not mitigate relapse following 
medication discontinuation.  
 A limitation of the Barlow et al. study is that patients with severe agoraphobia 
were excluded. Results are thus only generalizable to patients with no or mild 
agoraphobia. 
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 1.5.6 Meta-analytic reviews 
 
Several meta-analytic reviews have compared psychopharmacological, cognitive 
behavioral and combined treatment packages for PD with or without AG.
(62,69,111)
 An 
overview of meta-analyses is presented by Mitte.
(69)
 As she points out, several 
methodological problems associated with meta-analyses limit the validity of results. 
In an attempt to overcome these problems a random effects-model was applied in a 
meta-analysis including 124 studies.
(69)
 Results of this meta-analysis suggested that in 
the aggregate, CBT was equally or sometimes more effective as pharmacotherapy. 
No significant differences between CBT as monotreatment and CBT combined with 
pharmacotherapy were found. 
 The most recent meta-analysis that was published(112) included 21 randomized 
trials investigating the effects of (combined) psychotherapeutical and 
pharmacotherapeutical treatments for PD with or without AG. Psychotherapeutical 
treatments included behavior therapy, cognitive therapy, a combination of cognitive 
and behavior therapy, or other psychotherapy. Pharmacotherapeutical treatments 
included administering tricyclic antidepressants, SSRIs and monamine oxidase 
inhibitors. Results indicated that in the acute treatment phase, the combined 
treatments was 1.24 times more likely to produce a response compared to 
pharmacotherapy as monotreatment and was 1.6 times more likely to produce a 
response compared to psychotherapy as monotreatment and as compared to 
psychotherapy plus placebo. This advantage of the combined treatment was 
maintained while treatment was continued. Based on nine studies who conducted 
follow-up assessments, the advantage of the combined treatments disappeared 
after discontinuation of treatment. The combined treatment had a sustained 
advantage at follow-up over antidepressant therapy but no longer were there 
advantages over psychotherapy. Subgroup analyses revealed similar results for 
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studies focusing on PD patients with AG as compared to studies focusing on PD 
patients without AG. 
 
 1.5.7 Cost-effectiveness of PD treatments 
 
PD carries considerable social and economic costs.
(12,113-115)
 In the most recently 
published meta-analysis on PD however,
(112)
 the authors note that none of the 
included studies reported on cost issues. Indeed, data evaluating costs associated 
with PD and the treatment of PD are scarce.
(116)
 Further, drawing conclusions from 
the small number of studies is hampered by methodological differences between 
studies.(117) In current times, with limited health care resources, the question of cost-
effectiveness is an important one.(118) Only a few studies however have not only 
evaluated treatment by their effectiveness but also looked into the cost-benefit 
ratio.(116,118-120) 
 Our special interest in light of the current thesis goes to studies comparing costs 
of CBT and medication treatment within a single design. One such study is the 
previously discussed multi-site randomized trial comparing imipramine, CBT, and 
their combination for PD.(101) In the economic evaluation of these data, 
monotreatments proved to be associated with greater cost-efficacy as compared to 
the combined treatment. After three months, imipramine was the most cost-
efficacious treatment and six and nine months after treatment termination, this was 
the case for CBT.
(116)
 It is important to note that only direct costs were assessed in 
this study. No studies on PD to date have examined the cost-effectiveness of direct 
and indirect costs (e.g., productivity loss) of the combined CBT+SSRI treatment 
compared to both monotherapies within a single design. 
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1.6 Summary empirical findings  
 
Regarding CBT and SSRI as mono-treatments, evidence for short-term effectiveness 
is abundant. Long-term studies have been conducted less frequent. Regarding CBT, 
patients maintain high end state functioning in about half of the cases.
(66)
 There is a 
need for studies investigating long-term effectiveness of CBT without concurrent 
medication. Regarding SSRI, patients generally remain panic free while on 
maintenance treatment but may relapse following medication taper. About one third 
of patients experienced a renewal of panic complaints after discontinuing 
medication within 28 weeks
(97)
 but more studies are needed regarding this matter. 
 Two studies comparing both monotreatments found no superiority of CT over 
fluvoxamine(99) and paroxetine(100). Note that in these studies, exposure was not a 
part of the CBT that was offered to patients. Investigations of SSRI use in the context 
of CBT and CBT use in the context of SSRI reveal that adding one modality to another 
may benefit patients previously not responding. For the present thesis, studies 
applying a combined SSRI and SSRI treatment are of particular interest. We are 
aware of six studies investigating the effectiveness of a combined pharmacotherapy 
and CBT treatment for PD and only two of those compared this combined treatment 
to both monotreatments. Overall, the combined treatment outperformed placebo 
and monotreatments on short term, up to twelve weeks(104,106-109) and as 
maintenance treatment.
(101)
 Patients receiving pharmacotherapy were asked to taper 
medication in only two out of these six studies: in one study after 84 days
(106)
, and in 
one study after nine months.
(101)
 Both studies conducted a follow-up six months after 
treatment termination and found effects best preserved in treatment groups having 
received CBT. In the Sharp et al. study, patients in the combined treatment had 
needed the least additional treatment during follow-up. In the Barlow et al. study 
there was some evidence for a detrimental effect for the combined treatment being 
associated with a higher relapse rate as compared to the other groups. The other 
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studies listed in Table 1 report no post-treatment results except for the naturalistic 
follow-up study by De Beurs et al.
(110)
 who found no loss of gains for the combined 
treatment group at follow-up. 
 In conclusion, more research on the effectiveness of the combined treatment 
both on short term but also with respect to maintaining treatment gains after 




1.7 Discussion empirical findings  
 
 When comparing the different studies on the treatment of PD, some points 
deserve special consideration. First, drawing conclusions from different studies on 
CBT and/or SSRI is difficult due to methodological differences. Although recent meta-
analyses apply sophisticated statistical techniques, the merits of different modalities 
(mono- and combined), will surface especially in studies investigating different 
treatment modalities within a single design.  
 Second, we would like to stress the importance of covering multiple areas of 
functioning when assessing treatment effectiveness. In some (efficacy) studies a 
reduction in panic attack frequency serves as the primary outcome measure thereby 
disregarding the multiple dimensions defining the morbidity of PD.(85) 
 Third, several authors stress the relevance of generalizability of findings by 
enhancing external validity. At this time, we would like to reflect on the issue of 
effectiveness versus efficacy. Once efficacy studies have shown a particular 
treatment to be efficacious under ideal conditions, effectiveness studies ask the 
question of what happens when this particular treatment is delivered in real-
practice, under care as usual, and to a broad and representative group of 
patients.(121-123) When efficacy and effectiveness are seen as extremes on a 
dimensional scale, most studies described in this chapter are situated more on the 
efficacy than on the effectiveness side. Comparing CBT and/or SSRI in real-world 
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settings is considered an important endeavour which also enables evaluating 
treatments from an economic viewpoint.   
 In reviewing the existing literature on the treatment of PD, we conclude that 
there is a need for more data especially concerning the combined CBT+SSRI 
treatment. Questions awaiting further study include: Is the combined CBT+SSRI 
treatment more effective than either monotreatment? Is there a difference 
regarding different patient types e.g. patients with or without AG? What is the effect 
of tapering medication in patients receiving an SSRI? In summary, we observe the 
following points of consideration in designing future studies:  
- There is a need for studies on psychological versus psychopharmacological 
treatments versus combined treatments within a single design. 
 - There is a need for long-term studies with additional treatment during follow-up 
well documented. 
- There is a need for including patients both with (mild, moderate or severe) and 
without AG within a single design.  
-  In choosing outcome measures, there is a need for data covering multiple areas of 
functioning acknowledging the different aspects of PD morbidity.  
 - There is a need for more data on treatment gains after discontinuation of the SSRI. 
 - There is a need for studies on the effectiveness of PD treatments, e.g. data on 
‘real’ patients receiving treatment under care as usual conditions and being treated 
in real-world settings. 
 To satisfy these needs, a randomized clinical trial was conducted in the 
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2.1 General introduction randomized controlled trial 
 
A randomized clinical trial was conducted in the Netherlands comparing CBT, SSRI, 
and their combination aimed at treating PD with or without AG. The present thesis 
presents the results of this randomized clinical trial. Patients were treated for one 
year including medication taper and subsequently seen twice during the second 
(follow-up) year of the study. Tapering medication allowed us to investigate each 
modality’s potential for maintaining results after treatment discontinuation. Our 
study is couched within current views on the importance of gathering data relevant 
for clinical practice. The overall goal of the study was to establish the best possible 
treatment for patients with PD with or without AG. This chapter presents overall 
methods, detailed information regarding applied treatments, and an overview of 
included studies and research goals. To conclude this introductory section, we will 
highlight some main characteristics of the present study: 
- Three treatment modalities were investigated: CBT, SSRI, and CBT and SSRI 
combined. 
- Duration treatment one year (including tapering medication). 
- Duration study two years; two follow-ups in second year. 
- Patients without or with mild, moderate, or severe AG were included. 
- Data on costs were collected. 











This study was approved by the medical ethics committee of the University Medical 
Center in Groningen and subsequently by institutional review boards at each site. 
Patients were treated in eleven treatment facilities located throughout the 
Netherlands. Three kinds of sites participated: 1. university training and research 
centers (n = 2), 2. university research clinics (n = 2), and 3. regular mental health 
clinics (n = 7).  
 Sample size calculation was done beforehand and power analysis based on the 
Hamilton Anxiety Rating Scale (HAM-A),(1) also anticipating dropout, revealed that 
152 patients had to be included. Regular patients seeking care at the participating 
treatment centers and meeting the study criteria were asked to participate in the 
study. Patients were also recruited through media advertisements and flyers which 
were distributed in general practitioner offices. Patients were enrolled between April 
2001 and September 2003. Screening consisted of a structured interview, the 
M.I.N.I.(2) checking DSM-IV criteria for Axis I disorders.   
 Randomized patients suffered from a primary diagnosis of PD with or without 
AG. Inclusion was restricted to patients between 18 and 65 years of age. Patients 
who were pregnant, lactating, suicidal, psychotic, or severely depressed were 
ineligible to participate in the study. Further exclusion criteria comprised 
contraindications to either treatment or a concurrent competing treatment. Patients 
were not allowed to use psychotropic drugs except small doses of benzodiazepines 
(maximum the equivalent of 20 mg oxazepam per day). Patients were not required a 
predefined level of baseline severity (e.g. a minimum score on the HAM-A or a 
minimal number of panic attacks). The presence of comorbid Axis II disorders or Axis 
I disorders, other than severe depression or psychosis, was no reason for exclusion. 
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 Written informed consent was obtained prior to randomization and after a full 
explanation of procedures. Randomization was stratified by site. For each site, an 
envelope containing a number of raffle tickets (CBT, SSRI, or CBT+SSRI) was present. 
The number of raffle tickets in the envelope was based on the number of patients 
the particular site expected to recruit. After drawing lots, the raffle tickets were not 
placed back in the envelope. When a patient met study criteria, local coordinators of 
the participating centers contacted a member of the research team who performed 
the drawing at the University Medical Center in Groningen by phone or e-mail. 
Beforehand, no information about the patient was interchanged.  
 After randomization, participating patients were assessed before starting 
treatment (pretest), after nine months of treatment (posttest 1), immediately after 
discontinuation of treatment (posttest 2), and six and twelve months after treatment 
discontinuation (follow-up 1 and follow-up 2). In between pretest and posttest 1, 
patients received 18 CBT and/or 9 SSRI sessions. In between posttest 1 and posttest 
2, CBT patients received additional booster sessions resulting in up to 21 CBT 
sessions from pretest to posttest 2. SSRI patients tapered their medication during 
this period in which three additional sessions were scheduled resulting in up to 12 
SSRI sessions from pretest to posttest 2.  
 Assessment consisted of completing a booklet with self-report questionnaires, 
and visiting a research assistant to be interviewed. Also, through-out the first 
treatment year patients were asked to register the frequency of panic attacks. 
Specific measurements (e.g. questionnaires) are introduced in further detail in 
subsequent chapters of the thesis.  
 All interviews for the study were conducted by carefully trained research 
assistants who were not involved in delivering the actual treatments and did not 
belong to the research team. These research assistants were not blind to treatment 
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allocation. In the two university training and research centers, CBT was delivered by 
master-level student-therapists who underwent extensive training and who were 
closely supervised during weekly gatherings. In the remaining treatment centers, CBT 
was performed by experienced clinical psychologists. All therapists received ongoing 
supervision on site. The SSRI treatment was delivered by experienced psychiatrists, 
psychiatrists in training or trained physicians.  
 Following each treatment session, all therapists completed a detailed form 
regarding the content of that session. These forms were evaluated by the research 
team in order to check treatment adherence. No physiological treatment checks (e.g. 
blood) were applied. The research team, situated at the University Medical Center in 
Groningen, was always available for any questions regarding the treatment(manual) 
or study design. Each of the three treatments was delivered in every treatment 
center. Before the start of the study, coworkers of all participating treatment centers 
assembled to discuss the treatment modalities and to integrate existing views. 
Because the study was designed to follow common practice in the treatment of PD, 
the treatment manuals were based on the outcomes of these gatherings to satisfy as 
closely as possible “care as usual” requirements. The manual-based treatments are 
introduced below. 
 
 2.2.1 Cognitive behavioral therapy (CBT) 
 
The CBT protocol was based on the work of Clark, Craske, and Barlow.
(3-5)
 In order to 
prevent return of fear, sessions were expanded-spaced in the course of treatment 
(from once a week to twice a week, and from session 16 onward with 5 week 
intermissions).
(6)
 During the first session, the patient received information about the 
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nature of the disorder and the treatment to be delivered. The treatment rationale 
was delivered based on the model depicted in Figure 2.1.   
 In the second session, interoceptive exposure was introduced and exercises 
were performed (throughout sessions 2 to 6) to provoke relevant bodily sensations 
which may resemble those symptoms experienced during a panic attack. By 
performing those exercises patients learn that bodily sensations can indeed be 
provoked, that these sensations spontaneously subside, and that these sensations
(7)
 
are not dangerous and are not followed by any harmful consequences.  
 
 Figure 2.1. CBT model of panic disorder as used in offering the treatment 
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 From session 6 onward, patients received cognitive therapy. During cognitive 
therapy, patients were first taught about the role of thoughts in generating 
emotions. Detailed discussion of emotions and associated cognitions led to the 
identification of specific beliefs, appraisals and assumptions. Patients were 
encouraged to examine the validity of their cognitions by considering all the 
available evidence and actively collecting new evidence. Both automatic appraisals 
(such as “if I panic, I will faint”) and core-level beliefs or schemata (such as “I am 
weak”) were examined in this manner. Based on this hypothesis testing, alternative 
cognitions were generated that were more evidence based and were experienced by 
patients as helping.  
 In the tenth session, exposure in vivo was introduced. When starting exposure 
in vivo, an individualized fear hierarchy was constructed. In between sessions, 
patients conducted self-guided exposure in vivo. Each exposure assignment was 
carefully designed and written down jointly by therapist and patient. Patients were 
instructed to stay in the feared situation until their anxiety level had dropped 
significantly. Safety-seeking behaviors were prohibited during the exposure 
exercises.  
 From session 10 onwards, both cognitive therapy and exposure in vivo were 
offered. The emphasis on one of both was left to the clinical judgment of the 
therapist. Homework assignments were given throughout the treatment and were 
thoroughly discussed at the beginning of each session. Each new treatment 
component was introduced with a separate treatment rationale. These rationales 
were handed-out to patients on paper so they could read them at home.  
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2.2.2 SSRI treatment 
 
Patients randomized to receive pharmacological treatment either alone or in 
combination with CBT, received SSRI treatment for one year including medication 
taper. Patients receiving an SSRI visited their therapist 9 times, with weekly sessions 
during the first month and the remaining sessions distributed evenly over the 
treatment period. Each visit lasted approximately 20 minutes. SSRI prescriptions 
were in conformance with the pharmacotherapeutical guidelines as formulated by 
the Dutch Psychiatry Association.(8) Pharmacotherapists could choose between 5 
SSRIs currently prescribed in the Netherlands: fluvoxamine, fluoxetine, paroxetine, 
sertraline, and citalopram.  
 During the first SSRI session, patients received some general information on the 
role of serotonergic pathways in the brain involved in anxiety disorders and the 
working of SSRIs in panic disorder. Patients were administered a minimum dosage 
which was titrated upwards up to the effective range in the first month, and adjusted 
according to clinical response and tolerability. Pharmacotherapists were instructed 
to withhold from therapeutical interventions in order to avoid hidden exposure. 
Initiatives for exposing oneself to avoided situations were left to the patient.  
 
 2.2.3 Combined CBT+SSRI treatment 
 
This treatment was administered according to the CBT and SSRI manuals. The two 
treatments started simultaneously and were delivered parallel. The CBT was 
delivered by the CBT therapist and the SSRI treatment was delivered by the 
pharmacotherapist.  
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2.3  Outline and aims of present thesis 
 
The overall goal of the studies in the present thesis is to make a contribution to the 
on-going search for the best possible treatment for patients suffering from PD. To 
this end, we evaluated three empirically supported treatment modalities on short 
term, as maintenance treatment and post-treatment after discontinuation. Also, we 
aimed at testing the ‘context-safety hypothesis’ for which, based on outcome from 
treatment effectiveness studies, only limited evidence exists up to date. Additionally, 
the role of concurrent AG was investigated. Determining differential rate of 
improvement is also a goal of the present thesis. Finally, we evaluated treatment 
modalities economically e.g. determined their cost-effectiveness.  
 The present thesis starts with a general introduction. Chapters three through 
seven present the study results. To limit overlap between chapters, in the method 
sections of chapters three through seven only information regarding specific 
methods, relevant for the particular chapter, is presented. More general information 
on methods and design relevant for all studies presented in this thesis, are described 
only in the current chapter; chapter two. 
 In chapter three, treatment results after nine months are presented. The 
objective was to establish whether CBT+SSRI was more effective than either CBT- or 
SSRI-only after nine months of treatment before medication taper, and to evaluate 
any differential effects between the monotreatments.  
 In chapter four, long-term results are presented. The three treatment 
modalities were compared up to the second follow-up, twelve months after 
treatment discontinuation, in order to examine the differential long-term 
effectiveness of the three treatment modalities with the ultimate goal of 
determining the most effective treatment for PD with or without AG. Also in this 
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chapter, the relationship between treatment outcome and seven predictor variables 
was investigated. These variables included treatment site, baseline agoraphobia, 
duration of illness, Axis I en Axis II comorbidity, additional benzodiazepine use, and 
additional treatment during follow-up.  
 Next to pre-post outcome measures we also collected more continuous data. In 
order to establish possible differences regarding rate of improvement, frequency of 
panic attacks was assessed through-out the whole year of active treatment and 
subsequently analyzed. The results of these analyses are presented in chapter five. 
Research goals were to examine the rate of improvement in panic attack frequency 
during treatment and to establish possible differential effects in rate of improvement 
across treatment modalities. Also, the effect of tapering medication across 
treatment modalities was examined. Finally, the relationship between rate of 
improvement in panic frequency and baseline severity of agoraphobia was 
examined.  
 Chapter six presents the economic evaluation of the three treatment 
modalities. The following research question was addressed: Which intervention, CBT, 
SSRI, or CBT+SSRI is most cost-effective in the treatment of patients with PD with or 
without AG?   
 Finally, in chapter seven, overall results of the presented studies are discussed. 
Limitations are presented and suggestions for further research are provided. 
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The objective of the present study was to establish whether the combination of CBT 
with SSRI was more effective in treating PD than either CBT or SSRI alone, and to 
evaluate any differential effects between the monotreatments. PD patients (n = 150) 
with or without AG received CBT, SSRI, or CBT+SSRI. Outcome was assessed after 
nine months, before medication taper. CBT+SSRI proved clearly superior to CBT in 
both completer and ITT analysis. Completer analysis revealed superiority of CBT+SSRI 
over SSRI on three measures and no differences between CBT and SSRI. ITT analysis 
revealed superiority of SSRI over CBT on four measures and no differences between 
CBT+SSRI and SSRI. It was concluded that both the monotreatments (CBT, SSRI) and 
the combined treatment (CBT+SSRI) proved to be effective treatments for PD. At 
posttest, CBT+SSRI was clearly superior to CBT but differences between CBT+SSRI 
and SSRI, and between SSRI and CBT, were small.  
 





The life-time prevalence rate for PD without AG is estimated at 3.7%, and for PD with 
AG at 1.1%. 
(1)
 In clinical samples, the majority of the PD patients also suffer from AG. 
There is a wealth of data supporting the efficacy of both Cognitive-Behavioral 
Therapy (CBT) and pharmacotherapy using Serotonin Selective Reuptake Inhibitors 
(SSRI) in the treatment of PD.
(2-5)
 
 The successes of both pharmacotherapy and psychological treatments have led 
to the hope that the combination of these modalities might further increase efficacy. 
The added value of a combined treatment may stem from an attenuating effect of 
the medication on anxiety which in turn might facilitate the exposure component in 
CBT.(6) It is suggested however, that this attenuating effect lasts only as long as 
medication is continued.(7) If this is true, the superiority of the combined treatment is 
most evident when treatment effect is assessed before medication taper.    
 Several studies investigated the efficacy of the combination of antidepressants 
with CBT.(8-17) However, only two studies compared both monotreatments (CBT-only 
and antidepressants-only) with a combination of both.(8;16)  
 Sharp et al.(16) compared five treatments: CBT + fluvoxamine, fluvoxamine, CBT, 
CBT + placebo, and placebo (n = 190). After twelve weeks, before medication taper, 
the combination of CBT + fluvoxamine was found to be equally effective as the other 
active treatments. A similar design was employed in the study by Barlow et al.(8) 
Patients (n = 312) were randomly assigned to receive CBT + imipramine, imipramine, 
CBT, CBT + placebo, and placebo. After nine months, before medication taper, the 
combination of CBT and imipramine was superior to all other treatments on one out 
of two main outcome measures, a clinician rated scale of PD severity.  
 To our knowledge, head-to-head comparisons between CBT and 
antidepressants were made in five studies.(8;16;18-20) Before medication taper, Clark et 
al.(20) found imipramine and Cognitive Therapy (CT) to be equally effective, while 
Baker et al.(18) and Black et al.(19) both found an SSRI treatment to be superior to CT. 
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In the Barlow et al. and Sharp et al. studies,
(8;16)
 no significant differences were 
detected between CBT-only and pharmacotherapy-only.  
 In sum, some evidence favoring the combined treatment over monotreatments 
at treatment endpoint was established by one study with imipramine,(8) while no 
add-on effect of the combined treatment was found by another study with 
fluvoxamine.(16) Further, studies show either no differences between CBT and 
pharmacotherapy, or results favor the SSRI treatment. 
 When reviewing the data, two related issues must be taken into account. First, 
the delivered CBT-ingredients differ substantially which makes it difficult to compare 
overall results. Although consensus has not been reached regarding which CBT 
components are essential and which components might be redundant in the 
treatment of PD with and PD without AG, (in vivo) exposure is generally considered 
to be superior to CT in treating AG.(21) In both studies that yielded results favoring 
SSRI over CT, exposure techniques were not applied notwithstanding the fact that 
moderate to severe agoraphobics participated in these studies.(18;19) Second, 
although all studies included patients with PD, they differed on the inclusion of 
agoraphobics. For instance, Barlow et al.(8) included only patients with no or mild AG. 
Accordingly, methodological differences among studies preclude drawing 
unambiguous conclusions on outcome.  
 As a contribution to the quest for the best possible treatment for patients 
suffering from PD with or without AG the present study evaluated three treatments: 
CBT, SSRI, and the combination of both (CBT+SSRI). Because previous efficacy studies 
have established the superiority of the treatments under scrutiny over placebo,(3;4) a 
placebo group was not included. Our goal was to establish the effectiveness of 
treatment for PD in daily clinical practice and to ensure external validity, treatments 
were delivered at both research and non-research sites, within a naturalistic context. 
It was expected that any benefits of the combined treatment would be most obvious 
before medication taper. Therefore, in line with the Barlow et al. study,(8) posttest 
was scheduled after nine months of treatment so that patients had ample time to 
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benefit from treatment. Medication taper started after posttest was conducted.  
The objective was to establish whether CBT+SSRI was indeed more effective than 





Randomized patients suffered from a primary diagnosis of PD with or without AG. 
Once included, AG level was assessed by the first author based on chart review and 
the structured interview. Patients were classified as not suffering from AG, or 
suffering from mild, moderate or severe AG following guidelines set forth by the 
DSM-III-R. Patients received CBT, SSRI, or CBT+SSRI. Posttest was completed after 
nine months before medication taper; i.e. after 18 CBT sessions and/or 9 SSRI 
sessions. Patients in the CBT group received up to 18 CBT sessions each lasting 
approximately 50 minutes. Patients receiving an SSRI visited their therapist 9 times, 
with weekly sessions during the first month and the remaining sessions distributed 
evenly over the treatment period. Each visit lasted approximately 20 minutes. In the 
combined treatment CBT and SSRI started simultaneously and were delivered 
parallel. The CBT was delivered by the CBT therapist and the SSRI treatment was 
delivered by the pharmacotherapist.  
 
 Assessment     
 
In the present study we will report on six outcome measures: four continuous 
measures (regarding avoidance, anxiety, depression, and general psychopathology) 
and two categorical measures (responder status and panic free status). 
 Patients were defined panic free when they reported no panic attacks in a 
panic-log during a two week period after nine months of treatment (posttest). Also 
at posttest, PD severity and degree of improvement were evaluated by both the 
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patient and an independent rater using the Patient Global Evaluation (PGE), and the 
Clinical Global Improvement scale (CGI) respectively.
(27)
 On the improvement scales, 
a score of 1, 2 or 3 (very much improved to improved) was needed to meet 
responder criteria. On the severity scales, a score of 1 or 2 (no complaints or only 
mild complaints) was needed. Patients were classified as responders when they met 
these criteria for at least three out of four PGE/CGI scales (PGE Improvement, PGE 
Severity, CGI Improvement, and CGI Severity). 
 The Hamilton Anxiety Rating Scale (HAM-A)
(28)
 and the Hamilton Depression 
Rating Scale (HAM-D)
(29)
 were administered by trained research assistants. Two self-
report questionnaires yielded information regarding agoraphobic avoidance (the 5-
item Agoraphobia subscale of the Fear Questionnaire (FQ-AG),(30) and regarding 
general psychopathology (the total score on the Symptoms Checklist (SCL-90).(31;32)  
 
 Statistical Analyses 
    
Pretest differences between randomized groups were analyzed by univariate 
analyses of variance (ANOVAs) or nonparametric equivalents if called for. Chi-square 
analyses, Fisher Exact tests, and analysis of covariance were used to detect possible 
site differences. Time effects per treatment were analyzed with t-tests for 
dependent samples. Differential treatment effects were analyzed twice; for the 
completer (n = 100) and the intent-to-treat (ITT; n = 145) samples. In the ITT analysis, 
pretest scores for dropout patients were carried forward to posttest as an 
assumption of non-response or return to pretest level. Note that because no pretest 
scores for responder status were present, only completer results are available for 
this particular outcome measure. 
 Chi-square analyses were used to investigate overall differences in responder- 
and panic-free rates. Pair-wise differences between proportions were evaluated by 
the Wilson 95% confidence interval (CI) around this difference.(33) Analyses of 
covariance (ANCOVAs), using the pretest score as covariate, were used for all 
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continuous measures. Contrasts (non-orthogonal) were computed to evaluate pair 
wise differences among the adjusted means. For the multiple comparisons, alpha 
levels were corrected according to the Bonferroni-Holm procedure.
(34)
 When 
CBT+SSRI was compared to either monotreatment, the one-tailed P-value was used. 
Post hoc effect sizes (indexed by Pearson’s correlation coefficient r = √ t2/t2+ df) 
which ranges from 0 to 1) were calculated for both the within-group pre- to posttest 
changes and all between-group comparisons. According to suggestions made by 
Cohen,
(35)
, an effect size of ± .10 constitutes a small effect, an effect size of ± .30 
constitutes a medium effect, and an effect size of ± .50 constitutes a large effect.  




 Intake summary and pretest analyses 
 
One hundred and seventy-eight eligible patients were seen for screening (see Figure 
3.1). Subsequently, 150 patients started with CBT+SSRI (n = 49), CBT (n = 53), or SSRI 
(n = 48). In total, 54.7% of the sample was female (see Table 3.1). Mean age was 37.5 
years (range 18-61 years). 
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Unwilling to participate: n=9
Loss of Eligibility: n=9




Randomized to CBT:           
n=55
Dropped out: n=21






























Received pretest and at least 
one CBT+SSRI treatment 
session: n=49
Received pretest and at least 
one CBT treatment session: 
n=53
Received pretest and at least 





Withdrew after learned 
condition: n=3
Withdrew after learned 
condition: n=2




No data available: Completed CBT before 9 months due to early treatment success. 
 
 Sixty-three patients were treated at the two university training and research 
centers, 42 at the two university research clinics, and 45 patients at the seven 
regular mental health clinics.  
 When analyzing pretest scores, a significant difference was detected on the CGI 
(F=5.7; df=2 ; P = 0.004) indicating that patients treated at the university research 
clinics had somewhat higher pretest CGI scores than patients treated at the other 
sites. Also, the level of completed education was lower for patients treated at non-
research sites as when compared to patients treated at research sites (χ2 = 8.8 ; df = 
3 ; P = 0.03). No other significant site differences were detected at baseline (all P ≥ 
0.22).  
 The classification of AG types (no, mild, moderate, severe) was supported by 
pretest scores on the FQ-AG. The following means were found: no AG: mean FQ-AG 
6.3 (SD 6.3), mild AG: mean FQ-AG 13.3 (SD 9.1), moderate AG: mean FQ-AG 22.4 
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(SD 10.4), and severe AG: mean FQ-AG 31.1 (SD 8.0) (F = 29.1 ; df = 3 ; P <  0.001). 
About half of the patients (48%) had no or mild AG whereas 52% suffered from 
moderate or severe AG. 
At pretest, patients with moderate or severe AG obtained significant higher means 
(scored more severe) than patients without or with mild AG on each outcome 
measure (all P ≤ 0.05).     
 Patients in the CBT+SSRI group were slightly younger than in the other 
treatment groups (F=3.23; df=2; P = 0.04) with mean age ranging from 34.4 
(CBT+SSRI) to 39.4 (CBT). No other significant differences regarding patient 
characteristics among the three randomized treatment groups were found (all P  ≥  
0.18). Also, analyses performed on each outcome measure yielded no significant 
differences between treatment groups at pretest (all P  ≥ 0.27). 
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 Mean SD Mean  SD  Mean  SD Mean SD 
Duration of illness
*
 8.1       8.4 10.2 10.4 7.2 7.6 8.5 8.9 
Age 39.4 10.2 38.5 10.5 34.4 10.6 37.5 10.6 
Nr of Panic attacks
**
 5.44 9.57 3.62 4.50 5.08 5.75 4.74 6.99 
PGE, severity 3.45  1.08 3.53 1.06 3.51 1.12 3.47 1.07 
CGI, severity 2.94  1.00 2.90 .84 2.76 .94 2.89 .95 
FQ-subscale AG 18.08  11.94 17.32  12.21 20.94 10.70 18.78 11.66 
HAM-A 25.46  10.65 21.94 9.78 23.29 8.54 23.62 9.77 
HAM-D 15.21 7.30 14.23 7.47 14.61 6.51 14.70 7.07 
SCL-90 196.21 55.66 186.24  65.10 192.99 49.83 192.01 56.82 
 n % n % n % n % 
Female sex 33 62.3 26 54.2 23 46.9 82 54.7 
Currently married
***
 29 54.7 33 68.8 25 51.0 87 58.0 
Currently employed 30 56.6 31 64.6 31 63.3 92 61.3 
Level of completed 
education : 
       low 
       moderate 
       above moderate 


















































no or mild  
moderate or severe  
 

























 18 34 12 25 14 28.6 44 29.3 
Having received previous 
CBT treatment 
2 3.8 3 6.4 7 14.3 12 8.1 
Having received previous 
SSRI treatment 
17 32.1 12 25.0 14 28.6 43 28.7 
Comorbid Axis I disorder 
present 
28 52.8 20 41.7 20 55.1 75 50.0 
Notes: * in years ** mean number of panic attacks during two-week pretest period. *** or cohabiting with steady 
partner. ****benzodiazepine use could vary between very infrequent use to daily use. PGE = Patient Global Evaluation, 
CGI = Clinical Global Impression, FQ = Fear Questionnaire, HAM-A = Hamilton Anxiety Rating Scale, HAM-D= Hamilton 
Depression Rating Scale, SCL-90 = Symptoms Checklist.  
  





A total of 45 patients (30% of 150 patients who had started treatment) dropped out 
of treatment. There was no significant difference in patient dropout rate between 
treatment groups although more patients dropped out of CBT (39.6%: n = 21) as 
compared to CBT+SSRI (26.5%: n = 13) and SSRI (22.9%: n = 11) (χ2 = 3.76; df = 2; P = 
0.15). As compared to completers, significantly more patients who subsequently 
dropped out had previously used an SSRI (P = 0.02, Fisher’s exact test). No other 
significant differences between completers and dropouts on outcome variables or 
regarding patient characteristics at pretest were found (all P ≥ 0.07).  
 Reasons for dropout included side effects of medication (n = 11 (24.4%), 
including 4 CBT+SSRI and 7 SSRI patients), life events not related to treatment (n = 3 
(6.7%), all 3 CBT patients), non-compliance (n = 10 (22.2 %), including 4 CBT+SSRI, 5 
CBT, and 1 SSRI patients), needing other treatment (n = 6 (13.3%), including 3 
CBT+SSRI, 2 CBT, and 1 SSRI patients), loosing motivation because of good results (n 
= 1 (2.2 %), CBT patient), not satisfied with obtained results (n = 5 (11.1%), including 
1 CBT+SSRI and 4 CBT patients), using medication outside protocol (n=3 (6.7%), all 3 
CBT patients), and unknown reasons (n = 6 (13.3%), including 1 CBT+SSRI, 3 CBT, and 
2 SSRI patients).  
 
 Site differences  
 
To detect possible site differences, several analyses were performed. First, dropout 
rates were compared between the three types of sites (site clusters 1 to 3, see 
chapter 2) and between research and non-research sites (site clusters 1+2 compared 
to 3) and no significant differences were found (P-values 0.92 and 0.85 respectively). 
Second, possible differences in treatment effect between sites were analyzed and no 
significant differences were found (all P ≥ 0.09). Finally, analyses were repeated for 
only the patients who had received CBT because possible site differences were 
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believed to have the greatest impact on this group of patients. Next to comparing 
the three sites and comparing research and non-research sites, we also checked for 
differences between sites using student therapists (site cluster 1) and sites not using 
student therapists (site clusters 2 and 3) to see whether therapist level of experience 
was a factor of importance. For CBT patients, site differences were thus analyzed in 
three ways and taken these analyses together, no differences in dropout rate (all P ≥ 
0.95) or treatment outcome (all P ≥ 0.09) were detected. 
 
 Treatment effects  
 
Table 3.2 shows the adjusted posttest scores, confidence intervals, and effect sizes 
for the continuous outcome measures. The posttest proportions of panic free 
patients and responders are depicted in Figures 3.2 and 3.3 respectively. Mean 
within-group effect sizes are presented in Table 3.3. 
 Because patients in the CBT+SSRI group were slightly younger than in the other 
treatment groups, the effect of age on treatment effect was investigated using 
covariance analysis. No main effect of age was found on any measure (all P ≥ 0.11).  
 All patients, regardless of received treatment, showed significant improvements 
from pre- to posttest on all outcome measures, both in the completer and the ITT 
analysis (all P ≤ 0.01). For the sake of brevity, we will only report the pair wise 
comparisons. Regarding the ITT analysis, only the differences between the completer 
and the ITT analysis will be highlighted. 
 
 CBT+SSRI versus CBT :  Completer analysis revealed that CBT+SSRI was superior 
to CBT on the FQ-AG (F = 9.87 ; df = 1 ; P =  0.001), HAM-A (F = 9.17 ; df = 1 ; P = 
0.002), SCL-90 (F = 14.0 ; df=1 ; P < 0.001), HAM-D (F = 13.3 ; df = 1 ;  P < 0.001), and 
regarding the proportion of patients reaching panic free status (95% CI of difference 
in proportion from .17 to .58). Significance was not reached regarding the proportion 
of patients reaching responder status (95% CI of difference in proportion from - .36 
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to .13). In the ITT analysis, the hypothesized superiority of CBT+SSRI to CBT was 
confirmed on all outcome measures (all P ≤ 0.002, and for proportion panic free 
status 95% CI of difference in proportion from .20 to .56).   
 
 CBT+SSRI versus SSRI:  Completer analysis favored CBT+SSRI over SSRI on the 
HAM-D (F = 5.1; df=1; P = 0.01), SCL-90 (F = 3.0; df = 1; P = 0.04), and regarding the 
proportion of patients reaching panic free status (95% CI of difference in proportion 
from .08 to .43). Significance was not reached regarding the proportion of patients 
reaching responder status (95% CI of difference in proportion from -.28 to .08), not 
on the HAM-A (F = 1.9; df = 1; P = 0.08), and also not on the FQ-AG (F =2.7; df = 1; P = 
0.05). In the ITT analysis, no significant differences between CBT+SSRI and SSRI were 
observed on any measure. 
 
 CBT versus SSRI:   Completer analysis showed no significant differences between 
SSRI and CBT on any measure (all P ≥  0.03). In the ITT analysis, SSRI was superior to 
CBT on the HAM-A (F = 6.5 ; df = 1 ; P = 0.01), HAM-D (F = 5.1 ; df = 1 ; P = 0.02), SCL-
90 (F = 7.0 ; df = 1 ; P = 0.01), and regarding the proportion of patients reaching panic 
free status (95% CI of difference in proportion from .02  to .41).  
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Table 3.2. Adjusted posttest scores and confidence Intervals on four continuous outcome 















































CBT  10.83 7.89 to 13.77 .62 .45       
SSRI  7.69 5.20 to 10.19 .78 .68 .31 .17 .17 .24 .08 .16 
CBT+SSRI 4.76 2.28 to 7.24 .85 .72       
HAM-A 
(0-56) 
CBT  16.01 12.52 to 19.49 .69 .49       
SSRI 11.89 9.08 to 14.70 .76 .66 .30 .14 .19 .27 .07 .21 




CBT  11.17 8.79 to 13.55 .51 .37       
SSRI  8.61 6.68 to 10.54 .70 .62 .36 .23 .17 .36 .23 .17 
CBT+SSRI 5.50 3.54 to 7.46 .79 .68       
SCL-90 
(90-450) 
CBT  157.79 143.99 to 171.58 .58 .42       
SSRI 138.23 126.58 to 149.88 .73 .64 .37 .18 .22 .31 .09 .22 
CBT+SSRI 123.77 112.13 to 135.42 .83 .71       
   Mean between-group effect 
sizes: 
      
      .34 .18 .19 .30 .12 .19 
Notes: Posttest means are adjusted to pretest levels. CBT: n pretest=53, n posttest=27, SSRI: n pretest=48, n 
posttest=37, CBT+SSRI: n pretest=49, n posttest=36. FQ= Fear Questionnaire, HAM-A = Hamilton Anxiety Rating Scale, 
HAM-D = Hamilton Depression Rating Scale, SCL-90 = Symptoms Checklist. r= effect size: ranging from 0 to 1. com = 
completer analysis, ITT= intent-to-treat analysis. Between group effect sizes r:  C = CBT, S = SSRI, C+S= combined 
CBT+SSRI.  
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 In sum, CBT+SSRI was superior to CBT on five outcome measures in both 
completer and ITT analysis. CBT+SSRI was superior to SSRI on three measures in the 
completer analysis but not on any measure in the ITT analysis. SSRI did not 
outperform CBT in the completer analysis but proved superior to CBT on four 
measures in the ITT analysis. Thus, compared to the completer analysis, CBT 
performed poorer whereas SSRI performed better in the ITT analysis.  
  
Figure 3.2. Proportions of panic free patients at posttest for both completer and intent-
to-treat samples  











100 CBT+SSRI (90.6%) CBT (70.6%) SSRI (80.6%)
 
















completer sample ITT sample 
CBT+SSRI (completer 97%, ITT 75%)
CBT (completer 58.3%, ITT 34.8%)
SSRI (completer 71.9%, ITT 57.4%)
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Table 3.3. Within-group effect sizes for CBT-only, antidepressant-only, and the combination of 
both, for six studies 
a: Mean effect sizes based on effect sizes in Table 3.2. CBT: interoceptive exposure, cognitive therapy, and exposure in 
vivo. Antidepressants: fluoxetine, fluvoxamine, citalopram, sertraline, or paroxetine. 
b: Based on the means and SDs presented in Tables 1 and 2 (8), d was computed for one outcome measure. 
Subsequently d was converted into r. CBT: interoceptive exposure, cognitive restructuring, and breathing retraining. 
Antidepressant: imipramine. 
c: Based on the means and SDs kindly provided to us by Dr Sharp, Cohen's d was computed for three outcome 
measures. The mean d was subsequently converted into r. CBT: cognitive and behavioral panic management 
techniques including exposure. Antidepressant: fluvoxamine (16). ITT analysis was not performed. 
d: Based on the means and SDs presented in Table 2 (20), Cohen’s d was computed for 19 outcome measures. The mean 
d was subsequently converted into r. CBT: cognitive therapy. Antidepressant: imipramine. ITT analysis was not 
performed. 
e: Based on the effect sizes in Table 3 (18), a mean d was computed, subsequently d was converted into r. CBT: cognitive 
therapy. Antidepressants: par.=paroxetine, clom.=clomipramine.  
f: Based on the means and SDs presented in Table 2 (19), Cohen’s d was computed for six outcome measures. The mean 
d was subsequently converted into r. CBT: cognitive therapy. Antidepressant: fluvoxamine.  
 present 
studya 
Barlow et al. 
2000b 
Sharp et al. 
1996c 
Clark et al. 
1994d 
Bakker et al. 
1999e 





    CBT-only 
    antidepressant-only 
    combined therapy 
      
.60 .62 .71 .64 .44 .37 
.74 .72 .51 .53 .67 par., .54 clom. .63 
.84 .80 .69  / / / 
Intent-to-treat: 
    CBT-only 
    antidepressant-only 














.65 .45 / / .58 par. , .51 clom. .43 
.71 .59 / / / / 





The present findings corroborate the predicted superiority of CBT+SSRI over CBT. 
This superiority was demonstrated on all outcome measures in the completer 
analysis except the categorical outcome measure responder status. The predicted 
superiority of CBT+SSRI over SSRI was not confirmed. Although the mean posttest 
scores were consistently lower for CBT+SSRI as compared to SSRI, significance was 
reached for only three out of six measures in the completer and no measures in the 
ITT analysis suggesting that the added value of CBT to SSRI-only is limited. The small 
mean between-group effect sizes (ES) (both completer and ITT) for CBT+SSRI versus 
SSRI point in the same direction. Note that, to our knowledge, this is the first study 
on PD to report between-group ES which probably offer the most insight into the 
magnitude of observed differences between groups.  
 In the Barlow et al. and Sharp et al. studies,
(8;16)
 no significant differences 
between CBT-only and antidepressant-only emerged. Completer analysis revealed no 
significant differences between the monotreatments but SSRI was superior to CBT on 
four measures in the ITT analysis. This might raise questions regarding the CBT 
treatment as delivered in the present study. In order to be able to compare the 
present results to previous findings, (mean) within group ES were computed for 
relevant studies (see Table 3.3). In general, substantial differences between 
completer and ITT ES are observed. This might be explained by diverging attrition 
rates since an uneven distribution in dropouts between treatments may favor one 
treatment over another in the ITT analysis. For example, in the present study the 
dropout rates for respectively the combined treatment, antidepressant-only 
treatment, and CBT are 26.5%, 22.9%, and 39.6% compared to 38.8%, 62.7% and 
37.5% which we derived from the Barlow et al. study.(8) While in the present study 
the highest dropout rate was observed for CBT-only, in the Barlow et al. study, the 
highest dropout rate was observed for the anti-depressant only treatment. This 
explains why, in the latter study, the greatest change between completer and ITT ES 
 Page 78 
 
  
was observed for the antidepressant-only treatment, while in the present study the 
greatest change between completer and ITT ES was observed for the CBT-treatment. 
Based on the observed ES (CBT present study 0.60 completer, 0.43 ITT, CBT Barlow 
et al. 0.62 completer, 0.41 ITT) and dropout rates (present CBT dropout rate 39.6%, 
CBT dropout rate in the Barlow et al. study 37.5%,), it seems safe to conclude that 
CBT in the present study did not perform worse compared to previous studies but 
that the delivered CBT+SSRI and SSRI treatments simply performed better. Please 
note that the high antidepressant dropout rate in the Barlow et al. study (62.7% 
compared to 22.9% in the present study) might be explained by the use of 
imipramine instead of an SSRI. SSRIs are known for their greater tolerability in 
comparison to tricyclic antidepressants such as imipramine.(36) 
 Patients with different AG severity levels participated in the present study. At 
pretest, patients with moderate or severe AG obtained significant higher means 
(scored more severe) than patients without or with mild AG on each outcome 
measure. Post-hoc, univariate analyses of variance was applied again but this time 
on the posttest scores. By that time, except for the FQ-AG, differences between both 
AG groups were no longer significant. This might suggest that patients with 
moderate or severe AG, although still reporting more agoraphobic behavior at 
posttest, benefit as much from treatment as patients without or with only mild AG. 
Clearly, the relationship between AG level and treatment outcome warrants further 
investigation.  
 Strengths of the present study include the fact that both academic and non-
academic clinical sites participated. Results show that CBT, SSRI, and CBT+SSRI are 
effective treatments in clinical practice. No site differences were detected and 
patients improved equally well regardless of whether they were treated at research 
or non-research sites. Criteria for patient selection were liberal, and treatments were 
delivered according to care as usual. Therefore, the present findings can be 
considered highly externally valid with respect to type of patients, type of 
treatments, and type of treatment centers.  
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 Establishing the effectiveness of treatment for PD in daily clinical practice was 
set as the main goal. Therefore, in ensuring external validity, some decisions were 
made which might have affected internal validity. First, although therapists 
completed a detailed form regarding session content following each treatment 
session, more formal treatment integrity or treatment fidelity checks (such as audio 
taping each session or screening blood or urine samples) were not applied because 
this was found to be logistically impractical and also incompatible with our intention 
to simulate clinical practice.  
 Second, patients were allowed comorbid use of benzodiazepines and the effects 
of benzodiazepines and the SSRIs might thus be intertwined. It is however unlikely 
that the present findings can be accounted for by additional benzodiazepine use 
since pretest benzodiazepine use was evenly distributed across treatments and can 
therefore not account for the observed posttest differences in outcome. Also, Otto 
et al.
(37)
 found no significant difference in the effect size outcome between studies 
that prohibited and studies that allowed concurrent medication use.  
 Third, Sharp et al.(16) note that a problem of most comparative studies is the lack 
of control for therapist contact. The present study too suffers from this alleged 
problem because patients receiving CBT spent more time with their CBT therapist as 
compared to the time that patients receiving SSRI spent with their 
pharmacotherapist. However, contact time is a characteristic inherent to the 
different treatment modalities and correcting this ‘problem’ would have severely 
limited the generalizability of our results.  
 In summary, the present study demonstrated that, consistent with previous 
findings reported by Barlow et al.,(8) a combined treatment is superior to 
monotreatment although the difference between SSRI-only and the combined 
treatment was only modest. Also, this multicenter study supports the 
transportability of CBT, SSRI, and CBT+SSRI from research to non-research settings. 
Finally, patients with moderate or severe AG were not excluded and results are thus 
generalizable to the whole AG continuum.  
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 Probably the most urgent matter raised by present findings is the question of 
maintenance of treatment gains. The risk of relapse after tapering medication is 
considerable as is demonstrated in different studies in which only pharmacotherapy 
was studied.(38) One may reason that adding CBT to the pharmacotherapy might 
prevent relapse. However, there are also indications that the combined treatment 
does not prevent relapse but even encourages it.(8;39) Thus although present findings 
suggest that the combined treatment has a greater effectiveness after nine months 
of treatment as compared to CBT-only and, to a lesser extent, SSRI-only, the true 
challenge for the combined treatment may be still ahead, when the SSRIs are 
tapered off.  
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CHAPTER 4  










This chapter is a slightly altered version of a previous publication: 
CBT or SSRI or both combined for panic disorder with or without agoraphobia:  
Treatment results until one year follow-up. 
Franske J. van Apeldoorn, Marieke E. Timmerman, Peter Paul A. Mersch, Wiljo J.P.J. 
van Hout, Sako Visser, Richard van Dyck, Johan A. den Boer (2010).  
Journal of Clinical Psychiatry; 71(5): 574-586.






The main objective of the present study was to establish the long-term effectiveness 
of three treatments for PD with or without AG: CBT, SSRI, and CBT+SSRI. As a 
secondary objective, the relationship between treatment outcome and seven 
predictor variables was investigated. Patients were randomized to treatment. 
Academic and non-academic clinical sites participated. Each treatment modality 
lasted one year. Pharmacotherapists were free to choose between five SSRIs 
currently marketed in the Netherlands. Outcome was assessed after nine months of 
treatment (posttest 1), after discontinuation of treatment (posttest 2), and six and 
twelve months after treatment discontinuation (follow-up 1 and follow-up 2). About 
half of the patients did not suffer from AG or suffered from only mild AG (48.7%), 
while the other half suffered from moderate or severe AG (51.3%). Patients in each 
treatment group improved significantly from pre- to posttest 1 on the primary 
outcome measures level of anxiety, degree of coping, and remitter status, as well as 
on the secondary outcome measures depressive symptomatology, health related 
quality of life, and treatment satisfaction. Gains were preserved from posttest 2 
through-out the follow-up period. Some superiority of CBT+SSRI and SSRI as 
compared to CBT was observed at posttest 1. However, at both follow-ups, 
differences between treatment modalities proved non-significant. Thus, no fall-off in 
gains was observed for either treatment modality after treatment discontinuation. 
Gains produced by CBT were slower to emerge than those produced by CBT+SSRI 
and SSRI but CBT ended sooner and was not associated with adverse effects.  





Panic disorder (PD) is associated with substantial reduction in quality of life
(1)
 and 
carries considerable social and economic costs.
(2;3)
 Additionally, PD typically runs a 
chronic course and relapse rates are high.(4) The question of maintenance of gains 
post-treatment is therefore of considerable clinical relevance.  
 PD can be treated with both psychological and psychopharmacological 
interventions. Serotonin Selective Reuptake Inhibitors (SSRIs) are recommended as 
first choice treatment within the pharmacotherapeutical armamentarium.
(5;6)
 
Cognitive-Behavioral Therapy (CBT) is considered to be the most effective 
psychological treatment for PD.
(7;8)
 In clinical practice, patients with PD often receive 
a combination of these interventions and these combination treatments have 
increasingly received attention within the field.  
 In a review
(9)
 of 23 studies it was concluded that combined treatments were 
superior to antidepressants in all phases monitored, that is in the acute treatment 
phase, during continuation treatment and also after termination of treatment. 
Combined treatments were also superior to psychotherapy in the acute treatment 
phase and during continuation treatment. In contrast, after termination of treatment 
(follow-ups ranging from 6 to 24 months), the combined treatments and 
psychotherapy proved to be equally effective. Not all studies included in this review 
allowed a direct comparison between CBT-only, antidepressant-only and the 
combination of both. 
 In a study that did employ all three treatment modalities, Barlow et al.(10) 
randomized 312 patients to receive CBT, placebo, imipramine, CBT+imipramine, or 
CBT+placebo. Treatment lasted nine months (12 weeks of acute treatment followed 
by a six-month treatment continuation phase followed by the tapering of 
medication). Patients were re-assessed six months after treatment discontinuation. 
Results indicated that patients in the imipramine and CBT+imipramine groups had 
received the most additional treatment during the follow-up period. Also, 
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CBT+imipramine was associated with the highest relapse rate. At follow-up, the only 
groups found to be superior to placebo were CBT and CBT+placebo, not the 
medication groups, whether combined with CBT or not. 
 In sum, results of the Barlow et al.(10) study suggested that results of the 
combined treatment were not fully maintained during follow-up. These findings have 
led Otto et al. to suggest that the combined treatment may “sap some of the 
stronger effects of CBT over time” 
(11, page 78)
. Such a falling-off in gains of the 
combined treatment is explained by Otto et al.
(11)
 and others from the following 
theoretical viewpoint. According to the cognitive behavioral model, patients 
receiving CBT have tested and disconfirmed their feared catastrophes regarding 
feared bodily sensations (interoceptive exposure) and feared situations (exposure in 
vivo). In this way, a sense of safety is relearned.(7) However, animal(12) and human 
studies(13) suggest that this relearning of safety is context dependent. (14;15) Context 
refers to aspects of the external world, but also to an internal state. This means that 
when safety is learned within a medicated state, as in a combined CBT and 
antidepressant treatment, safety might be abated once the medication is withdrawn. 
A combined treatment may thus result in relapse after discontinuation of the 
medication due to a shift in context. (11;16)  We will refer to this as the ‘context-safety 
hypothesis’. 
 In the present study, we compared the differential long-term effectiveness of 
CBT, SSRI, and the combination of both (CBT+SSRI). Several clinical trials have shown 
each of these treatment modalities to be superior to placebo. Our goal was to 
compare the differential effectiveness of these treatment modalities in a more 
naturalistic setting. Patients with panic disorder with or without agoraphobia (AG) 
were treated at both academic and non-academic clinical sites in the Netherlands. 
Follow-up assessments were scheduled at six and twelve months after treatment 
discontinuation. Results after nine months of treatment were previously reported(17). 
Primary objective of the present study was to examine the differential long-term 
effectiveness of the three treatment modalities with the ultimate goal of 
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determining the most effective treatment for PD with or without AG. In light of the 
context-safety hypothesis, a fall-off in gains of the combined treatment after 
medication taper was expected and subsequently CBT was expected to have more 
durability during follow-up than either SSRI or CBT+SSRI. As a secondary objective, 
the relationship between treatment outcome and seven predictor variables was 
investigated. These variables were chosen based on previous studies (for a review 
see 
18;19
) and include treatment site, baseline agoraphobia, duration of illness, Axis I 
en Axis II comorbidity, additional benzodiazepine use, and additional treatment 




Participating patients in each treatment modality received one year of treatment, 
including three months of tapering in case of SSRI use. They were seen twice during 
the subsequent follow-up year. Patients received either CBT, SSRI, or CBT+SSRI and 
were assessed before starting treatment (pretest), after nine months of treatment 
(posttest 1), immediately after discontinuation of treatment (posttest 2), and six and 
twelve months after treatment discontinuation (follow-up 1 and follow-up 2). In 
between pretest and posttest 1, patients received 18 CBT and/or 9 SSRI sessions. In 
between posttest 1 and posttest 2, CBT patients received additional booster sessions 
resulting in up to 21 CBT sessions from pretest to posttest 2. SSRI patients tapered 
their medication during this period in which three additional sessions were 
scheduled resulting in up to 12 SSRI sessions from pretest to posttest 2.  
The CBT protocol is based on the work of Clark, Craske, and Barlow. (20;21) Patients in 
the CBT group received up to 21 CBT sessions each lasting approximately 50 minutes. 
The SSRI treatment was described in a treatment manual and was based on the 
guidelines as formulated by the Dutch Psychiatry Association regarding 
pharmacotherapy for anxiety disorders. (22) Pharmacotherapists were instructed to 
withhold from therapeutical interventions to avoid hidden exposure. 







Primary outcome measures 
The Hamilton Anxiety Rating Scale (HAM-A) (23) assesses general aspects of anxiety 
and was administered by trained research assistants. A higher score represents a 
higher degree of anxiety (range 0-56).  
 The coping scale of the Panic Appraisal Inventory (PAI)
 (24)
 assesses the degree of 
confidence in coping with future panic attacks. Reliability and validity of the PAI were 
established and especially the coping scale proved sensitive to treatment effects. 
(25;26) PAI Coping scores range from 0 to 100; a higher score representing better 
coping.  
 Patients were defined remitters according to the definition of high end-state 
functioning previously used by Roy-Byrne et al. (27) Patients had to meet all three of 
the following criteria: free of panic attacks, minimal anticipatory anxiety, and 
minimal agoraphobia. In the present study, these criteria had to be met in the 
following way: To meet the first criterion, patients had to report no panic attacks in a 
panic-log during the two-week posttest 2 assessment. Anticipatory anxiety was 
measured by the PAI anticipated panic scale.(24) In order to meet the second 
criterion, there had to be a clinically significant change on the PAI anticipated panic 
scale according to guidelines as set forth by Jacobsen and Truax.(28) Finally, an 
agoraphobia subscale score of 10 or less on the Fear Questionnaire(29) was needed to 
meet the third criterion. The resulting primary outcome measure remitter status was 
dichotomous: remitter or no remitter.  
 
Secondary outcome measures 
Health related quality of life was measured by the RAND-36,(30) a commonly used 
multidimensional self-report questionnaire assessing eight domains of health-related 
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quality of life which yields two summary scales: physical health and mental health. 
Each summary scale (RAND–P (Physical) and RAND–M (Mental)) generates a 
(transformed) score ranging from 0 to 100 with a higher score representing better 
health. The RAND-36 was completed at pretest, at posttest 2, and at follow-up 2.  
 To control for comorbid depression, the Hamilton Depression Rating Scale 
(HAM-D: range 0-52) (31) was administered together with the HAM-A.  
 The extent to which patients were satisfied with the received treatment was 
assessed (at posttest 2) with the Client Satisfaction Questionnaire (CSQ).
(32)
 The 




Screening of participating patients consisted of a structured interview, the M.I.N.I., 
(33)
 checking DSM-IV criteria for Axis I disorders. Axis I comorbidity was thus 
established based on this interview. Axis II comorbidity was assessed by means of a 
self-report questionnaire which patients completed at pretest. This ADP-IV(34) 
(Assessment of DSM-IV Personality disorders) was designed to prevent overdiagnosis 
by additionally assessing distress/impairment characteristics of each DSM-IV 
criterion. AG level was assessed, after inclusion, by the first author based on chart 
review and the structured interview. Patients were classified as not suffering from 
AG, or suffering from mild, moderate or severe AG following guidelines set forth by 
the DSM-III-R. 
 
 Statistical Analyses 
 
 In order to obtain a proper comparison between treatments, we distinguish 
three types of patients: completers, dropouts, and no-tapers. Patients were defined 
completers when treatment had ended with therapist consent. Also, completer 
patients received a minimum of 15 out of 21 CBT sessions and/or 8 out of 12 SSRI 
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sessions. Dropouts were lost during the first treatment year because of various 
reasons (see section ‘attrition’). No-tapers failed to taper medication and used an 
SSRI throughout the entire study period.  
 To investigate and compare the effects of the three treatments over time, 
multilevel modeling was used.(35;36) Three models were build for respectively the PAI 
Coping scale, the HAM measures (A and D), and the RAND measures (P and M). The 
latter two models involve a joint modeling of two outcome measures in a three-level 
model, to account for dependencies between those measures. In the multilevel 
models, the statistical significance of the fixed regression effects is tested using the 
approximate t-test, and of the random effects using the deviance test.
 
For each of 
the three models, the modeling strategy was as follows: Firstly, an adequate 
representation of the variance structure of the repeated assessments was found 
using dummy variables for posttest 1, posttest 2, follow-up 1 and follow-up 2. The 
dummy variables were coded such that each parameter expresses the change 
between the measurement concerned, and its predecessor. Because it was expected 
that no important changes in scores would occur between posttest 2 and follow-up 
1, the differential effect follow-up 1 was retained only when significant. Secondly, 
initial and differential effects of treatment across time were examined using two 
dummy variables for treatment, and in interaction with the four assessment 
dummies. Because of the randomization, no differences across treatments are 
expected at pretest, and the effect of pretest was only preserved when significant. 
To show possible differential effects across time, interactions between treatment 
and posttest 1 were always included in the model; the remaining interaction effects 
were preserved only when significant. Thirdly, it was assessed whether those who 
completed the study differed from those who dropped out or those who failed to 
taper medication, using dummy variables. Possible differential effects across time 
and treatment were examined, but those effects were preserved only when 
significant. Fourthly, possible effects of treatment site, baseline agoraphobia, 
duration of illness, Axis I en Axis II comorbidity, additional benzodiazepine use, and 
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additional treatment during follow-up were examined, both as main effect and as 
interaction with received treatment. As random effects, the between-individual and 
within-individual variance were estimated. Random effects for the difference 
between pretest and posttest 1 were examined, and preserved when significant. All 
models were build using the program MlwinN. (37) 
 Univariate analyses of variance (ANOVAs) and posthoc bonferroni pair wise 
comparisons were used to evaluate pretest differences between patient groups, 
posttest 2 differences between satisfaction scores, and differences regarding 
duration of received treatment. Chi-square analyses were used to investigate overall 
differences in dropout-rate and remitter proportions. The differences between 
proportions were further evaluated by the Wilson 95% confidence interval (CI) 




 Patient flow 
 
After randomization, 150 out of 178 patients who were seen for screening (see 
flowchart Figure 4.1) received a pretest and started treatment. Several pretest 
characteristics of the present sample are presented in Table 4.1.  
 According to our definition of patient types, 83 out of 150 patients are defined 
completers. Further, 14 out of 150 patients are defined no-tapers. These patients 
started with an SSRI treatment (either randomized to SSRI or to CBT+SSRI) but never 
tapered their medication during the course of the trial. Three of these made an 
attempt to taper their medication but failed, the other 11 never tried (refused) to 
taper their medication. Finally, 53 patients out of 150 did not complete treatment 
and dropped out during the first study year. 
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 Mean SD Mean  SD  Mean  SD Mean SD 
Duration of illness in years 8.1       
     
8.4 10.2 10.4 7.2 7.6 8.5 8.9 
Age 39.4 10.2 38.5 10.5 34.4 10.6 37.5 10.6 
Number of panic attacks
*
 5.44 9.57 3.62 4.50 5.08 5.75 4.74 6.99 
 n % n % n % n % 
Female sex 33 62.3 26 54.2 23 46.9 82 54.7 
Currently married
**
 29 54.7 33 68.8 25 51.0 87 58.0 
Currently employed 30 56.6 31 64.6 31 63.3 92 61.3 
Level of completed 
education : 
       low 
       moderate 
       above moderate 
























































Level of agoraphobia (AG): 
       no or mild AG 
      moderate or severe AG 
 













































































Notes: * mean number of panic attacks during two-week pretest period. ** or cohabiting with steady partner.  
 
 At follow-up 2, 12 months after treatment discontinuation, data was available 
for 83 patients of which 28 received CBT+SSRI, 32 received CBT, and 23 received SSRI 
(see Flowchart Figure 4.1). Patients not only dropped out during treatment (see 
“Attrition”) but also during the second follow-up year: these patients did not attend 
follow-up(s) despite efforts from the research team to contact them. In the SSRI 
group, eight patients were lost during the follow-up year, and in the CBT+SSRI group 
six patients. All completer patients in the CBT group stayed in the study during the 
follow-up year.  
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Figure 4.1. Flowchart of study recruitment, treatment allocation, and follow-up 
Not Randomized
Unwilling to participate: N=9
Loss of Eligibility: N=9
(e.g. continued prior medication or change of diagnosis)
Randomly assigned: N=169


















data available no data          total
completer            27                   /               27 
no taper 6                   1                7
dropout 4                  11              15 
total 37                 12              49 
data available no data          total
completer           26                     1               27
no taper 7                     /                  7
dropout /                    15               15
total 33                   16                49 
data available no data           total
completer            23                    4                27  
no taper 7                    /                   7
dropout /                   15                15   
total 30                  19                 49
data available no data           total
completer            22                    5                27  
no taper 6                     1                 7 
dropout /                   15               15



















data available no data          total
completer           26                    6                 32
no taper /                       /                   / 
dropout /                      21                21
total 26                    27                53  
data available no data           total
completer           32                    /                 32
no taper /                     /                   /     
dropout 9                   12                21
total 41                   12               53 
data available no data           total
completer           31                      1                32
no taper /                       /                  /
dropout /                      21                21
total 31                     22                53
data available no data           total
completer           32                      /               32 
no taper /                       /                 /
dropout /                      21              21
total 32                     21              53
data available no data          total
completer           23                     1                 24 
no taper 7                      /                    7
dropout 6                     11                17 
total 36                    12                 48
data available no data         total
completer            24                  /                   24 
no taper 6                  1                    7
dropout 2                  15                  17   
total 32                 16                  48  
data available no data         total
completer          20                    4                 24   
no taper 7                    /                    7  
dropout /                   17                 17   
total 27                   21                 48  
data available no data           total
completer          16                   8                 24    
no taper 7                   /                    7
dropout /                  17                 17    
total 23                 25                 48
Withdrew after learned condition: N=3
Received pretest and at least one CBT+SSRI 
treatment session: N=49
Withdrew after learned condition: N=2
Received pretest and at least one CBT treatment
session: N=53
Withdrew after learned  condition: N=5







Randomized to SSRI: N=53Randomized to CBT+SSRI: N=52
 
 
 Attrition  
 
Fifty-three patients were lost during the first treatment year resulting in an observed 
total dropout rate of 35%. Reasons for dropout, and the rates per treatment are 
listed in Table 4.2. No pretest differences regarding patient characteristics and 
pretest scores on all outcome measures were found between patients who 
subsequently dropped out and patients who subsequently completed treatment (all 
p ≥ .27). 
 Both the overall and pair wise differences between the three treatment groups 
regarding dropout rates proved non-significant (overall: χ2 = .91, df = 2, p = .64).  
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Table 4.2. Reasons for dropping out of study by treatment group (n=53 for 
total dropouts) 
 CBT+SSRI CBT SSRI 
Side effects of medication 4 / 7 








Non-compliance 5 5 2 
Other treatment needed 3 2 1 
Loosing motivation 



































(40% of CBT 
group) 




 Timing of treatment discontinuation 
 
Posttest 2 (to be administered after 52 weeks) was rescheduled when treatment 
termination was delayed or advanced. The CBT completers (n=32) showed a mean 
number of 50.4 weeks (SD 10.8, range 28.1-82.6) between pretest and posttest-II. 
The SSRI completers (n=24) a mean of 61.4 weeks (SD 14.5, range 49.0-110.1), and 
the CBT+SSRI completers (n=27) 60.0 weeks (SD 9.8, range 49.3-88.6). The overall 
difference between groups regarding number of weeks proved significant (F=7.68, 
df=2, p=.001). Pair wise comparisons revealed that CBT lasted significantly shorter 
than both the SSRI and CBT+SSRI treatments (95% CIs of difference in mean: 2.1 to 
17.3, and 3.3 to 18.8 weeks, respectively). Patients receiving an SSRI (either with or 
without CBT) thus needed more time to discontinue treatment as compared to 
patients receiving CBT-only.  
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Number of received sessions  
 
CBT completers received a mean of 19.0 (SD 4.0, range 7-25)
3
 sessions. SSRI 
completers received a mean of 11.6 (SD 1.3, range 9-15) sessions. CBT+SSRI 
completers received a mean of 18.6 (SD 3.01, range 11-22) CBT sessions and a mean 
of 11.8 (SD 1.3, range 9-14) SSRI sessions.  
 
 SSRI treatment and adverse effects 
 
The five SSRIs in order of times prescribed are: paroxetine (prescribed to 31 
patients), sertraline (23), fluvoxamine (22), citalopram (22), and fluoxetine (4)4. For 
paroxetine, the mean highest daily dosage throughout the treatment period was 
30.0 mg daily (SD 11.4 range 10-50 mg). For sertraline this was 85.9 mg daily (SD 
37.6, range 25-150 mg), for fluvoxamine 144.3 mg daily (SD 48.8, range 50-200 mg), 
for citalopram 29.0 mg daily (SD 13.0, range 10-60 mg), and for fluoxetine 32.5 mg 
daily (SD 18.9, range 20-60 mg). Adverse effects related to medication were 
recorded on a symptom-and-side effects checklist by the pharmacotherapist at each 
visit. Taking the five SSRIs together, the most frequent reported adverse effects 
include nervousness (reported by 72 patients, 79%), weakness/fatigue (reported by 
71 patients, 78%), headache (reported by 62 patients, 68%), sweating (reported by 
57 patients, 63%), and insomnia (reported by 55 patients, 60%). There were some 
differences in adverse effects between the different SSRIs, based on the top three 
most reported side effects for each SSRI. Anxiety and weakness/fatigue were 
frequently reported for all five SSRIs. Headache was frequently reported as well but 
with the exception of citalopram. Drowsiness was only reported for fluoxetine, 
memory problems only for paroxetine and nausea only for citalopram. 
                     
3 In four CBT-only cases, therapist and patient both agreed that more treatment sessions were not applicable because 
of early treatment success. These CBT completer patients received less than 15 CBT sessions (7, 11, 12 and 14 CBT 
sessions respectively). 
4 Numbers based on prescription data differ from number of SSRI users as can be obtained from the flowchart. This is 
explained by both missing data and by the fact that some patients have switched from one SSRI to another and thus 
more than one SSRI was prescribed to those patients. 
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 Outcome measures  
 
Estimated coefficients and standard errors of the multilevel models that were build 
for the measures HAM-A, PAI Coping, RAND-M/P, and HAM-D, are depicted in Table 
4.3. Figures 4.2, 4.3, 4.4, and 4.5 plot the model based estimated scores for HAM-A, 
PAI Coping, RAND-M/P, and HAM-D respectively, for a completer patient without or 
with only mild AG, without comorbid Axis I disorders, who does not or only 
occasionally uses benzodiazepines and who suffers from panic complaints for 8.22 
years (which is the mean duration of complaints as observed in the sample). 
Observed proportion remitters are depicted in Table 4.4. Possible differences 





Table 4.3. Estimated coefficients and standard errors of the hierarchical models for the measures HAM-A, PAI Coping, RAND-P, RAND-M, and HAM-D 
 
 HAM-A PAI Coping RAND-P RAND-M HAM-D 
Fixed effects: Estimate S.E. Estimate S.E. Estimate S.E. Estimate S.E. Estimate S.E. 
Intercept 






























32.2 3.5 NA 
 
NA NA NA -3.5 1.0 




2.3 1.5 3.5 2.6 
 
10.9 2.7 -2.0 0.9 








7.6 2.3 -1.7 0.7 
SSRI at pretest …. … … … … … … … … … 
CBT+SSRI at pretest …. … … … … … … … … … 







































































































































Dropout -1.9 1.8 2.2 2.9 -4.9 3.2 -6.4 3.2 1.3 1.1 
No-taper 4.2 2.1 -6.0 4.7 -7.7 4.5 -7.6 4.4 3.6 1.5 












































Duration of complaints  … …  0.2 0.2 … … … … … … 
Contrast posttest 1  






































Table 4.3. continued. Estimated coefficients and standard errors of the hierarchical models for the measures HAM-A, PAI Coping, RAND-P, RAND-M, and HAM-D 
  
 HAM-A PAI Coping RAND-P RAND-M HAM-D 
Fixed effects: Estimate S.E. Estimate S.E. Estimate S.E. Estimate S.E. Estimate S.E. 














































































Benzodiazepine  use … … -9.6 3.3 -16.4 4.0 -15.5 4.1 … … 













































Additional variance of 





















































































Note: NA = Not Applicable, S.E.= Standard Error, HAM-A = Hamilton Anxiety Rating Scale, PAI = Panic Appraisal Inventory, RAND-P= summary scale physical health-related quality of life, RAND-M= summary scale 
mental health-related quality of life. HAM-D= Hamilton Depression Rating Scale; contrast at a measurement occasion is the contrast between the measurement occasion and previous test occasion(s) 
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 Primary outcome measures 
 
HAM-A 
As can be derived from Table 4.3 and as depicted in Figure 4.2, on the HAM-A, 
CBT+SSRI outperforms CBT (and to a lesser extent SSRI) up to posttest 1, hence while 
treatment is continued. After treatment discontinuation however, CBT catches up 
and the monotherapies run on parallel tracks from posttest 2 up to follow-up 2. All 
treatment groups improved significantly from pre- to posttest 1. The improvement 
for the CBT group from posttest 1 to posttest 2 was significant as well. The slight 
increase observed from posttest 1 to posttest 2 for the CBT+SSRI and SSRI groups, 
proved non-significant. All treatment groups improved significantly from posttest 2 
to follow-up 2. At posttest 1, pair wise comparisons revealed that both CBT+SSRI and 
SSRI were superior to CBT. This superiority was no longer observed at subsequent 
assessments when all pair wise differences between treatment modalities proved 
non-significant.  
 
Figure 4.2. Model-based estimated scores for the HAM-A by treatment group 
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PAI Coping 
Regarding PAI Coping (see Figure 4.3), all treatment groups improved significantly 
from pre- to posttest 1 and no significant changes were observed after posttest 1 up 
to follow-up 2. This means that all treatment modalities were associated with an 
increased confidence in coping with future panic attacks and this effect was 
maintained throughout treatment and follow-up. Although visual inspection of the 
plot in Figure 4.3 reveals higher coping scores for CBT+SSRI as compared to the 
monotreatments, no significant differences between treatment modalities were 
observed for PAI Coping at any assessment.  
 
Figure 4.3. Model-based estimated scores for PAI Coping by treatment group 































Table 4.4 shows the number of observed remitters in the completer group at four 
assessments.  To assess possible differences between treatment modalities 
regarding remitter proportions, four Chi-square analyses (one for each assessment) 
were performed. These analyses revealed no significant differences at any 
assessment (all p ≥ .07).   
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 Table 4.4. Remitter status for completer patients at four assessments  
 Meeting Remitter criteria (Yes or No) 
 CBT+SSRI CBT SSRI 












Posttest 1 14 (52) 13 (48) 6   (19) 20 (63) 11 (46) 12 (50) 
Posttest 2 14 (52) 11 (41) 14 (44) 18 (56) 8   (33) 15 (63) 
Follow-up 1 10 (37) 12 (44) 14 (44) 16 (50) 6   (25) 14 (58) 
Follow-up 2 13 (48)  9  (33) 10 (31) 20 (63) 6   (25) 10 (42) 
Note: CBT+SSRI: n=27, CBT: n=32, and SSRI: n=24. Completer patients for who remitter status could not 
be established due to incomplete data were excluded from this Table.  
 
 
 Secondary outcome measures 
 
Health related quality of life 
As can be seen from Figure 4.4, at pretest physical health scores were higher as 
compared to mental health scores. This suggests that our sample of patients 
experienced problems regarding their mental health but not as much regarding their 
physical health. Estimated health scores were consistently lower for CBT patients as 
compared to SSRI and CBT+SSRI patients both regarding physical and mental health. 
For RAND-P, the improvement from pretest to posttest 2 was significant for the SSRI 
and CBT+SSRI groups but not for the CBT group. All treatment groups improved 
significantly from posttest 2 to follow-up 2. Pair wise comparisons revealed that both 
CBT+SSRI and SSRI were superior to CBT at posttest 2 and follow-up 2. For RAND-M, 
all treatment groups improved significantly from pretest to posttest 2 and from 
posttest 2 to follow-up 2. Pair wise comparisons revealed that SSRI (but not 
CBT+SSRI) was superior to CBT at posttest 2 and follow-up 2. 
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Figure 4.4. Model-based estimated scores for the RAND-M (left) and RAND-P 




As can be seen in Figure 4.5, the pattern of results for the HAM-D generally matches 
the results as described for the HAM-A however, HAM-D scores were lower to begin 
with in our sample of patients. Also, differences between treatment modalities were 
even smaller as indicated by almost perfect parallel tracks. All treatment groups 
improved significantly on the HAM-D from pretest to posttest 1. Subsequently, CBT 
improved significantly from posttest 1 to posttest 2 while posttest 1 – posttest 2 
differences proved non-significant for the CBT+SSRI and SSRI groups. All treatment 
groups improved significantly from posttest 2 to follow-up 2. Pair wise comparisons 
revealed that at posttest 1, CBT+SSRI was superior to CBT. This superiority could not 
be confirmed at subsequent assessments when pair wise differences between 
treatment modalities proved non-significant. 
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Client Satisfaction  
At treatment endpoint, patients completed the CSQ and the following means were 
established for the completer group: for CBT+SSRI: 3.62 (SD .39), for CBT: 3.29 (SD 
.48), and for SSRI 3.40 (SD .55). Given that the mean CSQ score ranges from 1 to 4, 
our sample of patients can be considered highly satisfied with the received 
treatment.
(32;40)
 Overall differences proved significant between treatment groups 
(F=4.45, df=2,106, p=.014). Subsequently, posthoc analyses revealed significant 
differences between CBT+SSRI and CBT (95% CI of difference: 0.06 to 0.60) implying 
that patients having received CBT+SSRI appear slightly more satisfied with treatment 
as compared to patients having received CBT-only. Finally, patients obtained 
equivalent high mean CSQ scores regardless of type of site in which they were 
treated, and regardless of whether they were treated by student-therapists or 
qualified therapists (all p ≥ .74). 
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Dropouts and no-tapers compared to completers  
The variable ‘type of patient’ categorized patients into completers, dropouts, and 
no-tapers. A main effect of dropout was found for the measure RAND-M which 
implies that dropout patients reported overall lower mental health scores as 
compared to completer patients. A main effect of no-taper was found for the 
measures HAM-A and HAM-D which implies that patients who failed to taper 
medication were associated with overall higher anxiety and depression levels as 
compared to completer patients. On no measure, an interaction effect between type 
of treatment and type of patient was observed which means that the effect of type 
of patient could not be shown to differ between treatments. At posttest 1, the 
difference between completers and dropouts was significant for PAI Coping, HAM-A, 
and HAM-D suggesting that from pretest to posttest 1, dropout patients had 
experienced a smaller decrease in anxiety and depressive complaints, and a smaller 
increase in coping, as compared to completer patients. Regarding treatment 
satisfaction, mean CSQ scores were compared. The mean for the completer group 
was 3.54 (SD .41), for dropouts 2.94 (SD .59), and for no-tapers 3.29 (SD .54). Overall 
differences proved significant between patient groups (F=10.37, df=2, p < .001). 
Subsequently, posthoc analyses revealed significant differences between the 
completers and the dropouts (95% CI of difference: 0.27 to 0.93) implying that 
patients who had completed treatment were more satisfied with treatment as 
compared to patients who had dropped-out of treatment.  
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 Predictor variables 
 
Site effects 
Sixty-three patients were treated at the two university training and research centers, 
42 at the two university research clinics, and 45 patients at the seven regular mental 
health clinics. Previous analyses
(17)
 revealed no differences between the three kinds 
of participating sites regarding pretest scores, dropout-rate, and treatment effect at 
posttest 1. In the present analyses, again no effect of site was found for any of the 
outcome measures at any assessment.  
 
No/mild versus moderate/severe AG 
About half of the patients in the present sample did not suffer from AG or suffered 
from only mild AG (48%) while the other half suffered from moderate or severe AG 
(52%). Only for the primary outcome measure PAI Coping, a significant main effect of 
AG status (no/mild vs. moderate/severe) was found indicating that patients with 
moderate/severe AG reported less confidence in their ability to cope with future 
panic attacks as compared to patients without or with only mild AG. 
  
Duration of illness 
At pretest, the number of years that patients suffered from their complaints ranged 
from six months to 43 years (mean: 8.23, SD: 8.53). For PAI Coping, a significant 
relationship was found between duration of illness, treatment effect over time and 
the level of confidence in the ability to cope with future panic attacks. At pretest, 
patients who had suffered from their PD complaints longer reported on average 
more confidence in their coping abilities as compared to patients who had suffered 
from their PD complaints for a shorter period of time. However, the increase in 
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confidence reported from pretest to posttest 1 appeared significantly lower for the 
longer suffering patients resulting in higher coping scores at subsequent assessments 
for the patients who suffered from their PD complaints for a shorter period of time. 
To illustrate this phenomenon, Figure 4.6 shows the model based estimated PAI 
Coping scores for the three treatment modalities when panic complaints were 
present for one year at the time of the intake and for twenty-five years. 
 
Figure 4.6. Model-based estimated PAI Coping scores for 3 treatment modalities 
for panic disorder duration of 1 year and 25 years 
 
 
Axis I Comorbidity 
Presence of comorbid Axis I disorders was checked for at intake. At that time, 50% 
(n=75) suffered from at least one additional Axis I disorder according to the 
standardized interview. 
On both Hamilton scales, patients with (at least one) comorbid Axis I disorder 
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reported significantly more anxious and depressive complaints at pretest as 
compared to patients with no comorbid Axis I disorder. At posttest 1, the difference 
between patients with and without comorbid Axis I disorders had become smaller 
but was still significant. The difference was maintained at subsequent assessments.  
 
Axis II Comorbidity 
Axis II disorders were not formally diagnosed but a screening self-report 
questionnaire34 was completed at pretest. At that time, 20% of the patients met the 
criteria of at least one Axis II disorder. There were no differences between treatment 
groups (χ2 = .03, df=2, p =.99). No main effect (or interaction effect with time of 
assessment) of Axis II comorbidity was found on any outcome measure. 
 
Additional benzodiazepine use 
According to protocol, patients were not allowed to use psychotropic drugs except 
small doses of benzodiazepines (maximum the equivalent of 20 mg oxazepam per 
day). Benzodiazepine use was scored on a 4 point scale, with 1 being ‘none’, 2 ‘only 
infrequently’, 3 ‘regularly, but not daily’, and 4 ‘daily’. The multilevel models for all 
measures revealed that patients scoring 1, 2, or 3 showed similar patterns of 
response and therefore these were pooled in the so called ‘no or occasional benzo’ 
group. This group of patients was compared to the patients that used 
benzodiazepines on a daily basis; the ‘daily benzo’ group. The multilevel models 
revealed that using benzodiazepines on a daily basis proved to be a factor of 
importance as reflected on the measures PAI Coping and RAND-M/P. On these 
measures, a significant main effect of additional benzodiazepine use was observed 
indicating that overall (in the same degree at each assessment) patients in the ‘daily 
benzo’ group reported lower health scores and less confidence in their ability to 
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cope with future panic attacks as compared to patients in the ‘no or occasional 
benzo’ group.  
 To gain insight in the frequency of benzodiazepine use across treatment 
modalities and assessments, benzodiazepine use is summarized in Table 4.5. It 
seems that, once treatment has started, a little more CBT-only patients use 
additional benzodiazepines as compared to patients using an SSRI, either combined 
with CBT or not. The majority of patients however (63% of completer sample), does 
not use any additional benzodiazepines, at any assessment.  
 
 




















    
   Benzodiazepine use at pretest and at 
least at one subsequent assessment no 





















    
   No benzodiazepine use at pretest and 
benzodiazepine use at least at one 
subsequent assessment 
 



















    















   Total 27 32 24 83 
Note: Only completer patients are included. Benzodiazepine use could vary between very infrequent use to daily 
use.  
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Additional treatment during follow-up 
 
For the patients who completed treatment and were assigned to follow-up, it was 
recorded whether additional treatment was received during follow-up. Of the 
completer sample, 64% (n=53) received no additional treatment during follow-up, 
23% (n=19) did receive additional treatment during follow-up, and information 
regarding additional treatment during follow-up was missing for 13% (n=11). With 
respect to the different treatment modalities, nine CBT+SSRI patients (33%) received 
additional treatment, five patients in the CBT (16%), and five patients (21%) in the 
SSRI group. The nine CBT+SSRI patients with additional treatment received CBT 
(n=2), an SSRI (n=5), a combined CBT+SSRI treatment (n=1), or a psychological 
treatment other than CBT (n=1). The five CBT patients with additional treatment 
received an SSRI (n=3) or a combined CBT+SSRI treatment (n=2). The five SSRI 
patients with additional treatment received CBT (n=2), SSRI (n=2), or both CBT and 
SSRI but not simultaneously (n=1). CBT+SSRI thus yielded the highest and CBT the 
smallest proportion of patients receiving additional treatment during follow-up. The 
overall difference proved non-significant (χ2 = 4.3, df=2, p =.12). Subsequent pair 
wise comparisons of proportions revealed an almost significant difference between 
CBT+SSRI and CBT (95% CI of difference in proportion from -.04 to 0.39) which might 
be indicative of a trend.  
 The variable ‘additional treatment’ was included in the multilevel models to 
investigate the possible influence of receiving additional treatment during follow-up 
on long-term treatment outcome. No main effect (or interaction effect with time of 
assessment) of additional treatment was found on any outcome measure. 
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DISCUSSION 
 
Based on the context-safety hypothesis, we expected CBT to have more durability 
during follow-up than CBT+SSRI and SSRI. However, no significant loss of gains after 
treatment discontinuation was observed for either treatment modality. One-year 
follow-up results suggested that the three treatment modalities were generally 
equally effective. Major changes occurred during the first nine months of treatment 
during which all three treatment modalities were associated with statistically 
significant, and clinically relevant, improvement on all outcome measures. 
Subsequently, results were maintained during follow-up. On the measures HAM-A, 
HAM-D, and RAND-M/P, even further improvement during follow-up was observed.  
 When pair wise evaluating treatment modalities, most differential effects were 
observed during the first treatment year. Significant differences on the primary 
outcome measures were observed at posttest 1 when SSRI and CBT+SSRI proved 
superior to CBT on the HAM-A. Subsequently, significant differences between 
treatment modalities were no longer observed at follow-up 2, twelve months after 
treatment discontinuation.  
 Results thus suggest that gains produced by CBT were slower to emerge than 
those produced by the other treatment modalities. The CBT treatment in the present 
study lasted one year, which is longer than the CBT in several other trials. In the 
Barlow et al. study, CBT lasted nine months. In the present study, at nine months 
CBT was not quite up to the level of the other treatments. Based on the comparison 
of effect sizes however, the CBT in the present study seems as effective as the CBT 
delivered in other trials. Previously, we reported an effect size of 0.60 for the CBT in 
the present study while we established an effect size of 0.62(17) for the CBT in the 
Barlow et al. study.(10)  
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 Consistent with previous reports, CBT was able to maintain its gains through-out 
follow-up. More surprisingly however, SSRI alone was also not associated with a fall-
off in gains and this is countering general consensus. It should be noted however 
that the general consensus is in part based on studies using benzodiazepines or 
antidepressant medication other than SSRI (e.g. imipramine). Studies presenting 
relapse rates after SSRI discontinuation are scarce. There is clearly a need for studies 
like the present, investigating the long-term effects of SSRIs following cessation of 
pharmacotherapy. 
 Considering the present results, we must conclude that we have not succeeded 
in determining the most effective treatment for PD with or without AG since no 
evidence was found for clear superiority of one treatment modality over another. 
Studies like the present should eventually result in recommendations that can be 
passed on to practitioners. (41) At this point however, we are not able to predict 
under what conditions and for which patients a stronger effect can be expected from 
a particular treatment modality. This leaves the practitioner with the task of making 
a thoughtful treatment selection for each individual patient. In this process, any 
previous patient experience with either treatment modality or a possible preference 
of the patient for either treatment modality can be taken into account. Also, taking 
into consideration some general drawbacks and plus points of each treatment 
modality might be helpful in selecting a treatment. In the present study, the delayed 
treatment effects associated with CBT might be considered a drawback of CBT-only. 
Plus points of CBT-only include the fact that it was not associated with adverse or 
withdrawal effects, and that treatment ended sooner (as in duration of treatment in 
weeks) than both the SSRI and CBT+SSRI treatments which is interesting from a cost-
effectiveness perspective. An advantage of the SSRIs is the observed more 
immediate effect as compared to CBT-only. Also, the SSRI treatment consisted of half 
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the number of treatment sessions of the CBT treatment while maintaining its gains 
equally through-out follow-up. On the other hand, SSRIs are associated with adverse 
events which can be considered a drawback of medication treatment. Almost 80% of 
the patients using an SSRI in the present sample reported at least one adverse effect.  
 When comparing CBT+SSRI to SSRI-only, it seems that CBT was a valuable and 
perhaps even indispensable addition to a pharmacotherapeutical treatment because 
CBT+SSRI was associated with lower HAM-A and HAM-D scores, higher PAI Coping 
scores and more patients achieving remitter status at each assessment as compared 
to SSRI-only. From a cost-effectiveness perspective however, CBT+SSRI might be less 
attractive as compared to a monotreatment. 
 Seven predictor variables for treatment effect were investigated in the present 
study and some interesting findings emerged. Patients who suffered from their 
complaints for a longer period of time reported considerably less improvement 
regarding confidence in their coping abilities. Considering some preliminary evidence 
for the relationship between the related concept of self-efficacy scores and 
relapse,(42) it seems worthwhile to promote early treatment interventions.  
 Benzodiazepines are associated with the issues of dependence and withdrawal 
difficulties.(6) Present data suggest that using benzodiazepines on a daily basis is 
associated with lower health scores and lower coping scores as compared to no or 
infrequently benzodiazepine use. In the present sample however, only a few patients 
used additional benzodiazepines on a daily basis. This might imply that when 
receiving adequate treatment, patients generally do not need additional 
benzodiazepines. 
 Twenty-three percent of the completer patients were in need of additional 
treatment during the one-year follow up period. Data on this subject from other 
studies is limited. About half of the patients received treatment during follow-up in 
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the study by Sharp et al.
(43)  
who stated that patients receiving post-study treatment 
should be excluded from follow-up analysis. In the present study however, no 
relationship between receiving additional treatment and treatment outcome was 
found. According to the context-safety hypothesis, one would expect more CBT+SSRI 
than CBT-only patients to require additional treatment during follow-up. Although 
we found some indications for this in the present data, results were non-significant. 
At least as interesting is the finding that, just as in the CBT group, only five patients in 
the SSRI condition received additional treatment during follow-up. At the moment, 
we cannot explain the difference between SSRI and CBT+SSRI regarding additional 
treatment during follow-up. Patients in the SSRI group experienced a shift of context 
when discontinuing medication just as patients in the CBT+SSRI group but less 
patients apparently were subsequently in need of additional treatment. Because the 
small numbers involved and the non-significance of the findings, future studies 
should again take this matter under scrutiny.  
 Strengths of the present study include the naturalistic character of the study, 
the fact that clinical sites as well as research sites participated, and the resulting high 
generalizability of findings. Also, our follow-up period was twice as long as previously 
reported studies(10;43)  thereby yielding more insight into the long-term effectiveness 
of treatments. Further, patients with moderate or severe AG were not excluded and 
results are thus generalizable to the whole AG continuum. Next, predictor variables 
were investigated in order to further clarify outcome. Finally, because we did not 
only look at differences between treatment modalities but also differentiated 
between different patients groups (completers, dropouts, and no-tapers), we were 
able to study specific treatment-patient interactions. Regarding this issue, please 
note the applied strict definitions of dropouts and completers. In the present study, 
a patient who received fourteen CBT sessions and subsequently terminated 
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treatment without therapist consent was considered a dropout while in some other 
studies
(43)
 such a patient would be categorized as a completer. We choose for this 
definition in order to ensure a homogeneous completer group but recognize that this 
has increased our number of dropouts.  
 Several limitations deserve mention. First, a binary variable such as remitter 
status naturally suffers from a loss of power. Furthermore, because remitter status is 
a composite measure, information on the effectiveness in terms of its separate 
constituents (agoraphobic avoidance, anticipation anxiety, and panic attacks) is lost. 
Second, the research assistants who administered the HAM-A and the HAM-D were 
thought to be independent and not partial to either treatment modality. However, 
they were not blind regarding allocation status and this presents a possible source of 
bias. Third, treatment adherence was checked by evaluating detailed forms 
regarding session content as completed by all therapists following each treatment 
session. We refrained from more formal treatment integrity and fidelity checks 
because this was considered to be incompatible with our intention to simulate 
clinical practice. Although these evaluations revealed no deviations from the 
treatment manuals, we realize that checking treatment integrity in this way is not 
soundproof. Finally, the present sample size was limited as compared to e.g. the 
sample size in the study by Barlow et al.
(10)
 This means that we must take into 
consideration the possibility that some effects were non-significant due to a lack of 
power. 
 
 The present findings could not confirm the context-safety hypothesis. Previous 
work suggests that context may refer to an internal state implying that when safety 
is learned within a medicated state, safety is abated once the medication is 
withdrawn. However, an internal state might be defined not simply by the presence 
or absence of medication but rather by how the use of medication is explained by 
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the individual patient. Context may thus refer to an internal state which in turn is 
defined by the individual attribution of improvement. If improvement is attributed 
solely to the medication then relapse following medication taper is to be expected. 
If, however, improvement is attributed to both CBT and SSRI, an internal state might 
not change so radically when tapering medication. This may explain observed 
differences between the combined treatment and the SSRI as a monotreatment. 
Some preliminary findings
(44)
 to date warrant further work into this matter.  
 In conclusion, the present findings indicate that both CBT-only, SSRI-only, and 
CBT+SSRI are effective treatments for PD with or without AG. Future research should 
continue to strive for a better understanding of the role of predictor variables and 
specific working mechanisms associated with different treatment modalities in order 
to aid the practitioner in the process of treatment selection.  
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CHAPTER 5  
 









This chapter is a slightly altered version of a previous publication: 
Rate of improvement during and across three treatments for panic disorder 
 with or without agoraphobia: Cognitive behavioral therapy,  
selective serotonin reuptake inhibitor or both combined. 
Franske J. van Apeldoorn, Wiljo J.P.J. van Hout, Marieke E. Timmerman,  
Peter Paul A. Mersch, Johan A. den Boer (2013). 
Journal of Affective Disorders; 150(2): 313-319. 




Existing literature on panic disorder yields no data regarding the differential rates of 
improvement during CBT, SSRI or both combined. The main objective of the present 
study was to examine the rate of improvement in panic attack frequency during 
treatment and the relationship between rate of improvement and baseline AG. 
Patients were randomized to receive CBT, SSRI or CBT+SSRI which each lasted one 
year including three months of medication taper. Participating patients kept record 
of the frequency of panic attacks throughout the full year of treatment. A significant 
decline in frequency of panic attacks was observed for each treatment modality. SSRI 
and CBT+SSRI were associated with a significant faster rate of improvement as 
compared to CBT. Gains were maintained after tapering medication. For patients 
with moderate or severe AG, CBT+SSRI was associated with a more rapid 
improvement on panic frequency as compared to patients receiving either 
monotreatment. In conclusion, patients with PD responded well to each treatment 
as indicated by a significant decline in panic attacks. CBT was associated with a 
slower rate of improvement as compared to SSRI and CBT+SSRI. Discontinuation of 
SSRI treatment did not result in a revival of frequency of panic attacks. Our data 
suggest that for patients without or with only mild AG, SSRI-only will suffice. For 








CBT and SSRIs are now widely accepted as the gold standard for the treatment of 
panic disorder (PD).
(1)
 In naturalistic settings, many patients receive a combination of 
these two treatment modalities. A handful of randomized trials have performed 
head-to-head comparisons between CBT and antidepressants for PD(2-9) but only 
three of these studies compared both monotreatments (CBT-only and 
antidepressants-only) with the combination of both within a single design allowing 
for an optimal comparison.
(3,6,7)  
 We previously reported on the differential long-term effectiveness of CBT, SSRI, 
and the combination of both (CBT+SSRI) in the treatment of PD with or without AG.
(5)
 
Patients were treated at both academic and non-academic clinical sites in the 
Netherlands. Patients received one year of treatment, including medication taper in 
case of SSRI use. Results from pre-, and posttest outcome measures suggested that 
gains produced by CBT were slower to emerge than those produced by the other 
treatment modalities. Follow-up results revealed no fall-off in gains for either 
treatment modality after treatment discontinuation. However, to obtain a detailed 
insight into symptom changes in the course of therapy and relate those changes to 
treatment modalities, intensive measurement across time is needed. Surprisingly, 
the existing literature on PD yields no actual data regarding the differential rates of 
improvement during CBT-only, SSRI-only and the combination of both. There is some 
evidence from treatment outcome studies (e.g., Sharp et al., 1996) suggesting a 
more rapid improvement for a combined CBT and SSRI treatment but rate of 
improvement was not fully investigated in these studies. Rate of improvement is 
however considered to be a critical clinical variable as rapid improvement not only 
diminishes ongoing suffering, but may also prevent attrition.(10)  
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 The primary goal of the present study is to gain insight into the rate of 
improvement both during and across the currently most effective treatments for 
panic disorder. As primary measure that reflects symptom change during treatment 
and that can be measured intensively, we choose frequency of panic attacks. The 
occurrence of panic attacks is a core symptom of PD and contributes greatly to the 
suffering of PD patients. PD patients are thought to reliably indicate the presence or 
absence of panic attacks.
(11)
 Panic attack frequency was examined for the period of 
one year in which treatment was delivered including medication taper.  
 Research goals for the present study are: 1. To examine the rate of 
improvement in panic attack frequency during treatment. We expect patients to 
improve significantly as indicated by a decline in the number of panic attacks in all 
three treatment modalities. 2. To determine possible differential effects in rate of 
improvement across treatment modalities. Based on previous results regarding 
differential treatment effectiveness, analyzing pre- and post-outcome data,
(5,6)
 we 
expect patients receiving an SSRI (either as monotreatment or in combination with 
CBT) to show a faster rate of improvement as compared to patients receiving CBT-
only. 3. To examine the effect of tapering medication across treatment modalities. 
From week 40, patients receiving an SSRI, either as monotreatment or combined 
with CBT, tapered their medication. Several authors suggest that patients are more 
prone to relapse following medication discontinuation due to a shift in context.(12-14) 
We previously referred to this theoretical frame-work as the ‘context-safety 
hypothesis’(5) but our previous findings could not confirm this hypothesis. In the 
present study, we further examine this issue. In accordance to former hypothesis, an 
increase in number of reported panic attacks following medication taper is expected 
for patients who received either CBT+SSRI or SSRI. 4. To examine the relationship 
between rate of improvement in panic frequency and baseline severity of 
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agoraphobia. In most clinical outcome studies, the proportion of PD patients with AG 
exceeds those of PD without AG,
(15)
 whereas some clinical trials excluded patients 
with agoraphobia altogether.
(3)
 PD patients with AG are associated with a greater 
disability as compared to PD patients without AG.
(15)
 The question whether 
treatment for PD patients should differ depending on the presence or severity of AG 
has been subject of debate. Results from a recent meta-analysis support the 
contemporary view that there is no reason to offer PD patients with AG a different 






Randomized patients met DSM-IV criteria for PD with or without AG as primary 
diagnosis. Patients were not required a minimum number of panic attacks during 
baseline. Participating patients in each treatment condition received one year of 
treatment. Patients received CBT, SSRI, or CBT+SSRI. For patients randomized to 
CBT+SSRI, the two treatments started simultaneously and were delivered parallel. 
AG level was assessed, after inclusion, by the first author based on chart review and 
a structured interview.(17) Patients were classified as not suffering from AG, or 
suffering from mild, moderate or severe AG following DSM-III-R definitions. Presence 
of panic attacks was assessed prospectively (i.e., using event-contingent recording): 
participating patients were asked to color a box in a panic plot each time a panic 
attack occurred. From those panic plots, we derived the frequency of panic attacks. 
Patients kept this panic plot through-out treatment and brought it to each treatment 
session: it was then showed to the therapist who copied the information to the 
therapist version of the panic plot. For analyses, scores were added up into weekly 
frequency scores. 
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 Statistical Analyses 
 
To investigate and compare the rate of improvement in frequency of panic attacks 
over time, two multilevel poisson models were build.
(18,19)
 We used poisson 
regression to adequately model the counts (i.e., the discrete non-negative responses 
(0,1,....)). The statistical significance of the regression effects was tested using the 
approximate t-test, and alpha was set at 0.05. The modeling strategy to examine the 
rate of improvement, the effect of tapering medication and possible differential 
effects across treatments (research goals 1 to 3), resulting in Model I, was as follows: 
Firstly, an adequate representation of the variance structure of the repeated 
assessments was found using the following predictors (and its meaning in brackets): 
Intercept (week 0), Week (long-term changes), Lnweek (logarithm of week; short-
term changes), Dcondition (dummy; differential effect of conditions at week 0), 
interactions of week with Dcondition, and Lnweek with Dcondition (differential 
effects of conditions in long-term and short-term changes, respectively), Dweek40 
(dummy, change in effect at week 40), interactions of Dweek40 with Dcondition 
(differential effects of conditions in effect at week 40), interactions of Dweek40 with 
Dcondition and lnweek (differential recovery effects of conditions of change at week 
40). Secondly, we retained the following effects (and their justification for not 
expecting) only when significant: Dcondition (due to random assignment, no initial 
differences expected), interaction Lnweek with Dcondition (if any, differential effects 
of conditions in long-term changes expected to suffice), Dweek40 (due to dummy 
coding, effect refers to CBT group, for which no tapering takes place). 
 To examine the relationship between rate of improvement of panic frequency 
and baseline severity of agoraphobia, we first removed from Model I non-significant 
effects to avoid instabilities of model estimates. Subsequently, we included the 
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following effects: AG status (dummy; differential effect of AG status at week 0), 
interactions of AG status with Week (differential effect of AG status in long-term 
changes), and interactions of AG status with Week with Dcondition (differential 
change effects of conditions and AG status), resulting in Model II.  
 All models were built using the program MlwinN. (20) In order to obtain a proper 
comparison between treatments, we distinguished three types of patients: dropouts, 
no-tapers, and completers. Dropouts were lost during the first treatment year 
because of various reasons such as non-compliance or needing other treatment. No-
tapers failed to taper medication and used an SSRI throughout the entire study 
period. Patients were defined completers when treatment had ended with therapist 
consent. Also, completer patients received a minimum of 15 out of 21 CBT sessions 
and/or 8 out of 12 SSRI sessions. For the present analysis, only completer patients 
were included because the other groups were too small (regarding both numbers of 
patients and of available time points) to obtain reliable results (total panic logs 
available: for dropouts: CBT n = 17, SSRI n = 9, CBT+SSRI n = 11; for no-tapers: SSRI n 
= 6, CBT+SSRI n = 5). Further, data from one (CBT completer) patient was excluded 
from analyses, because the extremely high reported panic attack frequency (i.e., 
about 20 attacks per week) casted doubt on the score reliability. The number of 
panic logs present for analyses varied somewhat from week to week. Table 5.1 
summarizes the number of available panic logs, as the mean number per treatment 
group for three time periods. To further evaluate differences between treatment 
groups per week, we used univariate analyses of variance (ANOVAs) and post-hoc 
pair wise comparisons, with bonferroni correction. Tests were two-tailed and alpha 
was set at .05. 
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Table 5.1. Mean numbers of available panic logs per week (min-max) at weeks 1-
17, 18-35, and 36-52. n indicates total number of patients in sample  
                                       CBT (n=32)                   SSRI (n=24)               CBT+SSRI (n=27) 
weeks 1 – 17 26.94 (25-29) 20.88 (20-21) 22.94 (22-23) 
weeks 18 - 35 23.50 (22-25) 19.55 (19-20) 20.66 (20-23) 





 Sample information 
 
After screening and randomization, 150 patients started treatment (see Figure 5.1 
for flowchart). According to our definition, 83 out of 150 patients who started 
treatment were completers of which CBT+SSRI: n= 27, CBT: n=32, SSRI: n=24 (total 
n=83). In the completer sample, 56.6% was female. Mean age was 36.6 years (SD 
10.7). On average, patients had suffered from PD for 7.4 (SD 7.9) years at pretest. 
About half of the patients in the completer sample did not suffer from AG or 
suffered from only mild AG (48.2%, n=40 of which n=7 no AG, and n=33 mild) while 
the other half suffered from moderate or severe AG (51.8%, n=43 of which n=32 
moderate, and n=11 severe).  
 CBT completers received a mean of 19.0 (SD 4.0, range 7-25)5 sessions. SSRI 
completers received a mean of 11.6 (SD 1.3, range 9-15) sessions. CBT+SSRI 
completers received a mean of 18.6 (SD 3.01, range 11-22) CBT sessions and a mean 
of 11.8 (SD 1.3, range 9-14) SSRI sessions.  
  
                     
5 In four CBT-only cases, therapist and patient both agreed that more treatment sessions were not applicable because 
of early treatment success. These CBT completer patients received less than 15 CBT sessions (7, 11, 12 and 14 CBT 
sessions respectively). 
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Figure 5.1. Flowchart of study enrollment, allocation, and treatment end-point 
Not Randomized
Unwilling to participate: n=9
Loss of Eligibility: n=9
(e.g. continued prior medication or 
change of diagnosis) 
Randomly assigned: 
n=169





























completer           32




completer             24     
no taper 7
dropout 17   
total 48
Withdrew after learned 
condition: n=3
Received at least one
CBT+SSRI treatment session: 
n=49
Withdrew after learned condition: 
n=2
Received at least one CBT 
treatment session: 
n=53
Withdrew after learned condition: 
n=5 
Received at least one SSRI 













Randomized to SSRI: 
n=53





 Rate of improvement 
 
Parameter estimates of Model I are presented in Table 5.2. As can be seen in Table 
5.2 and Figure 5.2, patients in all three treatment modalities improved significantly 
(effect of Week and Lnweek) on the frequency of panic attacks during treatment. As 
can be seen in Figure 5.2, the expected frequency of panic attacks declined fastest 
after starting treatment and then levels off, resulting in virtually no panic attacks at 
all by the end of the year.  
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Table 5.2. Estimated coefficients and standard errors of the multilevel poisson 
models 
 Model I Model II 
Fixed effects: Estimate S.E. Estimate S.E. 
Intercept  1.18
*
 0.16  1.20* 0.23 
Week -0.03* 0.00 -0.04* 0.01 
Lnweek -0.27* 0.05 -0.27* 0.05 
Week*SSRI -0.06* 0.01 -0.06* 0.01 
Week* CBT+SSRI -0.09*
 
0.01 -0.05* 0.01 
Dweek40*SSRI -4.45 27.82   
Dweek40* CBT+SSRI -29.64 17.62   
Dweek40*SSRI*Lnweek  0.97 7.32   
Dweek40*CBT+SSRI*Lnweek  8.25 4.61   
AG status   -0.03 0.31 
AG status * Week    0.02* 0.01 
AG status * Week * SSRI    0.00 0.01 
AG status * Week * 
CBT+SSRI 
  -0.05* 0.01 
Random effects:     
Intercept 1.18* 0.16 1.69* 0.29 
Note: NA = Not Applicable, S.E.= Standard Error, * p<0.05 
 
 
 Treatment differences in rate of improvement 
 
Model I revealed that the number of panic attacks in both SSRI and CBT+SSRI 
dropped significantly faster in time as compared to CBT (as indicated in Table 5.2 by 
the significant interactions between Week and SSRI, and Week and CBT+SSRI, 
respectively), whereas the difference in rate of improvement between SSRI and 
CBT+SSRI appeared to be non-significant (not shown explicitly in Table 5.2).  
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Figure 5.2. Plot of expected frequency of panic attacks according to Model I for 
three groups: CBT, SSRI, and CBT+SSRI 
 
 
 Additional analyses per week revealed significant differences in panic frequency 
between treatment groups at weeks 6,7,10,11,27-31,33-37 and week 40 (all p ≤ .03). 
Subsequent pair wise analyses revealed that in all these weeks CBT was 
outperformed by SSRI (weeks 11 and 33), or by CBT+SSRI (weeks 6 and 29), or by 
both CBT+SSRI and SSRI (the remaining weeks).  
 
 The effect of tapering medication on frequency of panic attacks 
 
From week 40, patients receiving an SSRI started to taper medication. For CBT+SSRI 
and SSRI, Model I revealed no significant changes in panic attack frequency from 
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week 40 (start tapering) up to week 52 (tapering completed) (indicated by non-
significant two-way interaction effects of Dweek40 by SSRI and CBT+SSRI, 
respectively) implying that gains were maintained throughout medication taper. 
Also, no differential effects between SSRI and CBT+SSRI were found from week 40 up 
to week 52 (indicated by non-significant three-way interaction effects of Dweek40 
and Lnweek by SSRI and CBT+SSRI, respectively). 
  
The relationship between rate of improvement and baseline severity of 
agoraphobia 
 
The parameter estimates of Model II are also presented in Table 5.2. The expected 
frequencies, on the basis of Model II, as a function of week and AG status (no/mild 
vs. moderate/severe) are depicted in Figure 5.3, for each treatment modality 
separately. As can be seen in Table 5.2, no significant main effect of AG status 
(no/mild vs. moderate/severe) was found indicating that the frequency of reported 
panic attacks appeared to be equal at week 0 among patients with moderate or 
severe AG and patients without of with only mild AG. We subsequently found a 
positive significant interaction effect of AG status with week (effect of AG status * 
Week) and no differential effect of SSRI (effect of AG status * Week * SSRI), 
suggesting that patients in the SSRI and CBT condition with moderate/severe AG 
showed less decrease in reported panic attacks during treatment as compared to 
patients with no/mild AG. Subsequently, we also found a negative significant 
interaction effect of AG status, week, and CBT+SSRI (effect of AG status * Week * 
CBT+SSRI), indicating that among patients with moderate or severe AG, rate of 
improvement was faster with CBT+SSRI as compared to SSRI and CBT.  
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Figure 5.3. Plot of expected frequency of panic attacks according to Model for 
CBT (nm/ms), SSRI (nm/ms), and CBT+SSRI (nm/ms) in which nm = no AG or mild 




To our knowledge, this is the first study to analyze the differential rate of 
improvement in panic frequency in a randomized trial evaluating CBT, SSRI and the 
combination of both for PD with or without AG. As expected, randomized patients 
who completed treatment showed a decline in number of panic attacks during 
treatment, resulting in virtually no panic attacks at the end of treatment. Thus, all 
three treatments tended to lead to improvement on the key symptom of PD, namely 
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panic attacks. Although it was expected that patients who received CBT would need 
more time to reach the same rate of improvement as patients who were assigned to 
SSRI and CBT+SSRI, we were surprised to find that patients who received CBT 
reported relatively more panic attacks not only in the first phase of treatment but 
throughout the entire year. Furthermore, the difference in frequency of panic 
attacks reached statistical significance even up to week 40. A treatment with SSRI-
only appeared equally effective in diminishing the frequency of panic attacks as the 
combined treatment implying that no additive value of CBT to SSRI-only was 
observed.  
 Clinical studies reveal that SSRIs need about four to six weeks of treatment 
before becoming effective.
(21)
 Visual inspection of Figure 5.2 suggests that frequency 
of panic attacks started to decline from week 1 in each treatment modality. 
Subsequent analyses revealed that there were no significant differences between 
treatment modalities up to week 6 suggesting that SSRIs indeed started to become 
effective from week 6, resulting in significant differences in weeks 6-12, while CBT 
treatment needed more time to become equally effective. This would be in 
agreement with current understanding of the neurobiology of PD.(22) It is thought 
that CBT and SSRI may operate through different pathways in the brain leading to a 
different pattern of response over time. Following this, it might be expected that 
when using an SSRI, effects will first be observed on the level of somatic symptoms 
resulting in a more rapid decline of panic attacks as compared to CBT. It could be 
presumed that CBT would reveal its therapeutic effect in the early phase of 
treatment on different process measures (e.g. belief in catastrophic cognitions) but 
up to date, no data is available to corroborate this.  
 Regarding the context-safety hypothesis, we found no evidence for the 
assumption that patients having discontinued the SSRI subsequently relapse due to a 
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shift in context. In the ten weeks following tapering medication, patients in SSRI and 
CBT+SSRI maintained achieved gains regarding panic frequency. It can be argued that 
for patients receiving both CBT and SSRI, CBT enhances patient’s confidence in 
coping with possible withdrawal effects during tapering. Interestingly however, 
patients receiving SSRI-only also maintained their gains following medication taper, 
questioning the additive value of CBT. Possibly, the adequate information and 
guidance of clinicians through-out the tapering process contributed to the 
prevention of relapse but more research is clearly needed on relapse factors.  
 Present findings support the notion that patients with PD and moderate or 
severe AG at baseline are more seriously impaired in daily functioning as compared 
to patients with PD without AG.
(15)
 Although it is suggested that there is no reason to 
offer PD patients with AG a different kind of treatment than patients without AG,(16) 
present findings suggest that specifically for patients with moderate to severe AG, a 
combined CBT and SSRI treatment offers a surplus value to both monotreatments. 
This is in line with the notion that especially exposure-based techniques are 
considered to be important in the treatment of moderate to severe AG. 
 Strengths of the present study include the advanced statistical techniques 
applied, which resulted in a sound model of rate of improvement in panic frequency 
during and across the different treatment modalities. Also, results can be considered 
highly externally valid with respect to type of patients, type of treatments, and type 
of treatment centers(6) which allows practitioners to draw inferences regarding 
clinical practice.  
 The fact that frequency of panic attacks was not assessed beyond the full year 
of treatment can be considered a limitation of this study. Panic frequency data was 
collected for one year (albeit long as compared to other studies), until ten weeks 
following medication taper. We cannot rule out the possibility that relapse occurred 
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in the weeks after that, although follow-up assessments, six and twelve months after 
medication taper, again revealed no relapse on several outcome measures.
(5)
 A 
second factor that possibly limits the reliability of our findings is the fact that 
patients’ compliance to accurate and immediate completing the panic plot is not 
assessed in this study. However, every session the panic plots were checked upon 
receipt for the accuracy of completion by the therapist. In general, event-contingent 
recording have been particularly suitable for data collection in the domain of 
psychopathology, when the clinical symptoms are sudden and have acute onset.
(23)
 A 
third limitation is that we did not collect another process variable, next to panic 
frequency, to supplement present findings. Although irrefutable a core symptom of 
PD, other important aspects of the disorder would have been interesting regarding 
rate of improvement as well. A suggestion for future research might be adapting a 
more process-oriented approach in which timing and sequencing of changes 
regarding different aspects of PD within and across treatments is the focus (for 
examples of such a process-oriented approach, see
(24,25)
). This might lead to a better 
understanding of processes involved in recovery from PD as a result from different 
treatment modalities.  
 In the treatment guidelines for PD we have seen a development from a more 
psychopharmacological approach to a more psychological approach. What can we 
suggest the practitioner facing the decision how to treat his PD patients, based on 
present findings? From a cost-effectiveness perspective, SSRI seems first choice 
because it results in a rapid decline in the number of panic attacks and leads to no 
relapse following medication taper. For patients with moderate or severe AG 
however, the combined CBT+SSRI treatment may be recommended because for this 
patient group, a combined package was associated with the most rapid decline in the 
number of panic attacks and again, no relapse after medication taper was observed. 
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The latter finding is especially important considering the hesitancy that clinicians 
tend to feel towards tapering, which can result in ongoing, perhaps even 
unnecessary, SSRI treatment.  
 We emphasize the need to integrate insights from contemporary learning 
theory in clinical studies under real life conditions with real life PD patients. The 
present study contributes to this endeavor as no stringent inclusion criteria were 
applied, clinical practice sites joined and treatments were delivered according to 
care as usual. In this way, we may come to understand how phenomena observed in 
the laboratory (such as context dependency in the extinction of fear), emerge into 
the clinical practice of treating PD patients. Future studies are required to examine 
the effects of SSRI, CBT, and CBT+SSRI on other process measures than frequency of 
panic attacks to validate our findings. 
    
Page 137 
References 
1.  Roshanaei-Moghaddam B, Pauly MC, Atkins DC, Baldwin SA, Stein MB, Roy-Byrne 
P. (2011). Relative effects of CBT and pharmacotherapy in depression versus 
anxiety: Is medication somewhat better for depression, and CBT somewhat better 
for anxiety? Depression and anxiety; 28:560-560-567 
2.  Bakker A, van Dyck R, Spinhoven P, van Balkom AJLM. (1999). Paroxetine, 
clomipramine, and cognitive therapy in the treatment of panic disorder. Journal 
of Clinical Psychiatry; 60:831-838.  
3.  Barlow DH, Gorman JM, Shear MK, Woods SW. (2000). Cognitive-behavioral 
therapy, imipramine, or their combination for panic disorder. Journal of the 
American Medical Association; 283(19):2529-2536.  
4.  Black DW, Wesner R, Bowers W, Gabel J. (1993). A comparison of fluvoxamine, 
cognitive therapy, and placebo in the treatment of panic disorder. Archives of  
General Psychiatry; 50:44-50.  
5.  Van Apeldoorn FJ, Timmerman ME, Mersch PPA, van Hout WJPJ, Visser S, van 
Dyck R, et al. (2010). A randomized trial of cognitive-behavioral therapy or 
selective serotonin reuptake inhibitor or both combined for panic disorder with 
or without agoraphobia: Treatment results through 1-year follow-up. Journal of 
Clinical Psychiatry; 71:574-586.  
6.  Van Apeldoorn FJ, van Hout WJPJ, Mersch PPA, Huisman M, Slaap BR, Hale WI, et 
al. (2008). Is a Combined therapy more effective than either CBT or SSRI alone? 
Results of a multicenter trial on panic disorder with or without agoraphobia. Acta 
Psychiatrica Scandinavica; 117:260-270. 
7.  Sharp DM, Power KG, Simpson RJ, Swanson V, Moodie E, Anstee JA, et al. (1996). 
Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in 
combination in the treatment of panic disorder and agoraphobia. Journal of 
Anxiety Disorders; 10:219-242.  
8.  Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M.A. 
(1994). Comparison of cognitive therapy, applied relaxation and imipramine in 
the treatment of panic disorder. British Journal of Psychiatry; 164:759-769.  
9.  De Beurs E, van Balkom AJLM, Lange A, Koele P, van Dyck R. (1995). Treatment of 
panic disorder with agoraphobia: Comparison of fluvoxamine, placebo, and 
psychological panic management combined with exposure and of exposure in 
vivo alone. American Journal of Psychiatry; 152:683-691.  
10. Penava SJ, Otto MW, Maki KM, Pollack MH. (1998). Rate of improvement during 
cognitive-behavioral group treatment for panic disorder. Behaviour Research and 
Therapy; 36:665-673.  
    
Page 138 
11. De Beurs E, Lange A, van Dyck R. (1992). Self-monitoring of panic attacks and 
retrospective estimates of panic: discordant findings. Behaviour Research and 
Therapy; 30:411-411-413.  
12. Bouton ME. (2000). A learning theory perspective on lapse, relapse, and the 
maintenance of behavior change. Health Psychology; 19:57-63.  
13. Otto MW, Smits JAJ, Reese HE. (2005). Combined psychotherapy and 
pharmacotherapy for mood and anxiety disorders in adults: Review and analysis. 
Clinical psychology: Science and Practice; 12:72-86. 
14. Craske MG, Kircanski K, Zelikowsky M, Mystkowski JL, Chowdhury N, Baker A. 
(2008). Optimizing inhibitory learning during exposure therapy. Behaviour 
Research and Therapy; 46:5-27.  
15. Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB, Smith S, et al. (2006). 
The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: 
Results from the national epidemiologic survey on alcohol and related conditions. 
Journal of Clinical Psychiatry; 67:363-374.  
16. Furukawa TA, Watanabe N, Churchill R. (2006). Psychotherapy plus 
antidepressant for panic disorder with or without agoraphobia. British Journal of 
Psychiatry; 188:305-312.  
17. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. 
(1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The 
Development and Validation of a Structured Diagnostic Psychiatric Interview for 
DSM-IV and ICD-10. Journal of Clinical Psychiatry; 59:22-33.  
18. Snijders TAB, Bosker RJ. (2000). Multilevel analysis. London: Sage.  
19. Verbeke G, Molenberghs G. (2000). Linear mixed models for longitudinal data. 
New York: Springer. 
20. Multilevel Models Project. (1995). MLN Command Reference. London: University 
of London.  
21. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. (2008). World Federation 
of Societies of Biological Psychiatry (WFSBP). Guidelines for the pharmacological 
treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders- 
First revision. The World Journal of Biological Psychiatry; 9:248-248-312.  
22. Gorman JM, Kent JM, Sullivan GM, Coplan JD. (2000). Neuroanatomical 
Hypothesis of Panic Disorder, Revised. American Journal of Psychiatry; 157:493-
505.  
23. Moskowitz D, Sadikaj G. (2011). Event-contingent recording. In: Mehl M, Conner 
T, editors. Handbook of research methods for studying daily life; pp 160-175. New 
York: Guilford.  
    
Page 139 
24. Stanley MA, Beck JG, Averill PM, Baldwin LE, Deagle EAI, Stadler JG. (1996). 
Patterns of change during cognitive behavioral treatment for panic disorder. The 
Journal of Nervous and Mental Disease; 184:567-567-572. 
25. Polman A, Bouman TK, van Geert PL, Den Boer JA. (2011). Dysfunctional beliefs in 
the process of change of cognitive treatment in obsessive compulsive checkers. 
Clinical Psychology and Psychotherapy; 18:256-256-272.  





















This chapter is a slightly altered version of a previous publication: 
Cost-effectiveness of CBT, SSRI, and CBT+SSRI in the treatment for panic disorder. 
Franske J. van Apeldoorn, A. Dennis Stant, Wiljo J.P.J. van Hout,  
Peter Paul A. Mersch, Johan A. den Boer (2013).  
Acta Psychiatrica Scandinavica; Jul 3. doi: 10.1111/acps.12169.




Knowledge about the cost-effectiveness of different treatment modalities can 
support providers in optimally allocating scarce resources. The objective of the 
present study was therefore to assess the cost-effectiveness of three empirically 
supported treatments for PD with or without AG: CBT, SSRI, or the combination of 
both. Cost-effectiveness was examined based on data from a multicenter 
randomized controlled trial. The Hamilton Anxiety Rating Scale was selected as 
primary health outcome measure. Data on costs from a societal perspective (i.e. 
direct medical, direct nonmedical and indirect nonmedical costs) was collected in the 
study sample (n=150) throughout a 24-month period in which patients received 
active treatment during the first twelve months and were seen twice for follow-up in 
the next twelve months. Results showed that total costs were largely influenced by 
costs of the interventions and productivity losses. The mean total societal costs were 
lower for CBT as compared to SSRI and CBT+SSRI. Costs of medication use were 
substantial for both SSRI and CBT+SSRI. When examining the balance between costs 
and health outcomes, both CBT and CBT+SSRI led to more positive outcomes than 
SSRI. It was concluded that CBT is associated with the lowest societal costs and that 
CBT and CBT+SSRI are more cost-effective treatments for PD with or without AG as 
compared to SSRI-only. 
 




Panic disorder (PD) is a disabling condition associated with reduced quality of life
(1)
 
and impaired functioning. In cases of additional severe agoraphobia (AG), PD can 
result in being completely housebound. Costs associated with PD thus not only 
include direct medical costs but also indirect costs resulting for instance from 
reduced productivity.(2) In this way, PD imposes a burden on both health care 
systems and society as a whole. It is estimated that for PD, costs per patient per year 
surpass the costs of depressive disorder.
(3) 
The need for economic evaluations of 
treatments for mental illnesses stems from the current context of managed care 
characterized by accountability and cost containment.
(4) 
Economic evaluations focus 
on the balance between costs and health outcomes (i.e. treatment outcome 
measures) of alternative interventions in the field of healthcare. In conducting these 
evaluations, data on both direct and indirect costs need to be collected.
(5)
 Knowledge 
about the cost-effectiveness of different treatment modalities can support providers 
in optimally allocating scarce resources. 
 Empirically supported treatments for PD include both cognitive behavioral, 
pharmacologic, and combined treatments. Numerous studies have demonstrated 
the effectiveness of both monotreatments but scientific interest in the combined 
treatment is from a more recent date and important questions regarding long-term 
effectiveness and relapse after treatment discontinuation await further 
investigation. Some studies suggest a detrimental effect of combined treatments on 
the long-term.(6) Tapering medication following successfully treating PD patients with 
both CBT and pharmacotherapy would lead to relapse. One of the explanations for 
relapse might be a shift in context: what is learned within the context of medication-
use might not be preserved in a non-medication context.(7) Following this line of 
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reasoning, it might be assumed that on the long-term (i.e. after completing 
treatment), a combined treatment is associated with higher costs as compared to 
monotreatments. Regarding monotreatments; while pharmacotherapy is generally 
associated with more relapse,
(8,9)
 CBT-only is characterized as durable on the long-
term,(10) and especially cost effective with patients needing no additional treatment 
after successfully completing therapy.  
 It must be noted however that these considerations are largely based on 
experimental- and treatment outcome data rather than on cost-effectiveness data. 
In fact, studies evaluating costs associated with these treatments are scarce
(4)
 and 
drawing conclusions is hampered by methodological differences between studies.
(2)
 
Specifically, there is a need for comparing costs of different treatment modalities 
within a single design. One such study is the multi-site randomized trial comparing 
imipramine, CBT, and their combination for PD.
(6)
 In the economic evaluation of 
these data, monotreatments proved to be associated with greater cost-efficacy as 
compared to the combined treatment. After three months, imipramine was the most 
cost-efficacious treatment and six and nine months after treatment termination, this 
was the case for CBT.(4) It is important to note that only direct costs were assessed in 
this study. No studies on PD to date have examined the cost-effectiveness of direct 
and indirect costs (e.g., productivity loss) of the combined CBT+SSRI treatment 
compared to both monotherapies within a single design. In the present study data 
from our randomized controlled trial comparing three empirically supported 
treatments(11)  were used in an economic evaluation from a societal perspective. 
 The aim of the present study is to determine the most cost-effective treatment 
for panic disorder with or without agoraphobia in an economic evaluation from a 
societal perspective comparing Cognitive Behavioral Therapy, pharmacotherapy 
using a Selective Serotonin Reuptake Inhibitor, or the combination of both. 




 Study participants, treatment modalities and study design 
 
Randomized patients suffered from a primary diagnosis of PD with or without AG. 
Patients were randomized to receive CBT, SSRI, or CBT+SSRI. During the first 
treatment year, CBT patients received up to 21 treatment sessions (50 minutes each) 
in 52 weeks. The CBT treatment manual was intended to satisfy as closely as possible 
“care as usual” requirements and was based on the work of Clark, Craske, and 
Barlow.
(12,13)
 Patients receiving an SSRI visited their therapist 9 times, with weekly 
sessions during the first month and the remaining sessions distributed evenly over 
the treatment period. For patients randomized to CBT+SSRI, the two treatments 
started simultaneously and were delivered parallel by two different therapists.  
 The economic analyses focused on the 24 months consisting of twelve months 
active treatment and twelve months follow-up period. Costs and health outcomes 
were assessed prospectively for all the included patients. Patients were assessed five 
times; before starting treatment (T0), after nine months of treatment (before 
starting medication taper) (T9), at treatment endpoint (after medication taper) 
(T12), six months after treatment termination (T18), and twelve months after 
treatment termination (T24), resulting in four measurement periods: T0-T9, T9-T12, 
T12-T18, T18-T24.  
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 Costs and unit prices 
 
The study was conducted from a societal perspective; direct medical, direct 
nonmedical and indirect nonmedical costs were registered. Direct medical costs 
included costs related to the interventions (CBT, SSRI, CBT+SSRI), inpatient and semi-
inpatient care, outpatient and community care, general healthcare, day activity 
institutions, and medication. Direct nonmedical costs included time costs and 
informal care. Informal care refers to care provided by caregivers such as neighbors 
or family. Indirect nonmedical costs included costs of productivity losses due to 
illness-related absence from paid work.  
 Costs of the interventions were based on the number of visits for medication 
management and or CBT treatment sessions, the wages of psychiatrists and or 
therapists, and additional costs (e.g. costs of housing). Costs of informal care were 
based on the monetary valuation of the time invested by informal caregivers in 
helping or assisting the patient. Medication use, including medication other than 
SSRI according to protocol, was registered in detail for all the included patients. Costs 
of productivity losses due to illness-related absence from work were estimated by 
means of the friction cost method.(15) Compensation mechanisms were taken into 
account when estimating productivity costs, in accordance with the methods 
described by Jacob-Tacken and colleagues.
(16)
 
 Most data was collected by means of a detailed questionnaire on costs 
administered by trained research assistants in a face-to-face interview with study 
participants. This interview was conducted five times and thus focused on the four 
measurement periods: T0-T9, T9-T12, T12-T18, T18-T24. The interview assessed, 
among others, admissions to psychiatric hospitals, contacts with healthcare 
professionals, and absence from work. Additional information was collected through 
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healthcare professionals involved, for instance on the use of (prescribed and non-
prescribed) medication. 
 In order to facilitate comparisons with other economic evaluations, unit prices, 
i.e. the price of one unit of each included cost type, were mainly based on Dutch 
standard prices.(17) True costs of used resources were estimated when standard 
prices were not available. All unit prices were based on the price level of the Euro in 
the year 2005. Reference prices established for previous years were adjusted to 
prices of 2005 by applying the consumer price index. 
 
 Cost-effectiveness analysis 
 
In cost-effectiveness analysis, costs and the primary health outcome associated with 
an intervention are used to calculate the incremental cost-effectiveness ratio (ICER) 
relative to one or more alternatives.
(18)
 In the present study, the Hamilton Anxiety 
Rating Scale (HAM-A)
(19)
 was selected as the primary health outcome measure for 
the cost-effectiveness analysis. This instrument is well-validated and widely used in 
studies aimed at anxiety disorders. The power analysis was based on characteristics 
of the HAM-A in the patient population under study. Previous analyses focusing on 
the HAM-A demonstrated that differences between groups were not statistically 
significant when focusing on the full 24 months of the study. Additional details on 
the results on effectiveness using the HAM-A as health outcome measure are 
presented elsewhere.(11) In the present study, we will present the cost-effectiveness 
results only. ICERs were calculated using the mean changes in HAM-A scores over 
time and societal costs of the three groups during the 24 months of the study.  
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The formula for calculating the ICER is presented below (only displayed for the 
comparison between the CBT and SSRI group):  
 
ICER =  
(C CBT – C SSRI) 
(HAM-ACBT – HAM-ASSRI) 
 
C CBT = mean costs in the CBT group  
C SSRI = mean costs in the SSRI group 
HAM-ACBT = mean HAM-A difference score in the CBT group  
HAM-ASSRI = mean HAM-A difference score in the SSRI group 
 
 
 The bootstrap method was applied to provide information on the uncertainty of 
the results of the economic evaluation. Bootstrapping
(20)
 is an iterative method that 
consists of randomly selecting patient data (with replacement) from the observed 
population to create a simulated distribution of data. ICERs were calculated for each 
of the bootstrap iterations (5000 in the present study). Simulated values of the mean 
estimates for the cost and outcome differences were added to the cost-effectiveness 
plane.(21) Subsequently, cost-effectiveness acceptability curves (CEACs)(22) were 
calculated. CEACs inform decision-makers on the probability that an intervention will 
be cost-effective, which depends on the willingness to pay per additional unit of 
health outcome.  
 Finally, two sensitivity analyses were conducted in order to provide information 
on the robustness of the results of the economic evaluation. There are currently 
several methodological approaches towards the measurement of productivity losses 
available, and estimates of these costs may vary considerably between approaches. 
In the first sensitivity analysis, costs of productivity losses were therefore excluded, 
which was also expected to simplify direct comparisons with previous economic 
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studies in which costs of productivity losses could often not be registered. 
 Patients were followed for 24 months and various measurements were 
scheduled during this time frame. Before the start of the study, it was anticipated 
that some patients might drop out of the study, or data might not be available for all 
patients at one or more of the measurements. Therefore, in a second sensitivity 
analysis an imputation technique (see also the section on statistical analysis) was 
applied as an alternative for the complete case approach in the standard cost-
effectiveness analysis.  
 
 Statistical analysis 
 
All analyses were conducted in agreement with the intention-to-treat (ITT) principle 
implying that participants were analyzed in the condition to which they were 
randomized. We have no data from patients who refused to participate and 
withdrew from the study before the first assessment; these patients were not 
included in the ITT analysis.  
 The significance of differences in mean total costs between groups was analyzed 
by 95% confidence intervals estimated with the bootstrap method for available cases 
per measurement, and complete cases over the 24 months of the study. In one of 
the sensitivity analyses, missing cost data were imputed with the expectation 
maximization (EM) algorithm. The EM algorithm consists of an iterative process, 
estimating values for missing data based on the observed data(23)  
 




 Study sample 
 
One hundred and seventy-eight eligible subjects were seen for screening. Nine 
subjects were unwilling to participate. One hundred and sixty nine subjects were 
randomized to treatment of which nine lost eligibility prior to starting treatment. 
Also, ten subjects withdrew from the study after they were told to which treatment 
they were randomized and before any assessment was conducted. Subsequently, 
150 patients started treatment of which CBT+SSRI: n = 49, CBT: n = 53, and SSRI: n = 
48. In total, 54.7% of the sample consisted of women. Mean age was 37.5 years 
(range 18–61 years). About half of the patients in the present sample did not suffer 
from AG or suffered from only mild AG (48%) while the other half suffered from 
moderate or severe AG (52%). 
 
 Cost types and healthcare utilization 
 
The various medical and nonmedical costs generated by each patient group during 
the 24 months of the study are depicted in Table 6.1. Furthermore, Table 6.1 also 
displays information on the utilization of healthcare services as the percentage of 
patients using each cost type is provided.  
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Table 6.1. Mean medical and nonmedical costs (in euro) for participants in three treatment groups 
during 24 months 
 CBT (n=52) SSRI (n=47) CBT+SSRI (n=49) 













Interventions:       
Therapy/contacts 690 (308) 98 257 (125) 89 924 (406) 92 

















      
Hospital admission 0 (-) 0 0 (-) 0 0 (-) 0 
Day care 0 (-) 0 8 (56) 2  0 (-) 0 
Sheltered 
accommodation 
0 (-) 0 0 (-) 0 0 (-) 0 
Outpatient and 
community care: 
      
Psychiatrist 5 (25) 4  21 (69) 15 52 (153) 20 
Psychologist 185 (453) 21 75 (219) 15 182 (512) 27 
Social psychiatric nurse 0 (-) 0 0 (-) 0 0 (-) 0 
Social worker 0 (-) 0 0 (-) 0 0 (-) 0 
Crisis intervention 0 (-) 0 5 (31) 2 0 (-) 0 
Psychiatric homecare 0 (-) 0 0 (-) 0 0 (-) 0 
CAD
2
 0 (-) 0 0 (-) 0 0 (-) 0 
Other outpatient care 47 (332) 4 51 (185) 11 1 (7) 2 
General healthcare:       
General practitioner 19 (58) 19 25 (78) 26 6 (20) 14 
Alternative healthcare 13 (89) 4 6 (23) 9 9 (47) 6 
Home care 0 (-) 0 0 (-) 0 21 (145) 2 
Emergency care 0 (-) 0 3  (21) 2 0 (-) 0 
Other general healthcare 46 (162) 12 21 (80) 9 17 (53)  12 
Day activity institutions:       
Day activity center 0 (-) 0 0 (-) 0 0 (-) 0 
Drop-in center 0 (-) 0 0 (-) 0 0 (-) 0 
Other institutions 0 (-) 0 0 (-) 0 0 (-) 0 
Nonmedical costs:       
Time costs 110 (49) 98 26 (13) 89 133 (58) 92 
Informal care 91 (541) 6 393 (1496) 15 72 (248) 8 
Productivity losses 776 (2284) 13 1136 (2576) 26 1068 (2337)  24 
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Medical costs directly related to the three interventions ranged from €257 for SSRI-
only, to €924 for the combination of CBT and SSRI. For CBT-only, mean costs of 
medication use were, as expected, considerably lower than in the other treatment 
modalities.  
 No patients were admitted to a hospital or stayed in a sheltered 
accommodation during the study. Of the various types of outpatient services, by far 
the most care was provided by psychologists. Approximately 20% of the patients 
visited their general practitioner at least once. Time costs directly related to the 
interventions were lower for SSRI as compared to CBT and CBT+SSRI. Patients in the 
SSRI group seemed to make more use of informal care than the other groups. Costs 
of productivity losses were substantial in all three groups ranging from €776 for CBT 
to €1136 for SSRI. 
 Total costs 
 
An overview of the mean total costs generated during the various measurement 
periods of the study is provided in Table 6.2. In addition, the number of patients 
available at each measurement is presented.  
 Costs were highest during the first twelve months of the study, which was 
related to the interventions that were provided during this period, the more 
intensive use of healthcare services, and the temporary increase in illness-related 
absence from work.  
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Table 6.2. Costs (in euro) for three treatment groups during 24 months and the 95% 
CI of mean differences between groups 
 













         
Measurement period         
T0-T9 52 1501  46 1904  49 1746 
T9-T12 51 403  45 202  48 596 
T12-T18 33 114  30 363  35 603 
T18-T24 34 140  27 196  33 266 
T0-T24 
1
 32 2224  27 3118  32 3590 
         
95% CI 
2
  LB   UB    
CBT versus SSRI  -3315   1071    
CBT+SSRI versus 
SSRI 
 -2182   2171    
CBT+SSRI versus CBT  -225   2481    
         
1
  Mean total costs during T0-T24, based on data of participants for whom all the relevant 
measurements were available (complete cases)
 
2
  95% confidence interval (CI) for the mean cost differences between the various groups during T0-
T24, based on complete cases. Lower (LB) and upper boundaries (UB) of the CI are presented 
 
 
 Mean total costs during the 24 months of the study were €2224 for CBT, €3118 
for SSRI, and €3590 for CBT+SSRI. Costs associated with the CBT-only group appeared 
to be considerably lower than in the other groups. However, differences between 
the mean total costs were not statistically significant, as indicated by the boundaries 
of the 95% confidence intervals assessed with the bootstrap method. The absence of 
significant differences between costs of the three groups should be interpreted with 
some caution, since the study was powered (as most economic evaluations) to 
demonstrate differences in health outcomes and not costs.  
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 Cost-effectiveness analysis 
 
For the current cost-effectiveness analysis, changes in mean HAM-A scores between 
baseline and the end of follow-up were assessed. The three groups all showed 
improvements over time (mean HAM-A improvement of 10.6 points in the SSRI 
group, 14.5 in the CBT group, and 16.2 in the CBT+SSRI group), but differences 
between groups were not statistically significant (F=1.815, p=.169). For the standard 
cost-effectiveness analysis only cases with complete data were included. Complete 
data (on costs and outcome) were available for 32 CBT patients (60% of the patients 
who started CBT treatment). For the SSRI group, complete data were available for 27 
patients (56% of the patients who started SSRI treatment). For the CBT+SSRI group, 
complete data were available for 32 patients (65% of the patients who started 
CBT+SSRI treatment).  
 The point estimate of the ICER and the results of the bootstrap analyses are 
presented in the cost-effectiveness planes (CEPs) in Figures 6.1 A/B/C. Furthermore, 
information is provided on the percentage of bootstrap simulations located in each 




    
Page 154 
Figure 6.1. Results of the cost-effectiveness analyses and bootstrap method 
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 For the comparison between CBT and SSRI (see Figure 6.1A), the point estimate 
and approximately 70 % of the bootstrap simulations is located in the southeast 
quadrant. In other words, CBT dominated SSRI in 70% of the simulations implying 
lower costs and better health outcomes for CBT as compared to SSRI. For the 
comparison between CBT+SSRI and SSRI (see Figure 6.1B), the point estimate is 
located in the northeast quadrant, i.e. mean costs were higher but health outcomes 
were better in the CBT+SSRI group as compared to SSRI. Furthermore, CBT+SSRI 
dominated SSRI in 40% of the cases.  
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 Finally, a direct comparison was made between CBT+SSRI and CBT (see Figure 
6.1C). CBT+SSRI was associated with higher costs but better health outcomes as 
compared to CBT. By far the most bootstrap outcomes are located in the northeast 
quadrant. Interpretation of outcomes in the northeast (and southwest) quadrant 
depends on how much decision-makers are willing to pay for an additional unit of 
health outcome.
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 Figure 6.2 shows the probability that the interventions will be cost-effective for 
increasing willingness to pay per additional unit of health outcome. CBT is preferred 
over CBT+SSRI if the willingness to pay is lower than approximately €700 per 
additional point on the HAM-A. When decision-makers are willing to pay more than 
this amount, CBT+SSRI is more likely to be cost-effective than CBT. 
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 Sensitivity analysis 
 
Results of the two sensitivity analyses are presented in Table 6.3.  
 
Table 6.3. Sensitivity analyses 










Type of analysis: 
   
Exclusion of productivity 
costs 
1625 (1354) 1804 (2181) 2271 (1132) 




2271 (3062) 2591 (3914) 3159 (3012) 
    
1  Imputation with the EM algorithm to account for missing cost data. Mean costs are based on the data of 52 CBT, 
47 SSRI, and 49 CBT+SSRI patients. 
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The exclusion of costs related to productivity losses was associated with much lower 
costs in all three groups, and resulted in smaller differences between groups. When 
excluding costs of productivity losses, mean total costs were €1625 for CBT, €1804 
for SSRI, and €2271 for CBT+SSRI.  
 In the second sensitivity analysis, missing cost data were imputed by means of 
the EM algorithm. Cost outcomes were again in favor of the CBT group, but 




To our knowledge, this is the first economic evaluation of the treatment of PD with 
or without agoraphobia in which SSRI, CBT, and the combination of both are directly 
compared within the same design. Although differences in costs and health 
outcomes between groups did not reach statistical significance when focusing on the 
24 months of the study, the presented results seem highly relevant for policy 
decisions in mental healthcare. Nowadays, there appears to be wide consensus that 
the focus of economic studies should actually be on estimation and the assessment 
of probability (of the relative cost-effectiveness of healthcare interventions), instead 
of hypothesis testing.
(25,26)
 In the present study, the uncertainty surrounding the 
current economic results was, among others, assessed by means of bootstrap 
techniques and graphically presented by cost-effectiveness acceptability curves. The 
provided information on the relative cost-effectiveness of CBT, SSRI, and CBT+SSRI 
(together with the uncertainty of the outcomes) could be used by decision-makers to 
re-allocate the limited resources within healthcare, and eventually optimize the 
treatment of PD in current healthcare systems.  
 In all three groups, total costs were largely influenced by costs of the 
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interventions and productivity losses. Furthermore, costs of medication use were 
substantial for patients in both the SSRI and CBT+SSRI group. When examining the 
balance between costs and health outcomes, both CBT and CBT+SSRI led to more 
positive outcomes than SSRI-only. Although CBT was associated with lower costs, 
assessed health outcomes were slightly more in favor of CBT+SSRI. Which of these 
two interventions is to be preferred depends on the decision-makers’ willingness to 
pay. When decision-makers are willing to pay less than €700 (€0 - €700) per 
additional point on the HAM-A, CBT is likely to be the most optimal intervention 
from a cost-effective perspective. When the willingness to pay exceeds €700 per 
additional point on the HAM-A, CBT+SSRI has the highest probability of being the 
most optimal intervention.  
 It is important to keep in mind that patients receiving CBT+SSRI and SSRI, 
tapered medication at the end of the first year and were thus not using an SSRI 
during the second year of the study. Direct costs of the intervention were, as 
expected, higher for the combined CBT+SSRI treatment as compared to intervention 
costs of the monotherapies. However, on the long term, CBT+SSRI proved to be 
more cost-effective than SSRI-only. Our data revealed no long-term detrimental 
effect of the combined treatment as was suggested by others.(6) 
 While the present cost-effectiveness analysis shows that CBT+SSRI and CBT are 
more cost-effective treatment modalities as compared to SSRI-only, results of the 
study by Mc Hugh et al., suggest monotherapies to be more cost-efficacious as 
compared to combined treatment.(4) However, this study differs from the present 
study on several methodological aspects. The Mc Hugh et al. study is presented as an 
efficacy study rather as an effectiveness study due to the fact that treatments were 
delivered in specialized treatment centers under best conditions possible. The 
present study on the other hand, aimed at delivering treatments in real-practice, 
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under care as usual conditions, and without stringent inclusion criteria which makes 
it an effectiveness study rather than an efficacy study.
(27,28)
 Further, patients 
receiving pharmacotherapy received imipramine rather than an SSRI while the latter 
is considered first-line pharmacological treatment for PD. Also, only patients without 
AG were included while in the present sample, half of the subjects suffered from 
moderate to severe AG. Finally, only direct costs were assessed in the McHugh et al. 
study thereby not addressing the issue of considerable indirect costs associated with 
PD.  
 Limitations of the present study include the fact that only complete cases were 
included although this was obviated by conducting an additional sensitivity analysis 
focusing on imputation of missing data which revealed similar overall results. 
Further, in contrast to several previous studies on the subject of cost-effectiveness in 
the field of anxiety disorders,
(2)
 QALYs (Quality-Adjusted Life Years) were not 
assessed in the current study. QALYs may, at least in theory, be used by decision 
makers to prioritize alternative healthcare interventions on a national level. 
Unfortunately, there is currently no (inter) national consensus on acceptable 
benchmarks per QALY gained, let alone for disease-specific outcomes like the HAM-A 
applied in the current study. Decision-makers will eventually have to interpret 
whether the indicated costs per additional unit of health outcome gained, as found 
in this study, warrant further implementation of CBT or CBT+SSRI. 
 Strengths of the present study include the design of the study in which patients 
were assessed not only while receiving active treatment but also after treatment 
discontinuation, e.g. after tapering medication in case of SSRI use. The follow-up 
period of one year provided extensive information on post-treatment course. Also, 
both direct and indirect costs were included in the analyses. Further, three 
treatment variants for PD with or without AG were directly compared within a single 
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cost-effective analysis, which makes optimal use of the data and enhances the 
interpretability of the current economic results. Finally, this study being an 
effectiveness study rather than an efficacy study attests to the generalizability of 
present findings. 
 In conclusion, the present cost-effectiveness analysis shows that the optimal 
treatment for PD with or without AG is CBT or CBT+SSI. Future research may attempt 
to further clarify the relationship between the level of comorbid AG and treatment 
allocation. The results from chapter 5 which focused on rate of improvement in the 
same multicenter trial, revealed that especially for PD patients with additional AG, 
the combined CBT+SSRI treatment was to be recommended over the 
monotherapies. Hypothetically, combining the results of this study and the present 
study would nominate CBT+SSRI as first-line treatment for PD patients with 
moderate or severe AG, and CBT as first-line treatment for PD patients without or 
with only mild AG. Future studies on this subject might benefit clinicians in the field 
resulting in a refinement of existing guidelines regarding treatment allocation. 
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7.1  Introduction 
 
The overall goal of the studies in the present thesis was to make a contribution to 
the on-going search for the best possible treatment for patients suffering from PD 
with or without AG. To this end, a randomized clinical trial was conducted in the 
Netherlands comparing CBT, SSRI, and their combination aimed at treating PD with 
or without AG. Patients were treated for one year including medication taper and 
subsequently seen twice during the second (follow-up) year of the study. Next to 
establishing long-term (differential) treatment effectiveness, we aimed at testing the 
context-safety hypothesis which predicts a detrimental effect of tapering 
medication. Based on outcome from treatment effectiveness studies, only limited 
evidence for this hypothesis existed up to date. Additionally, the role of concurrent 
AG was investigated. Determining differential rate of improvement was also a goal of 
the present thesis. Finally, we evaluated treatment modalities economically e.g. 
determined their cost-effectiveness. In the present chapter, the main results of the 
current thesis will be summarized, points of consideration and clinical 
recommendations will be discussed, and future directions for research will be 
proposed. 
 
7.2 Main results 
 
Main results of the current thesis will be summarized and discussed thereby 
addressing the following topics: treatment effectiveness, differential treatment 
effectiveness, context-safety hypothesis, role of concurrent AG, rate of 
improvement, and cost-effectiveness.  
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 Treatment effectiveness 
 
In the present design, patients were assessed before and after tapering, allowing us 
to directly study the effect of tapering medication. Patients in each treatment group 
improved significantly from pre- to posttest 1 (see chapter three) on the primary 
outcome measures level of anxiety, degree of coping, and remitter status, as well as 
on the secondary outcome measures depressive symptomatology, health related 
quality of life, and treatment satisfaction. Gains were preserved from posttest 2 
through-out the follow-up period. No fall-off in gains was observed for either 
treatment modality after treatment discontinuation up to the second follow-up (see 
chapter four).  
 
 Differential treatment effectiveness 
 
After nine months of treatment, before starting medication taper (see chapter 
three), CBT+SSRI was clearly superior to CBT in both completer and intent-to-treat 
analysis (ITT). Completer analysis revealed superiority of CBT+SSRI over SSRI on three 
measures and no differences were seen between CBT and SSRI. ITT analysis revealed 
superiority of SSRI over CBT on four measures and no differences between CBT+SSRI 
and SSRI. Thus, CBT+SSRI was clearly superior to CBT but differences between 
CBT+SSRI and SSRI, and between SSRI and CBT, were small. Long-term results were 
presented in chapter four. Some superiority of CBT+SSRI and SSRI as compared to 
CBT was observed at posttest 1. However, at both follow-ups, differences between 
treatment modalities proved non-significant.  
 These findings match those as reported by De Beurs et al.
(1)
 in their naturalistic 
follow-up study. At posttest, the combined fluvoxamine plus exposure treatment 
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proved superior to the other treatment modalities (placebo + exposure, 
psychological panic management + exposure, and exposure alone). Two years after 
posttest, this superiority was no longer present. It is suggested by the authors that 
this is not caused by a recurrence of symptoms in the exposure + fluvoxamine group 
but rather by the other treatment groups catching up during the follow-up period. 
These findings are in line with a review study on multiple disorders comparing 
combined CBT and pharmacotherapy with CBT and placebo. Four trials on PD were 
included. A median post-acute treatment effect was observed and no differences 
were found between treatment modalities at 6-month follow-up.
(2)
   
 It must be noted that in most treatment outcome studies, short term 
effectiveness is usually assessed within three months after starting treatment (see 
Table 1.1, chapter one). In a meta-analysis including 21 studies,(3) the typical length 
of the acute-phase active treatment was between 8 and 12 weeks. In the present 
thesis, the first assessment took place after nine months and this enables us to 
evaluate treatments as maintenance therapy. At that time, patients in all groups 
were significantly improved and CBT+SSRI outperformed CBT-only. 
 
 Context- safety hypothesis 
 
Based on the context-safety hypothesis (see chapter one), we expected CBT to be 
more durable as compared to SSRI and CBT+SSRI. As a result, a fall-off in gains of the 
combined treatment after medication taper was expected and patients receiving CBT 
were expected to need less aftercare as compared to the other groups. Overall, the 
results of the studies in the present thesis do not confirm the context-safety 
hypothesis. Regarding the need for aftercare, results indicated that a little more 
CBT+SSRI patients received some form of additional treatment during follow-up as 
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compared to the patients in the monogroups but the difference was non-significant 
(CBT+SSRI: 33%, CBT: 16%, SSRI: 21%).  
 Furthermore, on the outcome effect measures, no fall-of in gains for either 
treatment modality was observed. Visual inspection of Figure 2 (chapter four) might 
suggest a temporary detrimental effect of tapering medication (although non 
significant) followed by a recuperation in-between follow-up 1 and follow-up 2. 
Results of the Sharp et al.
(4)
 and Barlow et al.
(5)
 studies indicated that treatments 
incorporating CBT (as monotreatment or combined with drug treatment) may be 
more durable as compared to treatments not offering CBT. The difference in long-
term outcome between the present study and the studies by Barlow et al. and Sharp 
et al. might be explained by the longer follow-up period (twelve as compared to six 
months) but more research regarding this matter is needed. The context-safety 
hypothesis is mainly derived from experimental studies framed within the learning 
theory paradigm. Explaining present findings within this learning theory bridging the 
gap between laboratory findings and human pathological anxiety and treatment 
aimed at ameliorating this anxiety remains a challenge for future studies.(6) 
 
 Role of concurrent AG 
 
Out of the 150 patients that started treatment in the present study, 72 patients did 
not suffer from AG or suffered from mild AG (48%), and 78 patients suffered from 
moderate or severe AG (52%).  
 In a meta-analysis,(3) it was concluded that there are no reasons for a different 
treatment regimen in PD patients without AG  as compared to patients with AG. At 
least two findings from the present thesis are relevant in this respect. First, we found 
a significant main effect of AG status (no/mild vs. moderate/severe) as predictor 
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variable for the primary outcome measure PAI Coping (see chapter four) indicating 
that patients with moderate/severe AG reported less confidence in their ability to 
cope with future panic attacks as compared to patients without or with only mild AG. 
Second, regarding rate of improvement, results indicated that among patients with 
moderate or severe AG, rate of improvement was faster with CBT+SSRI as compared 
to SSRI and CBT. These findings are in accordance with the findings of De Beurs et 
al.
(7)
 suggesting the combined treatment to be most beneficial for PD with moderate 
or severe AG after twelve weeks. Also, Telch et al.
(8)
 found a combined imipramine 
and exposure treatment most beneficial for severe agoraphobics. These findings are 
in line with a meta-analysis by Van Balkom et al.
(9)
 which suggests that for PD with 
AG, a combination of antidepressants with exposure in vivo is the most potent short-
term treatment. Consequences for clinical guidelines are discussed in the section 
clinical recommendations. 
 
 Rate of improvement 
 
Regarding rate of improvement (chapter five), a significant decline in frequency of 
panic attacks was observed during the one year treatment period for each treatment 
modality. SSRI and CBT+SSRI were both associated with a significant faster rate of 
improvement on panic frequency as compared to CBT. This is in accordance with the 
study by Sharp et al. (1996). It was found that the combined fluvoxamine plus CBT 
group produced significant change earlier as the other treatments. The finding that 
SSRIs have a more immediate effect as compared to CBT is acknowledged by 
different authors(10,11) who subsequently fear that this rapid suppression of anxiety 
may deprive patients of robust safety learning and consequently predicts a stronger 
return of fear. Based on current findings this fear seems uncalled for.  




The economic evaluation of our data (chapter six) revealed that in all three groups, 
total costs were largely influenced by costs of the interventions and productivity 
losses. Furthermore, costs of medication use were substantial for patients in both 
the SSRI and CBT+SSRI group. When examining the balance between costs and health 
outcomes, both CBT and CBT+SSRI led to more positive outcomes than SSRI-only. 
Although CBT was associated with lower costs, assessed health outcomes were 
slightly more in favor of CBT+SSRI.  
 
7.3 Points of consideration 
 
Six topics will be addressed: dropout, remittance and relapse, no tapers, additional 




In the present study, 53 patients (35%) prematurely ended treatment. Note that 
dropout criteria differ between studies, are often related to completer criteria, and 
directly influence dropout-, completer- and relapse-rates (see next section) and 
thereby overall results of a study.  
 As explicated in chapter four, we applied rather strict definitions of dropouts 
and completers. In the present study, a patient who received fourteen CBT sessions 
and subsequently terminated treatment without therapist consent was considered a 
dropout while in some other studies such a patient would be categorized as a 
completer. We choose for this definition in order to ensure a homogenous 
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completer group but recognize that this has increased our number of dropouts. 
 In chapter three, present dropout rates are compared to the dropout rates 
derived from the Barlow et al. study.
(5)
 While in the present study the highest 
dropout rate was observed for CBT-only, in the Barlow et al. study, the highest 
dropout rate was observed for the anti-depressant only treatment. Based on the 
observed ES and dropout rates it was concluded that CBT in the present study did 
not perform worse compared to CBT in other studies (see chapter three) but rather, 
SSRI and CBT+SSRI performed better.  
   
 Remittance and relapse 
 
In the present study, patients were defined remitters when meeting all of the 
following criteria: free of panic attacks, minimal anticipatory anxiety, and minimal 
agoraphobia.  Subsequently, relapse was defined as no longer meeting remitter 
criteria at a particular assessment while these criteria were met at a previous 
assessment. Note that there are no single broad accepted definitions of remittance 
and relapse in studies on PD. When comparing outcome of different studies, applied 
definitions of remitter status and relapse therefore have to be taken into account. In 
the Barlow et al. study for example, relapse is defined as a drop on one particular 
outcome measure (e.g. the Clinical Global Impression scale). At follow-up, the 
combined CBT + imipramine treatment was associated with the highest relapse rate; 
40%, as compared to 8% for CBT-only and 25% for imipramine-only. In a naturalistic 
long-term pharmacotherapy study,(12) patients were defined remitters when 
reporting no panic attacks during an eight-week period. Of the patients that 
(spontaneously) discontinued medication treatment, 35% still met remitter criteria 
after three years. In comparison, present findings revealed that at follow-up 2, 48% 
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of CBT+SSRI, 31% of CBT, and 25% of SSRI patients still met remitter criteria. In a 
study by Biondi et al.,
(13)
 patients who had achieved remission after drug treatment 
and received concurrent CBT during follow-up were compared to patients who had 
achieved remission after drug treatment and subsequently did not receive 
concurrent CBT during follow-up. Relapse rates were significantly higher among 
patients who had received medication-only as compared to patients who had 
received both medication and CBT. Treatment allocation however was based on 
preference and this seriously limits the validity of these findings.  
 In sum, while in the Barlow et al. study the combined treatment was found to 
have the highest relapse rate; in the present study the combined treatment was 
found to have the highest remitter rate. The latter finding is in line with a naturalistic 
study(13) who also found the combined treatment to be most durable at follow-up.  
 Again returning to present findings, although results do not confirm CBT+SSRI 
and SSRI patients to be more vulnerable for relapse as compared to CBT patients, 
interestingly, the timing of relapse did differ between treatment modalities. Patients 
having received SSRI seemed most vulnerable to relapse in-between posttest 1 and 
posttest 2 (tapering period), patients having received CBT+SSRI seemed most 
vulnerable to relapse in-between posttest 2 and follow-up 1, and patients having 
received CBT seemed most vulnerable to relapse in-between follow-up 1 and follow-
up 2 (see remitter status in Table 4.4, chapter four). Relapse rates were low in the 
present study but a trend seems to be that in time, first gains of SSRI, than CBT+SSRI, 
and finally CBT are prone to abatement. This (non-significant) finding matches the 
context-safety hypothesis. 
 




Only a small proportion of the patients in the present sample, 16.2%, proved unable 
to taper medication according to protocol. This suggests that with good therapist 
guidance and a clear rationale, the vast majority of patients are indeed able to taper 
their medication. No-taper patients continued to improve and prolonging treatment 
resulted in additional patients achieving remitter status. Note however, that no-
taper patients never reached completer levels; they reported overall higher anxiety 
and depression levels and felt less confident about their ability to cope with future 
panic attacks as compared to completers (see chapter four). This lack of self-efficacy 
may cause these patients to fear taper or may be caused by not-tapering: it is 
difficult to differentiate between cause and effect in this matter.  
 Although present findings suggested subsequent improvement in this small 
group of patients, there is also some evidence suggesting that patients might 
experience a return of their complaints despite continued treatment. In a study by 
Simon et al.,(14) nearly half of the patients treated with pharmacotherapy 
(benzodiazepines, antidepressants, or both) who initially achieved remission 
relapsed within a 24-month follow-up period while pharmacotherapy was continued 
suggesting that prolonging medication treatment does not completely prevent 
relapse. 
 In the present study, medication taper was included in the design and scheduled 
after nine months of SSRI-use. Some naturalistic studies deal with long-term 
treatment adherence and spontaneous treatment discontinuation. Understanding 
why patients spontaneously discontinue drug treatment might be important when 
long-term treatment adherence is considered essential in preventing relapse and 
recurrence of symptoms. In several studies, patients are not invited to taper but 
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rather monitored naturalistically.  
 In one such naturalistic study,
(15) 
patients received paroxetine for twelve 
months. After twelve months, they were given the choice to continue for another 
twelve months or to taper medication. In the latter group, 14% of the patients 
subsequently relapsed during the follow-up year. Note that patients were not 
randomized at random but by preference. It was concluded that the extension of 
paroxetine maintenance treatment from 12 to 24 months did not further decrease 
the risk of relapse after medication discontinuation. 
 In a three-year naturalistic study,
(16,12)
 almost 55% of the 326 patients that were 
followed for three years spontaneously discontinued treatment. The observation 
that patients discontinue treatment spontaneously attests to the importance of 
studying post-treatment course. A substantial number of the patients who defaulted 
from further treatment did so due to achieving symptom remission (36.9%) and only 
a small portion of patients did so because of side effects. In comparison, in the 
present study, 24.4 % of all patients who dropped out (this included patients that 
had received CBT-only) did so because of side effects and no subjects reported 
symptom remission as a reason for dropout. 
 
 Additional treatment during follow-up 
 
In the present study, the number of patients in need of additional treatment during 
follow-up seems limited although comparison with other studies is difficult as data 
on this subject is sparse. No data regarding this matter is provided in the Barlow et 
al. study(5) nor in the other studies included in Table 1.1 (see chapter 1) with the 
exception of the Sharp et al. study.
(4)
 In the latter study, about half of the patients 
were in need of additional treatment in between end-point assessment and follow-
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up and these were excluded from analysis. In the present study, treatments lasted 
for one year and perhaps treatment duration contributed to the fact that relatively 
few patients were in need of additional treatment during follow-up. In a naturalistic 
follow-up study by De Beurs et al.
(1)
 77% of the original sample had received some 
form of additional treatment during a two year naturalistic follow-up. In comparison, 
this rate was 23% during the twelve month follow-up period for the completer 
sample in the present study. One possible explanation might be the shorter duration 
of treatment. Twelve treatment sessions were offered in the study by De Beurs et al. 
and posthoc, the authors considered this to be an insufficient number of sessions. 
Regarding CBT however, the assumption that longer treatment duration prevents 
relapse and thus the need for additional aftercare is at odds with studies reporting 
that shortening treatment has no detrimental long-term effect.(17) An interesting 
finding for CBT is that patients having received CBT received less aftercare as 
compared to patients having received CBT+SSRI and this finding, although not 
confirmed by other findings, does match the context-safety hypothesis.  
 
 Validity of results 
 
The concept of internal validity refers to the extent to which the particular 
intervention, rather than extraneous influences, can be considered to account for 
the observed results. Closely connected to internal validity is the concept of 
treatment integrity: the evaluation of the extent to which treatment was conducted 
as intended. It might be reasoned that CBT in this matter has more to prove than 
SSRI. The concept of external validity refers to the extent in which results can be 
generalized or extended to people, settings, times, measures, and characteristics 
other than those in this particular experimental arrangement. In our introductory 
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chapter, we stated that comparing treatments in real-world settings is considered an 
important endeavour. The present study can be viewed as a hybrid study
(18)
 
attempting to move from efficacy toward effectiveness (see chapter one for 
introduction of these concepts). Clinical randomized trials are usually designed to 
evaluate short-term clinical outcomes while effectiveness studies are usually 
designed to evaluate long-term clinical and morbidity outcomes. Some 
characteristics of effectiveness studies include large(r) study samples, a societal 
perspective (e.g. collecting cost data), less frequent follow-up assessments (e.g. 
every few months in stead of weekly), and less clinical detail (e.g. no stringent 
treatment protocols). Internal and external validity cannot both be optimized in one 
study. In general, efficacy studies place a higher priority on internal validity while 
effectiveness studies place a higher priority on external validity.(19) 
 In designing the present study, decisions were made enhancing external validity 
and consequently diminishing internal validity. Internal validity was threatened by 
the absence of blinding. Another threat to internal validity is the fact that no formal 
treatment integrity checks were applied. Treatment integrity was monitored through 
detailed forms regarding session content completed by therapists. Important to note 
at this point is that effect sizes were calculated (see chapter three) and these 
revealed that the CBT in the present study performed comparable to other studies 
while the SSRI and CBT+SSRI modalities performed even better as compared to the 
medication-only treatments and combined treatments in other studies. We can 
conclude therefore that indeed, treatments were delivered as supposed to and that 
treatment generally performed as expected.(20) Note that to our knowledge, this is 
the first study on PD to report between group ES. 
 A different threat to internal validity is the fact that it was decided to allow 
patients to use (small doses of) benzodiazepines. This is in accordance with the study 
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of Barlow et al. In the present sample, 37% of the patients used benzodiazepines at 
some point during the study (see chapter three for additional findings regarding 
benzodiazepine use). It was concluded that benzodiazepine use was limited and 
could not be held accountable for established results. 
 The present study can be considered highly externally valid. Rather than 
delivering treatments in specialized anxiety clinics only (like for instance in the 
Barlow et al. study) the present study was conducted in different settings, including 
general mental health centers and treatments were delivered by different therapists 
with different levels of experience (note that CBT treatment in the study by Sharp et 
al.
(4)
 is delivered by one single therapist). Further, no stringent inclusion criteria were 
applied and treatments were intended to approximate care as usual. CBT consisted 
of 21 sessions; although this is more than common in most other trials (see chapter 
one) this number might actually be more in line with common practice in general 
mental health centers. Visits concerning pharmacotherapy lasted 20 minutes each. 
This might be in line with general health care practice but data is limited. Regarding 
CBT, SSRI and combined treatment regimens; there is a need for collecting 
naturalistic data concerning treatment length and therapist contact time in general 




Next to the different limitations already explicated in chapters three to six, some 
general points deserve additional mentioning. First, different methodologies and 
corresponding statistical techniques were applied in the different studies included in 
the present thesis. In chapter three we choose for a completer and ITT analysis. 
Subsequently, when all data was collected, for the analysis of the long-term results, a 
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multilevel approach seemed more appropriate.  
 We have gathered a large amount of data from our participants but in hindsight 
there are, of course, ideas on additional information that would have been useful. 
For instance, we could have studied side effects not only in the SSRI and CBT+SSRI 
modality but also in patients receiving CBT-only. Further, besides gathering data on 
presence of side effects, the degree to which patients suffer from these side effects 
would have been interesting as well. This would have contributed to a better 
understanding on the subject of patients’ perspective on treatment acceptance. 
Also, more information on attribution of effect would have been of value (see 
section future research). 
 
7.4 Clinical recommendations 
  
With respect to present findings, we want to emphasize that each treatment 
modality proved effective and participating patients, regardless of which treatment 
they had received, were highly satisfied with the received treatment at treatment 
end-point (as indicated by scores on a questionnaire assessing treatment 
satisfaction). Nevertheless, current findings allow us to draw-up some guidelines in 
treatment allocation.  
 Several disadvantages of both monotreatments derive from the data. SSRI as 
monotreatment was: (1) less cost-effective; (2) associated with smallest remitter 
rates; and (3) patients reported lower coping scores. Disadvantages for CBT as 
monotreatment included: (1) highest dropout rate; (2) less remitters as compared to 
CBT+SSRI; and (3) longer time needed to achieve results similar to the combined 
treatment. Regarding the combined treatment, CBT+SSRI yielded excellent results up 
to treatment end-point and gains were preserved throughout the one-year follow-up 
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period. Advantages of the combined CBT+SSRI treatment as compared to both 
monotreatments include: (1) highest satisfaction scores; (2) lowest dropout rate; (3) 
most remitters at follow-up 2; and (4) faster rate of improvement as compared to 
monotreatments. 
 Interestingly, CBT treatment in the CBT+SSRI modality did not last longer (as 
measured in number of received sessions) as compared to CBT treatment in the CBT-
only condition: combining treatments may thus result in less CBT sessions thereby 
enhancing cost-effectiveness.  
 Taken results of chapters three to six together, we would suggest CBT+SSRI as 
first-line treatment for PD patients with moderate or severe AG, and CBT as first-line 
treatment for PD patients without or with only mild AG. Additional clinical points we 
would like to suggest based on the present study are: 
- Regarding the CBT+SSRI treatment, we would like to suggest waning patients 
from medication while CBT is ongoing. This may require biweekly of monthly CBT 
booster sessions during tapering. 
- Additional benzodiazepines are associated with more cons than pros. 
Furthermore, present findings suggest that patients can do without.  
- SSRIs may be tapered: the general fear of relapse after discontinuation seems 
uncalled for.  
- Providing information and guidance surrounding SSRI use and SSRI taper may 
contribute to the strength of the combined CBT+SSRI treatment.  
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 In the literature, barriers to treatment accessibility are put forward as a 
pragmatic argument in favor of SSRI-only. This might be a problem in some countries 
(e.g. the United States
(21)
), but is not well supported regarding current general 
mental health care settings in the Netherlands. Moreover, if limited CBT accessibility 
was indeed determined, correcting this problem by enhancing CBT availability seems 
more appropriate than resigning to a less favorite option.   
 Algorithms derived from the multidisciplinary guidelines from the 
Netherlands
(22) 
suggest to deliver combined CBT and SSRI treatment as a next step 
when monotreatment has been only partially successful (see paragraph 1.4.5 of 
chapter one). Regarding CBT, a distinction is made between exposure in vivo and 
panic management, e.g. panic control treatment, with the first being especially 
important when agoraphobic avoidance is present. This distinction might not be 
useful because in daily clinical practice, as in the CBT protocol used in the present 
study, both exposure in vivo and so called panic management interventions such as 
interoceptive exposure and cognitive restructuring are incorporated in most CBT 
packages.  
 In discussing clinical recommendations, it is interesting to take into account 
recent changes in diagnostic criteria as formulated by the American Psychiatric 
Association (APA). In the latest edition of the DSM, DSM-5 (first released in May 
2013), the occurrence of panic attacks can be listed as a specifier that is applicable to 
all DSM-5 disorders. Further, PD and AG are unlinked in DSM-5. This means that two 
disorders can be diagnosed: PD and AG each with separate criteria. This might imply 
that in future, for patient with only PD, CBT would be treatment of first choice and 
for patient with both disorders, PD and AG, the combined treatment is to be 
preferred.  
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7.5 Suggestions for future research 
 
Some of the present findings suggest a detrimental effect of tapering medication 
(e.g. timing of relapse and additional care during follow-up: see previous sections) 
but overall, contrary to prior expectations, we did not find evidence for the context-
safety hypothesis. Future research might contribute to the understanding of these 
results. In this light, the concept of attribution of effect may be of interest. Although 
speculative for now, it may be that context is also defined by degree of experienced 
self efficacy.
(13)
 When patients receiving drug treatment attribute treatment gains 
solely or mainly to the drug, this may be associated with a lower self efficacy defining 
internal context. Medication taper will then result in an internal context shift 
resulting in loosing safety and increasing vulnerability for relapse. This view would 
match findings as reported by a study
(23)
 in which drug treatment was combined with 
exposure or relaxation. It was found that patients who attributed their gains to 
medication (alprazolam or placebo) reported more withdrawal symptoms and 
greater loss of gains as compared to patients who attributed their gains to their own 
efforts during treatment. 
 In the present study, too little information regarding attribution of effect was 
available to reliably report this in our outcome studies. However, at each session 
therapists were asked to rate attribution of effect as expressed by their patients. It 
was found that at follow-up 1:  
- 13.6% of the patients in the CBT+SSRI group attributed effect mainly to the SSRI, 
- 40.9 % of the patients in the CBT+SSRI group attributed effect mainly to the CBT 
and, 
- 45.5% of the patients in the CBT+SSRI group attributed effect evenly to both. 
Note that patients already had tapered medication at this point. Subsequently, six 
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month later at follow-up 2 it was found that: 
- 5.6% of the patients in the CBT+SSRI group attributed effect mainly to the SSRI, 
- 55.6% of the patients in the CBT+SSRI group attributed effect mainly to the CBT 
and, 
- 38.9% of the patients in the CBT+SSRI group attributed effect evenly to both. 
For patients having received the combined treatment attribution to medication thus 
tends to diminish as time progresses and attribution to CBT tends to increase. 
 Closely related to this subject is the concept of locus of control. In a study by 
Bakker et al.(24) the Multidimensional Anxiety Locus of Control Scale (MALC) assessed 
different attributions of the course of PD and yielded one ‘internal’ and three 
‘external’ (chance, medication, therapist) scales. Patients were treated with 
cognitive therapy, clomipramine, or paroxetine (see chapter 1, paragraph 1.4.3). 
Treatment with cognitive therapy resulted in an increase of ‘internal’ anxiety control 
orientation, in comparison with antidepressant therapy. Perhaps future research will 
more firmly establish a differential effect between treatment modalities for PD with 
respect to attribution of effect and locus of control contributing to a better 
understanding of involved mechanisms of change.  
 Present findings advocate a wider implementation of CBT and SSRI 
simultaneously, as integrated treatment, especially for patients with concurrent 
moderate or severe AG. No fall-off in gains was observed for CBT+SSRI and this 
matches the finding of a meta-analysis reported in 2006.(3) The combined treatment 
should be further investigated with respect to the optimal sequencing of treatments, 
the optimal duration of medication with respect to CBT, the optimal duration of CBT 
with respect to medication, and treatment rationales offered to patients in relation 
to outcome. In the present design, patients tapered medication while receiving 
ongoing CBT. Future studies might differentiate between (at least) two combined 
    
Page 185 
treatment regimens: tapering medication following CBT discontinuation, and 
tapering medication while receiving ongoing CBT. Although the latter treatment 
modality might intuitively be accredited with relapse prevention, data corroborating 
this is not present up to date.  
 With respect to CBT; the present findings regarding rate of improvement raise 
the question if interventions within CBT can be optimized in order to set in change 
sooner e.g. by changing the order of interventions or by intensifying home-work in 
the first phase of treatment. In the last twenty years, there have been relatively few 
innovations in CBT protocols
(25)
: these may however be necessary with respect to 
timing of response. As an example of new innovations, pilot studies are being 
conducted in which coping skills are added to exposure therapy in the hope of 
improving outcome.(26) 
 In the present design, the first assessment was after nine months of treatment. 
Future studies should evaluate treatments earlier in time. There is evidence that 
continuing treatment in patients who in the early phase fail to respond is less 
effective.(27) Also, evidence from an open trial on CBT corroborates the importance 
of early treatment evaluation allowing clinicians to consider alternative treatment 
strategies early in treatment.(28) 
 Further, the follow-up period might be extended; twelve months is (albeit 
longer than in most clinical trials) too short from an effectiveness perspective. 
Finally, patients may be monitored more repeatedly. In the same manner as 
frequency of panic attacks was studied in chapter five, process oriented studies 
could clarify course in time regarding different PD morbidity aspects.  
 




PD is a well treatable disorder and patients were satisfied with treatment regardless 
whether they had received SSRI, CBT or CBT+SSRI. In the long-term and especially for 
patients with concurrent moderate or severe AG, the combined CBT+SSRI treatment 
modality might be recommended as the treatment of choice being cost-effective and 
yielding results early in treatment with long-lasting effect. Contrary to some previous 
findings, in the present study the combined treatment was found to have no 
disadvantages on the long-term after medication taper. Further inquiry into involved 
mechanisms of action might shed new light on the proposed context-safety 
hypothesis and ultimately result in even more effective treatments.   
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DE BEHANDELING VAN PANIEKSTOORNIS 





Het doel van het onderzoek beschreven in dit proefschrift is een bijdrage leveren aan 
het optimaliseren van de behandeling van paniekstoornis met of zonder agorafobie. 
Het ondergaan van een paniekaanval is een bijzonder nare ervaring. Plotseling, 
zonder duidelijke aanleiding, treedt er angst op waarna de angst snel oploopt en een 
piek bereikt. Lichamelijke sensaties die optreden zijn bijvoorbeeld hartkloppingen, 
trillen, duizeligheid, een versnelde ademhaling en een druk op de borst. Tijdens een 
paniekaanval worden deze sensaties doorgaans als gevaarlijk geïnterpreteerd. 
Mensen kunnen bijvoorbeeld denken dat ze stikken, een hartaanval krijgen, 
flauwvallen, de controle verliezen of gek worden. Niet iedereen die wel eens een 
paniekaanval heeft ervaren, ontwikkelt een paniekstoornis. Mensen met een 
paniekstoornis zijn ook tussen aanvallen door bijna voortdurend bang voor volgende 
aanvallen of bezorgd over de gevolgen van aanvallen. Als er daarnaast sprake is van 
vermijding van situaties of plaatsen waar een volgende aanval zou kunnen optreden 
spreken we van agorafobie. Paniekstoornis kan dus zowel met als zonder agorafobie 
voorkomen. Paniekstoornis wordt behandeld met psychofarmaca of met 
psychotherapie en soms ook met beide. Als er gekozen wordt voor farmacotherapie 
is een behandeling met een SSRI eerste keus; een antidepressivum wat bij zowel 
depressie als angst wordt voorgeschreven (SSRI staat voor ‘selective serotonin 
reuptake inhibitor’. In het Nederlands: ‘selectieve serotonine heropname remmer’). 
Wat psychotherapie betreft is cognitieve gedragstherapie (CGT) eerste keus.  
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In hoofdstuk 1 van dit proefschrift wordt onder andere een overzicht gegeven van 
bestaande behandelvormen en beschikbare empirische evidentie. Voor beide 
monotherapieën, CGT en SSRI, geldt dat er veel onderzoek gedaan is naar de 
werkzaamheid op kortere termijn. Onderzoek naar de werkzaamheid op langere 
termijn is veel minder vaak uitgevoerd. Wat betreft farmacotherapie is er bovendien 
behoefte aan meer informatie over het behoud van effect na het afbouwen van de 
medicatie. De grootste lacune bestaat op het gebied van onderzoek naar de 
effectiviteit van de combinatiebehandeling waarbij patiënten gelijktijdig een SSRI en 
CGT ontvangen. Er zijn maar weinig studies uitgevoerd waarin SSRI, CGT en de 
combinatie van beide, binnen hetzélfde onderzoek werden vergeleken. Uit 
onderzoek tot op heden blijken de verschillende behandelvormen allen effectief en 
zijn er daarnaast kleine verschillen gevonden. Zo wordt er verondersteld dat 
patiënten die de combinatiebehandeling hebben ontvangen na het staken van de 
medicatie mogelijk gevoeliger zijn voor terugval in vergelijking met patiënten die 
alleen een psychologische behandeling hebben ontvangen voor hun klachten. Dit zou 
verklaard kunnen worden vanuit de zogenoemde context–veiligheid hypothese: als 
veiligheid wordt aangeleerd in de context van medicatiegebruik zou die veiligheid 
wellicht komen te vervallen in een nieuwe context ontstaan na het afbouwen van de 
medicatie. Experimenteel onderzoek op het gebied van aan- en afleren van angst 
biedt enige ondersteuning voor deze hypothese maar het is nog te vroeg om 
uitspraken te kunnen doen met betrekking tot klinisch onderzoek bij patiënten met 
paniekstoornis.  
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In hoofdstuk 2 wordt het onderzoek zoals beschreven in dit proefschrift nader 
geïntroduceerd. Het betreft een zogenaamde RCT: een Randomized Clinical Trial. 
Proefpersonen mochten niet zelf kiezen welke behandeling zij wilden ontvangen 
maar werden toegewezen aan één van de behandelcondities door middel van loting. 
Enkele uitgangspunten bij het opzetten van het onderzoek waren:  
 - Het onderzoeken van CGT, SSRI en de combinatiebehandeling (CGT+SSRI) binnen 
één onderzoeksdesign. 
- Het onderzoeken van de effectiviteit ook op langere termijn en ook na staken van 
de medicatie. 
- Patiënten zonder agorafobie maar ook met (lichte, matige, of ernstige) agorafobie 
deel laten nemen om meer zicht te krijgen op de rol van agorafobie in de 
behandeling van paniekstoornis.  
- Het nastreven van een goede externe validiteit; dat wil zeggen dat we de 
omstandigheden waaronder behandeling plaatsvond zoveel mogelijk wilden doen 
lijken op de gangbare klinische praktijk. 
 Deelnemers aan het onderzoek waren allen patiënten met paniekstoornis met 
of zonder agorafobie. Zij werden behandeld in elf verschillende instellingen in 
Nederland. De criteria die gehanteerd werden bij de inclusie worden in hoofdstuk 2 
beschreven alsook de gebruikte meetinstrumenten en protocollen. Proefpersonen 
werden toegewezen aan één van drie behandelcondities: CGT, SSRI, of CGT+SSRI. 
Voor iedere deelnemer duurde het onderzoek twee jaar: het eerste jaar bestond uit 
de behandeling, het tweede jaar was een follow-up jaar. Er waren vijf 
meetmomenten: voorafgaand aan de behandeling, na negen maanden behandeling 
(terwijl ingesteld op een adequate dosering van de SSRI in het geval van SSRI 
gebruik), na afloop van de behandeling (na het staken van de CGT en / of na het 
afbouwen van de SSRI), en zes en twaalf maanden na het staken van de behandeling 
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(de follow-up metingen). Metingen bestonden eruit dat proefpersonen geïnterviewd 
werden en dat hen gevraagd werd diverse vragenlijsten in te vullen.  
 De behandeling met CGT besloeg 21 sessies en patiënten kregen uitleg over 
paniekstoornis en de behandeling, gevolgd door interoceptieve exposure, cognitieve 
therapie en exposure in vivo. Exposure is een ander woord voor blootstelling. Bij 
interoceptieve exposure worden mensen blootgesteld aan de interne lichamelijke 
sensaties die op kunnen treden tijdens paniek. Bij exposure in vivo gaan mensen 
oefenen in het opzoeken van situaties en het verblijven op plaatsen die ze uit angst 
voor volgende paniekaanvallen mogelijk liever vermeden. Cognitieve therapie richt 
zich op het veranderen van de angst opwekkende gedachten en opvattingen 
(cognities) die mensen er op na houden.  
 De behandeling met een SSRI bestond uit negen behandelcontacten. 
Proefpersonen kregen uitleg over paniekstoornis en de behandeling en werden 
ingesteld op een van vijf SSRIs: fluvoxamine, sertraline, fluoxetine, paroxetine en 
citalopram. Na ongeveer negen maanden werd de SSRI weer langzaam afgebouwd 
zodat proefpersonen aan het einde van het behandeljaar medicatievrij waren. 
Proefpersonen die geloot werden in de CGT+SSRI groep ontvingen zowel CGT als 
SSRI. Deze behandelingen werden gegeven door twee verschillende behandelaars en 
liepen parallel aan elkaar. 
 Het doel van het onderzoek was een bijdrage leveren aan de verdere 
optimalisering van de behandeling van paniekstoornis. Vragen die we onder andere 
graag wilden beantwoorden waren: zijn de behandelingen effectief? Is er verschil 
tussen de drie behandelvormen? Vinden we aanwijzingen voor de context-veiligheid 
hypothese? Blijft het effect van behandeling behouden na het staken van de CGT en 
/ of SSRI? Is de aanwezigheid en de ernst van de agorafobie van invloed op het 
therapieresultaat? Is er verschil tussen de behandelingen met betrekking tot het 
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tempo waarin verbetering optreedt? Is er een verschil tussen de behandelingen met 
betrekking tot de kosten die ermee gemoeid zijn in relatie tot hun effectiviteit? 
 
(Differentiële) therapie effecten 
 
In hoofdstukken 3 en 4 worden de resultaten beschreven van het 
effectiviteitsonderzoek.  
 In hoofdstuk 3 worden een aantal kenmerken van de onderzoekgroep 
gepresenteerd. In totaal zijn er 150 patiënten met paniekstoornis gestart met de 
behandeling. Deze groep bestond voor ongeveer de helft uit vrouwelijke 
proefpersonen (54.7%). Ongeveer de helft van de proefpersonen had geen of slechts 
milde agorafobie, bij de andere helft (52%) was er sprake van matige of ernstige 
agorafobie. Hoofdstuk 3 presenteert de resultaten van de meting na negen maanden 
toen de CGT gaande en / of de SSRI nog niet afgebouwd was. Er werd gevonden dat 
op dat moment alle drie de behandelvormen effectief waren; dat wil zeggen dat 
proefpersonen in alle drie de groepen een significante daling van hun klachten 
rapporteerden. CGT+SSRI bleek op een aantal maten effectiever dan CGT terwijl er 
niet veel verschil geconstateerd werd tussen CGT+SSRI en SSRI.  
 De effectgroottes van de drie behandelmodaliteiten werden berekend en 
vergeleken met effectgroottes zoals gerapporteerd in, of afgeleid uit, vergelijkbare 
onderzoeken. We wilden zodoende een uitspraak kunnen doen over de kwaliteit van 
de CGT, SSRI en CGT+SSRI binnen ons onderzoek. We vonden dat de CGT minstens zo 
goed presteerde als de CGT in andere onderzoeken en dat de SSRI en de 
combinatiebehandeling zelfs hógere effectgroottes opleverden in vergelijking met 
deze behandelmodaliteiten in andere onderzoeken.  
 Hoofdstuk 4 presenteert de resultaten tot en met de laatste follow-up aan het 
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einde van het tweede jaar. Naast de differentiële therapie effecten werd ook de 
relatie tussen therapie effect en zeven voorspellende variabelen onderzocht. Een 
aantal patiënten (35% van de onderzoeksgroep) stopte om verschillende redenen 
met de behandeling en / of het onderzoek gedurende het eerste behandeljaar. Hier 
vallen ook patiënten onder die bijvoorbeeld na een aantal weken CGT tevens 
begonnen met een SSRI behandeling; als zij geloot waren in de CGT groep werden ze 
als ‘uitvallers’ beschouwd in de analyses. Het aantal uitvallers was niet significant 
verschillend tussen de drie behandelgroepen. Een klein aantal van de patiënten die 
volgens protocol een SSRI ontvingen, hebben deze SSRI aan het einde van het 
behandeljaar niet af kunnen of willen bouwen. Deze ‘niet afbouw’ groep (14 
proefpersonen) werd in de analyses vergeleken met de ‘uitvalgroep’ (53 
proefpersonen) en de ‘completer’ groep (83 proefpersonen). Deze laatste groep was 
de grootste; het betreft de patiënten die de therapieën volgens protocol hadden 
afgerond. Patiënten in de ‘niet afbouw’ groep rapporteerden meer angst- en 
depressieve klachten vergeleken met patiënten in de ‘completer’ groep.  
 Uit de resultaten voor de completer patiënten bleek opnieuw dat patiënten in 
alle drie de behandelgroepen significant waren verbeterd. De 
combinatiebehandeling, CGT+SSRI, had als voordeel dat verbetering sneller optrad in 
vergelijking met alleen CGT terwijl deze laatste als voordeel had dat er geen 
bijwerkingen aan verbonden waren en iets korter duurde in tijd.  
 Gebaseerd op de context-veiligheid hypothese zouden we verwachten dat 
proefpersonen in de CGT+SSRI groep méér nabehandeling nodig zouden hebben in 
vergelijking met proefpersonen in de CGT groep. Samenhangend zou terugval na het 
afbouwen van de medicatie tot uiting kunnen komen door een terugkeer of 
verergering van klachten of een toename van het aantal paniekaanvallen. We 
vonden in onze resultaten over het algemeen geen bevestiging voor de context-
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veiligheid hypothese. Meer dan de helft (64%) van de ‘completer’ proefpersonen 
zocht gedurende het follow-up jaar géén aanvullende hulp. De proefpersonen die 
wel hulp zochten tijdens het follow-up jaar bleken ongeveer gelijk verdeeld over de 
drie behandelcondities: er waren weliswaar iets meer proefpersonen in de CGT+SSRI 
groep die nabehandeling nodig hadden maar het verschil bleek niet significant. De 
gunstige therapie effecten werden bovendien behouden tot en met het laatste 
meetmoment. Er vond dus over het algemeen geen terugval plaats gedurende het 
follow-up jaar nadat de behandelingen gestaakt waren.  
 Een van de voorspellende variabelen was ‘type instelling’; het bleek voor het 
therapie-effect niet uit te maken in welk type instelling (bijvoorbeeld een 
onderzoeksinstelling of een GGZ instelling) een proefpersoon behandeld werd. Dit is 
een belangrijke bevinding want het betekent dat de behandelingen die 
oorspronkelijk vanuit een onderzoekssetting ontwikkeld zijn goed toepasbaar blijken 
in de klinische praktijk. Wat betreft de aanwezigheid van agorafobie bleek er alleen 
een relatie te zijn met de mate waarin patiënten vertrouwen hadden in hun 
vermogen om met toekomstige paniekaanvallen om te gaan: patiënten met matige 
en ernstige agorafobie hadden hier minder vertrouwen in vergeleken met patiënten 
zonder of met milde agorafobie. Het gebruik van additionele benzodiazepines 
(medicijnen die angst onderdrukken waarbij het effect snel optreedt en ook relatief 
snel weer verdwijnt) werd binnen het huidige protocol niet aangemoedigd maar in 
minimale dosering toegestaan. Meer dan de helft van de proefpersonen (63%) 
gebruikte op geen enkel moment gedurende het onderzoek benzodiazepines. 
Proefpersonen die gedurende de behandeling dagelijks benzodiazepines bleven 
gebruiken bleken zich minder gezond te voelen en hadden minder vertrouwen in hun 
vermogen om met toekomstige paniekaanvallen te gaan in vergelijking met 
proefpersonen die geen of slechts heel af en toe benzodiazepines gebruikten.  
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Snelheid van verbetering 
 
In hoofdstuk 5 wordt een studie beschreven naar de snelheid van verbetering binnen 
de verschillende behandelgroepen. De deelnemende patiënten werd gevraagd om 
gedurende het eerste behandeljaar iedere paniekaanval die optrad te noteren. Dit 
leverde informatie op over de frequentie van paniekaanvallen en het verloop van die 
frequentie gedurende het behandeljaar. Als maat voor snelheid van verbetering 
kozen we de afname in de frequentie van gerapporteerde paniekaanvallen. Alle drie 
de groepen, CGT, SSRI en CGT+SSRI lieten een significante daling van het aantal 
paniekaanvallen zien tijdens het behandeljaar. Na twaalf maanden kwamen 
paniekaanvallen niet of nauwelijks meer voor ongeacht welke behandeling de 
patiënten hadden ontvangen. We vonden een duidelijk verschil in tempo van 
verbetering: de frequentie van paniekaanvallen nam in de SSRI en in de CGT+SSRI 
groep significant sneller af in vergelijking met de CGT groep. Het verschil tussen SSRI 
en CGT+SSRI bleek niet significant. Het aantal paniekaanvallen nam niet toe tijdens 
of na het afbouwen van de medicatie in de SSRI en CGT+SSRI groepen. De 
aanwezigheid van agorafobie bleek niet voorspellend voor het algemene verloop in 
frequentie van paniekaanvallen. Wel bleek dat patiënten met matige of ernstige 
agorafobie die een van beide monotherapieën ontvingen een kleinere afname van 
paniekaanvallen lieten zien in vergelijking met patiënten zonder of met milde 
agorafobie. Ook bleek dat patiënten met matige of ernstige agorafobie een snellere 
afname van het aantal paniekaanvallen lieten zien als zij CGT+SSRI ontvingen in 
vergelijking met patiënten met matige of ernstige agorafobie die een van beide 
monotherapieën ontvingen.  
 




In hoofdstuk 6 worden de resultaten van een studie naar de kosteneffectiviteit van 
de drie behandelmodaliteiten beschreven. Psychiatrische aandoeningen gaan 
gepaard met maatschappelijke kosten. Naast de directe kosten verbonden aan de 
behandeling van een aandoening zijn er ook indirecte kosten bijvoorbeeld als gevolg 
van productieverlies wanneer patiënten in de ziektewet terechtkomen. De laatste 
jaren heeft onderzoek naar kosteneffectiviteit een grotere nadruk gekregen in de 
wetenschappelijke literatuur. Dit past bij de maatschappelijke ontwikkelingen van de 
noodzaak van kostenbeheersing en het moeten verantwoorden van interventies op 
het gebied van de (geestelijke) gezondheidszorg richting 
verzekeringsmaatschappijen. Een interventie is kosteneffectief, doelmatig, als de 
kosten die ermee gepaard gaan in verhouding staan tot de effecten van de 
interventie. 
 In het geval van paniekstoornis met of zonder agorafobie is dergelijk onderzoek 
nog maar weinig uitgevoerd en in het bijzonder was er nog niet eerder onderzoek 
gedaan waarbij naast de directe kosten ook de indirecte kosten werden vergeleken. 
In de kosteneffectiviteitanalyse beschreven in hoofdstuk 6 werd als therapie 
uitkomstmaat de score op de HAM-A gebruikt (HAM-A: Hamilton Anxiety Rating 
Scale). Daarnaast werd uitgebreide informatie verzameld over zowel directe als 
indirecte kosten door middel van een gestructureerd interview. Deze informatie 
werd verzameld tijdens de vijf eerder beschreven meetmomenten gedurende de 
twee jaar dat proefpersonen deelnamen aan het onderzoek. Het bleek dat er over de 
twee jaren heen geen statistisch significante verschillen gevonden werden tussen de 
drie behandelmodaliteiten met betrekking tot kosten en therapie uitkomsten. Een 
onderlinge vergelijking liet zien dat CGT en CGT+SSRI kosteneffectiever bleken in 
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vergelijking met SSRI als monotherapie. CGT ging gepaard met iets lagere kosten 
terwijl CGT+SSRI gepaard ging met een iets groter therapie effect. Welke van deze 





In het afsluitende hoofdstuk van dit proefschrift, hoofdstuk 7, worden de resultaten 
van de beschreven studies samengevat en gerelateerd aan eerder onderzoek. 
Aansluitend worden er een aantal discussiepunten besproken. Tot slot worden er 
aanbevelingen gedaan met betrekking tot de klinische behandelpraktijk en 
toekomstig onderzoek. 
 Zowel CGT als SSRI als de combinatiebehandeling, CGT+SSRI, blijken effectieve 
behandelingen voor paniekstoornis met of zonder agorafobie. De positieve effecten 
van therapie werden behouden na het staken van de behandeling tot en met de 
laatste follow-up. Er werden geen duidelijke aanwijzingen gevonden voor de context-
veiligheid hypothese. Dat wil zeggen dat er geen nadelige effecten van het afbouwen 
van de medicatie gevonden werden. Dit is een belangrijke bevinding die uit eerder 
onderzoek nog niet zo duidelijk naar voren was gekomen. Patiënten die SSRI of 
CGT+SSRI ontvingen verbeterden sneller (als gemeten in frequentie paniekaanvallen) 
in vergelijking met patiënten die alleen CGT ontvingen. Vanuit een 
kosteneffectiviteitsperspectief zouden CGT en CGT+SSRI de voorkeur verdienen 
boven alleen SSRI. Bij het toewijzen van behandeling aan patiënten zal in de 
toekomst het wel of niet aanwezig zijn van matige of ernstige agorafobie mogelijk 
een factor van belang zijn. Er werd namelijk gevonden dat patiënten met matige of 
ernstige agorafobie sneller verbeterden op de combinatiebehandeling in vergelijking 
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met de monotherapieën. Andere voordelen verbonden met de 
combinatiebehandeling waren dat CGT+SSRI geassocieerd was met de hoogste 
tevredenheidsscore
6




 Omdat er nog maar weinig onderzoek gedaan is zoals dit, is het belangrijk dat 
huidige bevindingen gerepliceerd gaan worden. Die herhaling is nodig zodat we met 
meer zekerheid klinische aanbevelingen kunnen doen. Het zou zinvol zijn om daarbij 
nog meer patiënten te betrekken en deze nog langer te volgen dan de twee jaar in 
de huidige onderzoeksopzet. Met betrekking tot de combinatiebehandeling is 
bovendien nader onderzoek gewenst naar de meest optimale volgorde, duur en 
fasering van de verschillende onderdelen en de uitleg die patiënten aangeboden 
krijgen over deze behandeling. Vervolgonderzoek zou mogelijk ook meer ideeën 
kunnen opleveren over hoe huidige resultaten te verklaren zijn in het licht van 
bevindingen vanuit experimenteel onderzoek naar het aan- en afleren van angst. 
Eenvoudig gesteld: hoe verklaren we dat er wel aanwijzingen gevonden zijn voor de 
context-veiligheid hypothese in experimenteel onderzoek bijvoorbeeld met muizen 
maar niet in huidig klinisch onderzoek bij mensen?  
 Ondanks het besef dat voorzichtigheid geboden is en het nog te vroeg is voor 
definitieve conclusies willen we toch een poging doen de huidige resultaten te 
vertalen naar aanbevelingen voor de klinische praktijk. In hoofdstuk 7 worden 
daarom een aantal suggesties gedaan. Er wordt voorgesteld dat voor patiënten met 
paniekstoornis zonder of met milde agorafobie een CGT behandeling eerste keus is. 
Voor patiënten met paniekstoornis en matige of ernstige agorafobie is CGT+SSRI de 
eerste keus behandeling; deze blijkt kosteneffectief en is snel en blijvend effectief. 
                     
6 Zoals gemeten op een vragenlijst over de mate van tevredenheid met de ontvangen behandeling die patiënten, na 
afloop van de behandeling, hebben ingevuld. 
7 Een ‘remitter’ was een proefpersoon die aan een aantal verbetercriteria voldeed zoals uitgelegd in hoofdstuk 4. 
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Wat betreft het voorschrijven van additionele benzodiazepines aan patiënten met 
paniekstoornis suggereren de resultaten van huidig onderzoek dat dit niet nodig is en 
dat dagelijks benzodiazepinegebruik bovendien geassocieerd is met een aantal 
nadelen. In de klinische praktijk zijn artsen soms aarzelend om SSRIs af te bouwen na 
het bereiken van volledige remissie. Huidige resultaten ondersteunen de opvatting 
dat SSRIs wel degelijk afgebouwd kunnen worden: behandeling hoeft niet te worden 
voortgezet uit angst voor terugval na afbouwen. Het is mogelijk verstandig om de 
SSRI af te bouwen terwijl de CGT nog gaande is. Het is tevens aan te bevelen 
patiënten goed voor te lichten over en te begeleiden in het afbouwen van de SSRI.  
 In tegenstelling tot enkele eerdere bevindingen vonden wij op langere termijn 
geen nadelige effecten van de combinatiebehandeling CGT+SSRI. Toekomstig 
onderzoek zal mogelijk nieuwe inzichten opleveren met betrekking tot de context-
veiligheid hypothese, werkingsmechanismes die een rol spelen in therapie-effecten 
en de wijze waarop de combinatiebehandeling het beste aangeboden kan worden. 
Zo zal wetenschappelijk onderzoek bij blijven dragen aan de verdere optimalisering 
van de behandeling van paniekstoornis.  




















Als iemand mij in de afgelopen jaren vroeg wanneer ik zou promoveren grapte ik ‘in 
ieder geval voor mijn 40e’…dat leek me nog veilig heel ver weg. Nu ben ik 40! Lang 
geleden (in 2001) begon ik als assistent in opleiding bij de toenmalige afdeling 
Biologische Psychiatrie en werd het doel ‘een boekje schrijven’ zo langzamerhand 
een constante in mijn leven. Er kwam nogal eens wat tussendoor (professioneel en 
privé, leuk en niet leuk) en dan lag het onderzoekswerk weer een hele poos stil. Ook 
in die periodes van stilstand twijfelde ik er eigenlijk nooit aan dat het proefschrift op 
een dag wel af zou zijn. Misschien maar goed dat ik nooit geweten heb dat die dag 
pas eind 2013 zou komen... Deze tekst schrijf ik vlak voor het boekje naar de drukker 
gaat, mijn promotie is nu wel heel dichtbij en het leukste heb ik bewaard voor het 
laatst: het bedanken van de mensen die een aandeel hebben gehad in het tot stand 
komen van dit proefschrift. 
Ik wil als eerste de mensen die als proefpersoon hebben meegewerkt aan dit 
onderzoek bedanken voor hun bereidheid om mee te doen met de loting, het zich 
laten interviewen en het invullen van vele vragenlijsten.  
Bill Hale en Bernhard Slaap zijn (voor mijn komst) begonnen met het uitdenken en 
opzetten van het onderzoek en zijn verantwoordelijk voor de aanvraag 
ontwikkelingsgeneeskunde waarvoor dank.  
Hans den Boer, mijn promotor, wil ik bedanken voor de kans die hij mij geboden 
heeft door mij aan te stellen als onderzoeksassistent. Beste Hans; in de jaren die 
volgden bleken je optimisme, pragmatisme en vertrouwen eindeloos: gelukkig maar. 
Peter Paul Mersch, copromotor: aan jou bewaar ik goede herinneringen aan de jaren 
van mijn AIO-zijn. Aan onderzoeken, laat staan schrijven, kwam ik eigenlijk niet toe 
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maar we hebben samen veel plezier beleefd aan het tot laat in de avond in elkaar 
zetten van vragenlijstboekjes en protocollen, het trainen en superviseren van 
studenten, het overleggen over patiënten en het bezoeken afleggen aan instellingen 
in het land. Je maakte altijd alle tijd voor me en toonde je zeer betrokken. Ook jij kon 
niet weten dat het zo’n lange rit zou worden maar ik ben blij dat jij er aan het einde 
van de rit weer bij bent!  
Wiljo van Hout, copromotor: jij kwam pas later aan boord en dat bleek al snel een 
geweldig goed idee. Ik leerde je kennen toen ik student was en jij, dankzij je grote 
klinische-, therapeutische- en onderwijstalenten, al snel mijn voorbeeld werd. Als 
copromotor bleek je zeer betrokken en deskundig. Dank je wel voor je 
zorgvuldigheid, helderheid, steun en blijvende vertrouwen.  
De leden van de leescommissie, Anton van Balkom, Claudi Bockting en Robert 
Schoevers wil ik bedanken voor hun bereidheid mijn proefschrift te beoordelen. 
Als AIO ‘op de zesde’ (op de toenmalige afdeling Biologische Psychatrie) was het fijn 
werken met de andere AIOs en met Margot Jongsma en Jaqueline Reisel op het 
secretariaat. Met Annemiek Polman deelde ik die jaren een kamer en ook het nodige 
lief en leed: dank je wel voor het goede gezelschap Annemiek.   
Robert Schoevers, vanuit zijn functie als hoofd van het UCP, wil ik bedanken voor de 
werktijd die ik af en toe vrij mocht maken om weer een stukje verder te komen met 
mijn onderzoek. 
Veel dank ben ik verschuldigd aan Marieke Timmerman die verantwoordelijk was 
voor het ontwerpen en uitvoeren van de multilevel analyses. Beste Marieke; je bent 
uitermate deskundig, precies en betrouwbaar. Je bleef onvermoeibaar, altijd 
bereidwillig en enthousiast reageren op weer eens een vraag van mijn kant. Bedankt 
voor de zeer plezierige en vruchtbare samenwerking. 
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Peter Hulshof was als hele fijne arts betrokken bij de behandeling van de patiënten 
in Groningen en hielp ook met het verder uitwerken van het SSRI protocol. Dennis 
Stant wil ik bedanken voor de prettige samenwerking met betrekking tot de 
kosteneffectiviteitsanalyse. Mark Huisman wil ik bedanken voor zijn adviezen en hulp 
met betrekking tot de analyses in hoofdstuk 3.  
In de jaren dat het onderzoek liep waren er gelukkig altijd studenten psychologie van 
de RuG bereid om mee te draaien met het invoeren van data en om te fungeren als 
therapeut en onderzoeksassistent. Dank aan Wendy, Willy, Mariëlle, Manja, 
Theodoor, Geralien, Esther, Rieneke, Marije, Marieke, Eva, Yvonne, Judith, Ingrid, 
Shirley, Annemarie, Irma, Bianca en Greta. Laura van Bergen was er gelukkig ook; om 
de studenten te helpen met hun vragen over statistiek en om de datainvoer te 
bewaken.  
In de participerende instellingen waren de volgende onderzoeksassistenten 
werkzaam die ik wil bedanken voor hun inzet voor het onderzoek: Jaqueline Reisel, 
Paulien Klomps, Noor Tromp, Ina Kliphuis, Ilona de Vries, Gepke Danhof, Chris Albers, 
Marij Bär en Manon van de Werken. 
Mijn dank gaat ook uit naar alle therapeuten en coördinatoren van de participerende 
instellingen. In het bijzonder ben ik Sako Visser en Daniëlle Cath dank verschuldigd 
voor hun inzet om de inclusie vanuit Amsterdam te realiseren. 
Lieve collega’s (jammer; teveel namen om hier te noemen): dank jullie wel voor jullie 
collegialiteit en belangstelling. Dat ik op zo’n leuke en inspirerende plek 
patiëntenzorg mag leveren en dat samen met jullie maakt me blij. Ik heb zin in nog 
vele goede jaren op het UCP.  
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De mensen die dicht bij me staan, (ex-schoon)familie en vrienden, wil ik bedanken 
voor hun steun en belangstelling en bovenal voor de gezelligheid en het goede 
gezelschap. In het bijzonder wil ik mijn ouders bedanken. Lieve Freek en Ciska: mijn 
dankbaarheid voor jullie onvoorwaardelijke liefde, trots en steun in alle opzichten is 
eigenlijk niet in woorden te vatten (maar dit was een poging). Dank ook voor het 
vele oppassen in de afgelopen jaren lieve (opa) Gerard, (oma) Henny, (opa) Freek en 
(oma) Ciska. Mijn paranimfen wil ik bedanken voor het helpen met het organiseren 
van een feestje en hun aanwezigheid straks bij de plechtigheid. Lieve broer, lieve 
Bastiaan; zoveel jaar geleden was ik in Florence bij jouw promotie aanwezig en het 
doet me veel plezier dat je nu als paranimf aanwezig zult zijn bij die van mij. Dank je 
wel voor je nooit aflatende steun en belangstelling. Lieve Henriëtte; ik heb je leren 
kennen toen we samen de GZ-opleiding deden en wat ben ik daar blij mee; laten we 
voor altijd vriendinnen blijven. De ‘meiden’ (ja sorry, toch aanhalingstekens 
inmiddels:-)) van de eetclub, mijn ‘zussen’ Anneke, Floor, Marije, Maaike, Muriël en 
Roos: jullie laten mij al meer dan 20 jaar zien wat de kracht is van vriendschap en 
solidariteit; dank jullie wel. Auko, dank je wel voor je vriendschap en de vele 
broodnodige herhalingsgesprekken. Maaike, dank je wel voor je vriendschap en 
(bijvoorbeeld) de leuke herinneringen aan een weekje Caïro. Maaike, bedankt voor 
de mooie omslag van dit boekje. Roos, dank je wel voor de leuke foto hieronder. 
Tot slot: Niets vervult mij met grotere trots en meer dankbaarheid dan het feit dat ik 
moeder ben van vier fantastische kinderen; mijn dochters Madelief (18) en Sam (13) 
en mijn zonen Daan (15) en Abel (8). Mijn hart behoort aan jullie. 
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